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Abstract 
This thesis describes the development of novel photoactivatable antagonists for the 
GABAA receptor. GABAA receptors are ligand-gated Cl
-
 channels belonging to the 
Cys-loop superfamily of ionotropic receptors, which play an important role 
inhibiting cell excitation in the nervous system. To date, no research has probed the 
mobility of native, unmutated GABAA receptors. In order to do this, we planned to 
design a series of molecules that could bind to the GABAA receptor covalently, 
causing inhibition. A brief overview of the GABAA receptor and the concept of 
photoaffinity labelling are outlined in the first chapter, followed by a chapter 
detailing our results and discussion. 
Firstly, our efforts focussed on the development of a lead compound. The molecule 
gabazine was chosen as our template, since the molecule possesses a highly specific 
affinity for the GABAA receptor. In our ongoing studies into the development of 
labelled analogues of gabazine as probes for the GABAA receptor, we discovered 
that a relatively minor addition to the gabazine skeleton significantly enhances its 
antagonist potency. 
The development of several new photoaffinity-labelled reagents capable of 
photochemically blocking the function of the GABAA receptor was subsequently 
explored. We were able to demonstrate that these reagents could block up to 49% of 
recombinant GABAA receptors in cultured cells. Finally, our efforts centered on 
creating an analogue incorporating a photoaffinity label in addition to a detectable 
tag. It is hoped that such a compound could be useful for exploring the spatial and 
temporal mobility of native GABAA receptors microscopically.  
The tools created are the first with the potential to knock out GABAA receptors in 
vivo, and avoid the need for any prior receptor transfection. 
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1 Introduction 
1.1 Introduction to the GABAA receptor 
1.1.1 Neurotransmission 
The word ‘neurotransmission’ is a compound derived of two words; from the Greek 
neuro meaning ‘nerve’, and the Latin transmissio meaning ‘crossing’. In the central 
nervous system (CNS), nerve signals, known as action potentials are transmitted 
along nerve cells, known as neurons. Each action potential is a wave of current, and 
in order to continue transmission from one neuron to the next, the impulse must 
traverse the synaptic gap that separates the two. At all synapses, this transmission is 
achieved by inducing a postsynaptic potential – a change in electrical potential that 
can trigger an action potential in the postsynaptic neuron. The majority of neurons 
achieve this transmission by the use of chemical mediators, known as 
neurotransmitters.
1,2
 Neurotransmission describes the process by which the 
neurotransmitter is secreted by a presynaptic neuron and subsequently activates a 
receptor on a postsynaptic neuron (Figure 1.1). Upon arrival at an axon terminal, an 
electrical impulse initiates the release of neurotransmitters from synaptic vesicles 
into the synaptic cleft. Receptors found on the postsynaptic neuron can then bind 
these molecules and respond by opening ion channels in the postsynaptic neuron or 
by initiating signaling cascades.  
 
Figure 1.1 – Synaptic neurotransmission  
1. Introduction 
2 
 
For ionotropic receptors, the binding of a neurotransmitter directly activates an ion 
channel. Upon activation, ion channels selectively let ions pass through. Depending 
on the nature of the neurotransmitter and receptor, ions are able move in or out and 
alter the local transmembrane potential of the cell. These ions are characteristically 
Na
+
, K
+
, Ca
2+
 and Cl
-
, and their relative concentrations ultimately influence the 
membrane potential in any neuron. A change in relative ion concentrations resulting 
in a more negative potential is known as hyperpolarisation. Conversely, a change in 
ion concentrations causing a more positive or less negative potential is known as 
depolarisation. Depolarising ion flux increases the postsynaptic potential, and if the 
potential increases above the threshold voltage, an action potential is triggered in the 
postsynaptic neuron.
3
 In its resting state a neuron is polarised to approximately !70 
mV relative to its surroundings.  This is achieved through having a high intracellular 
concentration of K
+
 ions and a high extracellular concentration of Na
+
 ions. In a 
quiescent neuron, the resting voltage is around !70 mV, and the threshold voltage is 
around !55 mV (Figure 1.2).2 When the axon hillock (the linkage between the cell 
body and the axon) is adequately depolarised to the threshold voltage, voltage-gated 
Na
+
 channels open and more Na
+
 ions are able to permeate into the cell.  At 
approximately +40 mV, the Na
+
 channels inactivate. K
+
 channels increasingly open 
and hyperpolarisation occurs, where K
+
 ions flow out of the cell.  It is this reversal of 
transmembrane potential which initiates an electrical impulse.
2
  
 
Figure 1.2 – An action poteniial 
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1.1.2 GABA 
Two competing pathways control the overall activity of the brain. Excitation by the 
neurotransmitter glutamate 1 depolarises neurons,
4
 whilst inhibition by the 
neurotransmitter !-aminobutyric acid (GABA) 2 leads to the hyperpolarisation of 
neurons (Figure 1.3).
5
 
O
O
O
O
NH3
L-Glutamate 1
O
O
NH3
!-Aminobutyric acid 
GABA 2  
Figure 1.3 
GABA is considered one of the most important inhibitory neurotransmitters in the 
mammalian CNS.
6
 Roberts and Frankel first demonstrated the relative abundance of 
the amino acid within the brain, believing the biosynthetic pathway of GABA to 
originate from the decarboxylation of L-glutamate, a process catalysed by the 
enzyme L-glutamate decarboxylase (GAD).
7
 GABA was finally proven as an 
inhibitory neurotransmitter by Krnjevic et al. in the 1960s.
8
 Three sub-classes of 
receptors are activated by the release of GABA; GABAA, GABAB and GABAC 
receptors. Both GABAA and GABAC receptors are ligand gated ion channels 
(LGICs), whereas GABAB receptors are G-protein coupled receptors (GPCRs).
9
 
Glutamate and GABA are essential to the functionality of the CNS; they play 
fundamental roles in maintaining a balance between neuronal excitation and 
inhibition, the two major inputs that govern overall brain activity.
10, 11
  
GABAA receptors are GABA-gated Cl
-
 ion channels, which cause the firing of the 
neuron to be inhibited. Upon the binding of GABA, the receptor is activated and the 
intrinsic Cl
-
 ion channel opened. This allows Cl
-
 ions to flow through the channel and 
into the cell, causing hyperpolarisation and leading to inhibition of the cell.
12
 
Neurons in the CNS can display two forms of GABAergic inhibition, referred to as 
either phasic or tonic.
13
 Phasic inhibition is a short-lived hyperpolarising event of the 
cell, which is brought about through the rapid, transient activation of GABA 
1. Introduction 
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receptors, located on the postsynaptic neuron, by GABA released in high 
concentration from adjacent presynaptic termini. Tonic inhibition is a result of a 
persistent low concentration of GABA, which has passed out of the synaptic cleft, 
activating receptors located at extrasynaptic positions. Instead of undergoing a short 
period of activity, extrasynaptic GABA receptors are tonically active. The result is a 
slight but prolonged hyperpolarisation of the postsynaptic neuron.
14, 15
 
1.1.3 GABAA receptor structure 
The GABAA receptor belongs to the Cys-loop superfamily of ionotropic receptors. 
Cys-loop receptors are exclusively ligand-gated ion channels (LGICs);
16
 ion 
channels that mediate rapid synaptic transmission via the movement of ions through 
channels gated by neurotransmitters. Each Cys-loop receptor is pentameric in 
structure, and is found in both homo- and hetero-pentameric forms. This results in a 
large family of receptors, each with distinct conformational diversities (Figure 
1.4).
17
 Nineteen subunits have been identified for the GABAA and GABAC receptors. 
The subunits are divided into eight subfamilies, related by structure (#1-#6, $1-$3, 
!1-!3, %, &, ', (, and )1-)3).
5, 18
 Genes that code for GABAA subunit proteins are 
found in a different chromosomal locations to the genes coding for GABAC )-
subunit proteins. As a result, subunits )1-)3 are exclusive to GABAC receptors and 
form homomeric LGICs. )-Subunits have been shown to arrange in a heteromeric 
fashion in vitro, but so far, this has not been demonstrated in vivo.
19
 
 
Figure 1.4  - GABAA  and GABAC receptor assemblies 
The distribution of receptor subunits is known to vary between regions in the brain.
20
 
With respect to # subunit distribution, the #1 subunit is ubiquitous throughout the 
brain, whereas the #6 subunit is found predominantly in the cerebellum.
21-23
 
1. Introduction 
5 
 
Regarding $ subunit distribution, the $2 subunit is the most abundant isoform,
24
 
whereas the $1 subunit is the least prevalent.
24
 !1 and !3 subunits are also fairly rare, 
centralised in the thalamus, whilst the !2 subunit exists in many brain areas.
25
 The % 
subunit predominates extrasynaptically, and is thought to be related to the action of 
tonic inhibition in the brain.
26
 The &, ' and ( subunits are rare subunits sparingly 
located in the basal ganglia, thalamus, hypothalamus and amygdala.
27
 The archetypal 
GABAA receptor is comprised of two #, two $ and one ! subunits. The #1$2!2 
receptor isoform accounts for roughly 35% of GABAA receptors encountered in the 
CNS.
20
 A number of permutations are therefore possible for receptor subunit 
composition due to the number of subunits genetically encoded, and it has been 
suggested that the subunit composition of GABAA receptors can even vary between 
synapses on the same neuron.
28, 29
 
Each subunit that makes up the receptor contains an extracellular N-terminal domain, 
which carries binding sites for agonists, antagonists and modulators.
9
 GABA binding 
takes place at the interface between # and $ subunits. Subunits also hold a sequence 
of 13 residues, bounded by cysteine residues that bond covalently, giving a closed 
loop situated between binding and channel domains giving the receptors their generic 
name of Cys-loop receptors.
16
 
A GABAA receptor subunit also possesses four hydrophobic membrane-spanning 
domains (M1 to M4), an intracellular loop of variable length and a small 
extracellular C-terminus (Figure 1.5). The intracellular loop is located between the 
M3 and M4 domains and contains protein kinase A (PKA), protein kinase C (PKC) 
and tyrosine kinase phosphorylation sites. This intracellular loop is believed to be 
responsible for the membrane clustering of the receptor, and is required for 
subcellular targeting.
30
 The transmembrane domain M2, from all five subunits, is 
arranged so that it lines the channel pore. The M2 domain is crucial for receptor 
gating and ionic selectivity.
9
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Figure 1.5 - GABAA receptor arrangement in the channel pore 
1.1.4 Trafficking of GABAA receptors 
The trafficking of the GABAA receptor from intracellular creation to the synapse is 
largely dependent on various receptor-associated proteins (Figure 1.6).
31
 
Figure 1.6
31
 - GABAA receptor life cycle 
GABAA receptors are constructed in the endoplasmic reticulum and transported to 
the Golgi apparatus (a, Figure 1.6). Aided by GABARAP (GABAA receptor 
associated protein) and NSF (an N-ethyl maleimide sensitive factor), receptors are 
transferred via intracellular vesicles to the membrane surface. GABARAP assists in 
the clustering of GABAA receptors at a synapse as an anchoring protein (b, Figure 
1. Introduction 
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1.6).
32-34
 The protein PLIC-1 (protein linking IAP to cytoskeleton) assists in 
membrane insertion of GABAA receptors at a synapse (c, Figure 1.6).  
Several signalling molecules can bind to the receptor; Src (sarcoma), RACK1 
(receptor of activated protein C kinase 1), PKC (protein kinase C), PKA (protein 
kinase A) with AKAP (A-kinase anchor protein), and gene PRIP1 (phospholipase C 
related catalytically inactive protein) with PP1c (protein phosphorylase 1c). It is 
thought that PLIC-1, PRIP1 and GABARAP are involved in an endocytotic pathway 
(d, Figure 1.6). Clathrin, a protein that assists in the formation of vesicles, is also 
believed to be important in the endocytotic recycling and degradation pathway.
31
 
Some GABAA receptors recycle back to the surface, resulting in a steady state 
population of the receptors at the surface.
35, 36
 The cycling of receptors is significant 
for the efficacy of synaptic inhibition.
37, 38
 
Research by the Smart group determined that receptors are dynamically mobile 
between synaptic and extrasynaptic domains.
39
 By introducing a cysteine mutation 
into the channel of the common #1 subunit, they were able to demonstrate that a 
complete block of cell surface GABAA receptors resulted in a rapid (~10 min) 
replenishment of functional receptors following irreversible inhibition. The 
inhibition was initiated by the addition of sulfhydryl modifying agents that could 
permanently alter the receptor through the introduction of a disulfide bond in the 
channel, rendering them inactive. Partial selective inhibition of synaptic receptors 
resulted in a compensation mechanism, where lateral diffusion of unblocked 
extrasynaptic membrane receptors assisted the recovery of functional receptors at a 
given synapse. This mechanism superseded the insertion of GABAA receptors from 
the intracellular pool of receptors (Figure 1.7).
39
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Figure 1.7
39
 – Pathways of GABAA receptor insertion 
A disadvantage of this method lies in the use of a cysteine mutation to inactivate 
populations of receptors. While the mutation lies deep within the ion channel, it has 
been documented that inducing such a genetic change might lead to overexpression 
of transmembrane receptors.
40-43
 To date, research into the trafficking of native 
GABAA receptors is scarce, though the mobility of other native transmembrane 
receptors has been examined.
44-46
 
1.1.5 Compounds interacting with the GABAA receptor 
GABAA receptors are among the most complicated of the Cys-loop receptors, partly 
due to the large number of receptor subtypes and the variety of ligands that can 
interact with specific sites on the receptor. It is not known exactly how many regions 
are available for interaction with such structurally diverse substances; in fact many 
agents will act at overlapping sites on the receptor protein subunits.
18
 
It has been proposed that different ligands are able to interact at different locations 
on the GABAA receptor.
18
 These include: (i) agonist recognition sites, which are the 
point of interaction for agonists, partial agonists and competitive antagonists; (ii) 
benzodiazepine sites, which are located between the # and ! subunit; (iii) neuroactive 
steroid sites requiring # subunits; (iv) picrotoxinin sites that are associated with the 
Cl
-
 ion channels; (v) sedative-hypnotic barbiturate sites, which can interact with the 
picrotoxinin and agonist recognition regions; (vi) stereoselective sites for inhalation 
anaesthetics such as isoflurane; (vii) furosemide sites, which are associated with the 
Cl
-
 channels of GABAA receptors containing the #6 subunit; (viii) Zn
2+
 sites, which 
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are found in GABAA receptors that do not contain the !2 subunit; (ix) divalent cation 
sites for ions such as Ca
2+
, Sr
2+
, Ba
2+
, Cd
2+
, Mn
2+
, and Mg
2+
, which can act on the Cl
-
 
ion channels and modulate GABAA receptor function; (x) La
3+
 regions that are 
different from the other cation sites. Along with these, there is also the possibility of 
phospholipid, phosphorylation and microtubule interacting regions.
18
 
1.1.5.1 Agonists 
Although GABA is the principal ligand that modulates GABAA receptor function, a 
number of agonists are also able to bind to the same binding site and mediate the 
passage of Cl
-
 ions. One such compound is the full agonist muscimol 4 which 
originates from Amanita muscaria, more commonly known as the fly agaric, a lethal 
psychoactive mushroom.
47
 Muscimol is the decarboxylative product of the 
predominant metabolite of the Amanita genus, ibotenic acid 3 (Scheme 1.1); an 
agonist of the ionotropic glutamate NMDA receptor.
48
 
N
O
HO NH2
OH
O
N
O
HO NH2
Ibotenic acid 3 Muscimol 4
CO2
 
Scheme 1.1 
An atomic alteration to muscimol, from an isoxazole to an isothiazole gives another 
agonist for the GABAA receptor, thiomuscimol 5 (Figure 1.8). Thiomuscimol has 
been reported as being equipotent to muscimol as an agonist at the GABAA 
receptor.
49
 
N
S
HO NH2
Thiomuscimol 5  
Figure 1.8 
Other agonists that can modulate receptor function at the GABA binding site include 
the full agonist isoguvacine 6 and the partial agonist gaboxadol, also known as THIP 
7 (Figure 1.9).
50-53
 The latter has been shown to act as an analgesic in humans, 
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however it increases glucose metabolism in epileptic patients, limiting its clinical 
use.
54
 
HN O
NH
O
THIP 7
EC50 = 134 µM
HN
O
OH
Isoguvacine 6
EC50 = 48 µM  
Figure 1.9 
1.1.5.2 Benzodiazepines 
Benzodiazepines are a heterocyclic class of compounds that augment the effect of 
GABA or other agonists. Structurally, benzodiazepines combine benzene and 
diazepine ring systems. In medicine, the benzodiazepine has been shown to remedy 
anxiety and insomnia.
55
 Benzodiazepines have been used clinically since the 1960’s 
and one of the most well-known examples is diazepam 8 (Figure 1.10).
56
 
NHN NN
Cl
O
1,4-benzodiazepine
ring system
Diazepam 8
 
Figure 1.10 
The location on the GABAA receptor where benzodiazepines interact is frequently 
referred to as the benzodiazepine site, located between the # and ! subunits of the 
GABAA receptor. At this location, they are able to amplify the synaptic inhibition 
caused by GABA.
57, 58
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1.1.5.3 Neurosteroids 
Neurosteroids are the most potent endogenous modulators of GABAA receptor 
function in the brain. They are able to potentiate receptor activation by GABA at low 
concentrations (1 - 10 nM) and can directly activate the receptor in the absence of 
GABA at higher concentrations (200 nM - 10 µM).59, 60 Studies by Hosie et al. 
proposed that two discrete binding sites for neurosteroid binding exist on the 
GABAA receptor; one for receptor activation and the other for receptor 
potentiation.
61, 62
 In order to regulate GABAA receptor function, neurosteroids 
require a tetracyclic structure possessing a C3" hydroxyl moiety on the A ring and a 
C20 ketone group on the D ring (Figure 1.11).
62, 63
 
Nomenclature of steroids
1
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C D
 
Figure 1.11 
Typically, neurosteroids are synthesised in the CNS. Pregnenolone 10 and its 
metabolites, including allopregnanolone or ALLOP 11, are the products from the 
breakdown of cholesterol 9 in the brain (Scheme 1.2).
64
 
HO
H
HH
Cholesterol 9
O
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H
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O
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H
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H
 
Scheme 1.2 
A metabolite of the hormone deoxycorticosterone 12, tetrahydrodeoxycorticosterone 
or THDOC 13, is another endogenous neuroactive steroid, which is able to modulate 
GABAA receptor function (Scheme 1.3).
65
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Scheme 1.3 
1.1.5.4 Antagonists 
Antagonists are compounds which, when bound to a receptor, will inhibit the 
response caused by an activating drug. In the case of GABAA receptors, binding of 
an antagonist prevents inhibition of the neuron. Antagonists can work competitively 
or non-competitively. Competitive antagonists will bind directly to the agonist 
binding site and so block the access for the agonist. Non-competitive antagonists will 
not bind to the same location as the agonist but to another site on the receptor, 
potentially altering the conformational shape of the receptor and leading to the 
agonist-binding site being affected.  
Well-known GABAA receptor antagonists include the steroid derivative R5135 14 
(Figure 1.12), which antagonises the GABAA receptor non-competitively by 
interacting with benzodiazepine binding sites.
66, 67
 However, 14 is not a selective 
inhibitor and also blocks inhibition caused by glycine receptors. Iso-THAZ 15, 
derived from the agonist THIP, inhibits the GABAA receptor competitively but also 
impedes neuronal inhibition by glycine.
68
 Bicuculline 16, isolated from the Corydalis 
genus, acts as a competitive and reversible antagonist and has been shown to block 
the action of GABA on the GABAA receptor.
69
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N
O
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Ki = 43 nM Ki = 56 µM Ki = 44 µM  
Figure 1.12 – Common GABAA receptor antagonists 
1.1.5.5 Gabazine and related compounds 
In 1985, Wermuth et al. reported the syntheses of several specific, competitive 
antagonists for the GABAA receptor.
66
 Heaulme et al. showed SR 95103 17 (Figure 
1.13) to be a selective antagonist at the GABA binding sites on GABAA receptors.
70
  
SR 95103 17
N N
NH.HBr
OH
O
Ki = 2.2 µM
1
3
45
6
2
 
Figure 1.13 
Antagonist 17 was shown to have a 20-fold greater potency for the GABAA receptor 
than bicuculline 16.
70
 The enhanced potency was linked to the presence of an 
aromatic ring at the 6-position of the pyridazine ring and it was concluded that the 
carboxylic acid side-chain was essential for antagonism at GABAA receptor agonist 
binding sites.
71
 Furthermore, it was also noted that substituents attached to the 
peripheral aromatic ring influenced antagonist potency. Structure-activity studies 
showed that the removal of the pyridazine-methyl group and the inclusion of a para-
methoxy group yielded a more potent antagonist. The ensuing compound - SR 95531 
also known as gabazine 18 - has been demonstrated to be a selective, competitive 
and reversible antagonist for the GABAA receptor, 250 times more potent than 16 
(Figure 1.14).
72
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N N
NH.HBr
OH
O
O
Gabazine
SR 95531 18
Ki = 150 nM
 
Figure 1.14 
It has been suggested that the antagonistic nature of gabazine and other similar 
compounds originate from the N-substitution of GABA by a charge-delocalized 
guanidinic or amidinic system.
67, 72
 The binding of gabazine has been probed on a 
microscopic level and tritiated derivatives of gabazine are commercially available.
73, 
74
 Ueno et al. demonstrated that gabazine partially inhibited direct activation of the 
receptor by the barbiturate pentobarbital and by the steroid alphaxolone, not by 
blocking their binding, but by acting as an inhibitor of GABAA receptor channel 
opening.
75
 Since its inception, gabazine has become a widespread tool in scientific 
research of the GABAA receptor.
76-79
 
Exploration of the core antagonist structure by the Wermuth group revealed that the 
potent nature of the antagonist can be negated if the pyridazine is encumbered with a 
sterically large group. SR 95132 19 (Figure 1.15) exhibited a drastically suppressed 
affinity compared to 18.
80, 81
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Figure 1.15 
Molecular modelling of the GABA-binding site suggested that bicuculline and 
gabazine both inhibit the GABAA receptor competitively, but by lying in different 
orientations. Previous research had already indicated that the two families of 
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compounds possessed similar structure-activity relationships.
82
 Rognan et al. 
proposed that the para-methoxyphenyl group on 18 and the (methylenedioxy)phenyl 
group on bicuculline 16 may share a common hydrogen-bonding site. SR 96073 20 
(Figure 1.16), a 3,4-(methylenedioxy) analogue of gabazine, was synthesised in 
order to test this hypothesis and was shown to be three times more potent than 
gabazine, supporting the theory that the compounds 16, 18 and 20 all share a 
common hydrogen-bonding site.
81
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Figure 1.16 
Melikian and co-workers later showed that further antagonists could be yielded from 
compound 20 by aminopyridazine substitution of other GABAA receptor agonists. 
The substitution of the GABA backbone for muscimol or thiomuscimol as 
bioisosteres, was envisaged to give further families of GABA antagonists. 
Replacement of GABA in SR 96073 by muscimol leads to analogue 21 with a 
similar affinity, whereas substitution by thiomuscimol lead to analogue 22 
possessing enhanced affinity (Figure 1.17). Melikian et al. proposed that the 
enhanced affinity of 22 may originate from a greater degree of lipophilicity and 
lower ionization of the side chain than in analogues 18 and 20.
83
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Figure 1.17 
1. Introduction 
16 
 
1.1.5.6 Synthesis of gabazine 
As well as being essential to the antagonistic character of gabazine and its related 
compounds, the pyridazine core is an important building block in medicinal 
chemistry. Some examples of medicinally relevant pyridazine derivatives are shown 
in Figure 1.18. Compounds containing the pyridazine nucleus and the closely related 
pyridazinone core have been shown to display several properties, such as 
antidepressant,
84
 antibacterial,
85
 analgesic,
86
 anticancer,
87
 antifungal
88
 and 
hypotensive
89, 90
 activities. 
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Figure 1.18 – Medicinally relevant pyridazine and pyridazinone derivatives 
Gabazine contains an arylaminopyridazine functionality and historically, synthesis of 
this building block has been cumbersome and prolonged due to the difficult 
construction of this motif (Scheme 1.4).
91
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Scheme 1.4 
3-Benzoyl propionates 23 are reacted with hydrazine to give dihydropyridazinones 
24. Following oxidation by bromine to pyridazinones 25, reaction with phosphoryl 
chloride gives the corresponding chloropyridazine 26.
91
 Reaction of 26 with 
hydrazine gives 27, followed by the reduction using a Ni catalyst to furnish the 
desired arylaminopyridazine 28.
92
  
Following the development of Pd-catalysed carbon-carbon bond formation, several 
groups have put forward accelerated syntheses of arylpyridazines.
93-95
 Parrot and co-
workers were able to show that reaction of commercially available 
dichloropyridazine 29 with an appropriate amine, followed by Pd-mediated cross 
coupling of chloropyridazine 30 with an arylboronic acid could furnish substituted 
arylaminopyridazines 31 in two steps (Scheme 1.5).
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Scheme 1.5 
3-Amino-6-arylpyridazines 33 can also be directly prepared through reaction of 
commercially available 3-amino-6-chloropyridazine 32 and a boronic acid, as 
described by Maes and researchers (Scheme 1.6).
94
 The Wermuth group also 
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reported the syntheses of arylaminopyridazines 33 using analogous reaction 
conditions.
93
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oC)  
Scheme 1.6 
Perhaps the remaining drawback of the Suzuki-Miyaura conditions employed by the 
aforementioned groups are the long conversion times necessitated by the majority of 
transformations. While the approach is clearly more ‘atom economical’ than 
preceding conversions (Scheme 1.4), there remains a palpable desire to curtail the 
sluggish nature of the reaction. To this end, several research groups have tried to 
circumvent the issue by applying microwave irradiation.
97, 98
 Numerous organic 
transformations, including Pd-mediated cross-couplings have been expedited by the 
use of microwave technology. Lin and co-workers were able to illustrate that the Pd-
mediated coupling of a boronic acid with dichloropyridazine 29 under microwave 
conditions could swiftly lead to arylpyridazines 34 in good yields (Scheme 1.7).
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Reagents and conditions: a) Pd(PPh3)2Cl2 (3 mol %), K2CO3, Ar-B(OH)2, 
CH3CN/H2O (3:2), microwave (10 min, 120 
oC), 53-93 %  
Scheme 1.7 
Beyond the construction of the arylpyridazine core, in order to function as a potent 
GABAA antagonist, the arylpyridazine must be conjugated with a unit of GABA. It 
has been suggested that antagonistic nature of gabazine and other similar compounds 
originate from the N-substitution of GABA by a charge-delocalized guanidinic or 
amidinic system.
67, 72
 Alkylation of arylpyridazines 33 by GABA is conventionally 
achieved through reaction with ethyl 4-bromobutyrate 35 giving protected 
antagonists 36, followed by acidic deprotection, to yield GABAA antagonists 37 
(Scheme 1.8).
71, 72, 81
 The ability to selectively achieve N(2)-alkylation of 
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arylpyridazine 33 stems from a combination of steric effects from the adjacent aryl 
moiety and resonance stabilisation. If the aryl group is replaced for an alkyl group, 
then a mixture of N(1) and N(2)-alkylated products are often formed. Nevertheless, 
these are usually easily separable by recrystallisation.
72, 99
 
N N
NH2Ar
33
a
Br
EtO
O
N N
NH.HBrAr
O
OEt
b
N N
NH.HBrAr
O
OH
3736
35
Reagents and conditions: a) DMF, reflux; b) HBr, water, reflux
1 2
3
45
6
12
3
45
6
 
Scheme 1.8 
In a recent example, Gavande et al. showed that microwave-accelerated synthesis 
can be applied to the total synthesis of gabazine 18, achieved in just four steps from 
dichloropyridazine 29, where three of the four reactions were accelerated by 
microwave irradiation (Scheme 1.9). In their synthesis, the deprotection of the ethyl 
ester 38 is achieved using basic conditions.
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Scheme 1.9 
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1.2 Introduction to Photoaffinity Labelling 
1.2.1 Photoaffinity Labelling 
Photoaffinity labelling is a biochemical method that has been exploited in the 
analysis of many biological systems.
101
 
Often, photoaffinity probes consist of two parts.
102
 The first part, the photoaffinity 
label, forms a covalent bond between the probe and target molecule, through 
photoirradiation. Photoaffinity labels absorb radiation and subsequently form a 
highly reactive species. These reactive intermediates are then able to undergo largely 
non-specific reactions (e.g. C-H or X-H insertion reactions) with adjacent residues to 
form cross-linked products that are covalently bound to one another.
103
 In this way, 
useful information can be garnered about the environment that a particular molecule 
may reside in (Figure 1.19). Photoaffinity labels are often introduced chemically, 
genetically or metabolically into target molecules.
104
 
 
Figure 1.19 – Photoaffinity labelling in structural elucidation 
The second part can be a detectable tag that is sometimes incorporated into a 
photoaffinity probe.
102
 One such method is through the incorporation of a radiolabel. 
Identification of products post-photolysis can necessitate a group that can be easily 
traced by spectroscopic methods; in this instance, a radioisotope labelled probe 
becomes a valuable tool in elucidation. Isotopes commonly used include 
3
H, 
14
C, 
32
P, 
35
S and 
125
I. Vitamin B7, also known as biotin 39, can also be employed as a 
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detectable tag, due to its high affinity to avidin, thus allowing immediate analysis or 
purification of labelled molecules (Figure 1.20).
105-107
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Figure 1.20 
Several photoaffinity labels have been used extensively in biology. The three 
discussed in detail in this chapter, the aryl azide, benzophenone and aryl diazirine, 
are among the most commonly used. 
1.2.2 Aryl Azides  
Aryl azides 40 can be photoactivated to nitrenes 41 by wavelengths ranging from 
250 to 400 nm (Scheme 1.10).
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Scheme 1.10 
The label is synthetically small and is in common use due, in part, to the relatively 
simple synthesis. Upon photoactivation, the aryl azide loses dinitrogen to become a 
highly reactive nitrene 41. Aryl azides are most commonly photoactivated beneath 
350 nm. The potentially high-energy radiation required to form nitrenes can hamper 
the environment of a photoaffinity probe, as proteins and biomolecules can be 
damaged by the low-wavelength irradiation.
103
 
Originally, it was thought that reactions took place solely via the nitrene; however, it 
is now known that this intermediate is rather short-lived. A rapid intramolecular ring 
expansion of 41 is able to give the azacycloheptatetraene 42 which is highly 
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electrophilic in nature. It is thought that 42 is able to react with neighbouring 
nucleophilic residues. 42 is not able to insert into nonactivated C-H bonds, and as a 
result azacycloheptatetraenes are considered undesirable, as they are essentially less 
reactive than their nitrene precursors.
108-110
 
One strategy to limit the unfavorable conversion to 42 is to fluorinate positions on 
the neighbouring aryl group. Perfluorophenylazides 43 undergo the same 
photochemical conversions as aryl azides 40 but fluorine substitution greatly slows 
down the rate of ring expansion of perfluorophenylnitrene 44 to the corresponding 
azacycloheptatraene 45 (Scheme 1.11).
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Scheme 1.11 
The reactions of the photoactivated nitrene with an array of simple organic molecules 
are shown in Scheme 1.12. Reaction of nitrene 44 with secondary amines leads to 
hydrazines 47, whereas reaction with alkenes leads to aziridines 48.
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Scheme 1.12 
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Aryl azides can be simply synthesised from the corresponding aryl amine.
112
 The 
Sharpless group demonstrated that para-toluidine 49 can be converted to the 
corresponding azide 50 in excellent yield (Scheme 1.13).
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oC, then NaN3, NaOAc, 0 
oC, 95 %.  
Scheme 1.13 
Aryl azides 52 can also be formed from a corresponding boronic acid. Grimes et al. 
recently reported the copper(II)-catalysed formation of aryl azides by addition of 
sodium azide to arylboronic acids 51 (Scheme 1.14).
114
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Scheme 1.14 
1.2.2.1 Aryl azides in biological probes 
One instance where aryl azides have been employed as photoaffinity labels for 
receptor study was by Seidman and co-workers in their synthesis of the radiolabelled 
prazosin analogue, [
125
I]CP65526 55.
115
 Prazosin 53 is a high affinity "1-
adrenoceptor blocker used to treat high blood pressure. The synthesis of the analogue 
relies on the formation of an aryl amine precursor 54, which is simply converted to 
the desired azide 55 in the final step (Scheme 1.15). The resulting photoaffinity 
probe 55 was able to bind competitively to the "1-adrenoceptor prior to photolysis of 
the azide. Following photoactivation, Seidman et al. were able to demonstrate that 
the binding site of probe 55 was identical to that of prazosin 53. 55 was also recently 
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used as a research tool in competition assays with other drug molecules towards the 
eradication of HIV reservoirs in the brain.
116
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Scheme 1.15 
Blanton and co-workers were able to exploit the aryl azide photoaffinity label for the 
specific labelling of the nicotinic acetylcholine receptor, in the synthesis of the 
photoaffinity labelled ligand [
125
I]ASA-PS 57. This was achieved by incorporating 
an aryl azide into the structure of a known phospholipid, phosphatidylserine 56 
(Scheme 1.16). Subunits of the receptor that covalently incorporated the ligand could 
subsequently be mapped via a Staphylococcus aureus protease digestion. 
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Scheme 1.16 
Photoaffinity labelling has been used to probe the specific binding sites of numerous 
natural products.
118-121
 Strømgaard et al. were able to create photoaffinity labelled 
1. Introduction 
25 
 
analogues of terpenes from the Ginkgo genus, which are interesting synthetic targets 
because of their positive effects on a number of degenerative disorders including 
Alzheimer’s disease.
122
 The group incorporated a perfluorinated aryl azide 58 into 
Ginkgolide B 59 and Ginkgolide C 61 through Williamson ether syntheses, to give 
analogues 60 and 62 respectively (Scheme 1.17).
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Scheme 1.17 
Hosoya et al. were able to incorporate the aryl azide 63 through a Pd-mediated cross-
coupling reaction for the synthesis of a photoaffinity labelled dantrolene analogue 
64, a selective inhibitor of Ca
2+
 release from the sarcoplasmic reticulum (Scheme 
1.18). The benzylic azide in ligand 64 also allows for the possible incorporation of a 
detectable tag through a Staudinger ligation or the Cu-mediated azide-alkyne 
Huisgen cycloaddition. 
102
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Scheme 1.18 
1.2.3 Benzophenones 
Another class of photoaffinity labels are the benzophenones 65, which can be 
photoactivated by wavelengths usually ranging from 350 to 365 nm, depending on 
the substitution of the aryl groups (Scheme 1.19). 
h!
350-365 nm
65 66
R R
O O
 
Scheme 1.19 
The photolysis at these wavelengths actuates an n to #* transition, resulting in the 
formation of a triplet biradical 66, which is known to be effective at hydrogen 
abstraction.
124
 Benzophenones can be photoactivated in aqueous media, without the 
inconvenience of the label being quenched.
103
 An additional facet of the 
photoaffinity label is that benzophenones are able to fall back to their ground state, 
should they not find a partner to covalently attach to. The benzophenone can 
therefore be irradiated again to give the reactive biradical. Hence, ligands possessing 
benzophenone photoaffinity labels generally have a greater degree of covalent bond 
formation to their intended substrates compared to their aryl azide and aryl diazirine 
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analogues. This is due to their capacity to be repeatedly irradiated without 
irreversible breakdown of the probe to an unreactive form.
125
 
Although the benzophenone carries many advantages compared to its photolabel 
counterparts, the label is relatively large in size and incorporation of such a sizeable 
moiety can be detrimental to the binding affinity of a given ligand. In addition, the 
label can necessitate comparatively long photoirradiation times for tagging.
101
 
The reactions of the photoactivated biradical with an array of simple organic 
molecules are shown in Scheme 1.20. Exposure of 67 to simple alkanes leads to 
alcohol 68, reaction with alcohols leads to hemiketals 69. Contact of the biradical 67 
with alkenes is documented to leads to oxetane 70 in high yields.
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Scheme 1.20 
Benzophenones are usually synthesised via the Friedel-Crafts acylation of a relevant 
benzoyl chloride with benzene, catalysed by aluminium trichloride (Scheme 1.21).
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Scheme 1.21 
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1.2.3.1 Benzophenones in biological probes 
Benzophenone substituted ligands have been used in the labelling of several 
targets
129
 including the angiotensin II receptor,
130, 131
 human luteinizing receptor 
subunits
132
 and the insulin receptor.
133
 Nakamoto and co-workers were able to label 
the parathyroid hormone receptor-binding site in 1995 by substituting amino acid 
residues on the hormone for photoaffinity labelled amino acid residues 72 and 73 
(Figure 1.21).
134, 135
 Suva et al. subsequently incorporated 72 in analogues of the 
hormone calcitonin in order to label the calcitonin receptor.
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Figure 1.21 
In 2003, Zhang et al. synthesised HIV-1 integrase inhibitors containing 
benzophenones for studying enzyme interactions. In their synthesis of inhibitor 75, 
benzophenone 74 is introduced to the core structure through a Williamson ether 
synthesis (Scheme 1.22). While the photoaffinity labelled nature of the ligand was 
not explored, 75 was found to inhibit integrase activities in low micromolar 
ranges.
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Scheme 1.22 
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Bringmann and co-workers introduced benzophenone 74 in a similar fashion, for the 
synthesis of a photoactivatable, fluorescently labelled naphthylisoquinoline alkaloids 
76, which exhibit strong antiplasmodial activities (Scheme 1.23). Pharmacological 
and microscopic investigations were carried out by the group in order to examine the 
distribution of 76 within Plasmodium-infected red blood cells.
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Scheme 1.23 
More recently, the benzophenone photoaffinity label has also been used to tag 
Ginkgolide A 77 (Figure 1.22). Advancing the previous work mentioned by 
Strømgaard, Kato et al. were interested in probing the mode of action of the 
Ginkgolide family with biological receptors. They were able to create probe 78, 
which incorporated a biotin moiety via the photoaffinity label to the core natural 
product. Probe 78 could also be used for the discovery of novel Ginkgolide binding 
sites.
139
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Figure 1.22 
In the aforementioned example, probe 78 possesses a photoaffinity label which is 
substituted on both phenyl groups, yet this substitution does not alter the efficiency 
of covalent bond formation. The alkyne is introduced via a Pd-mediated Sonogashira 
coupling. 
A boronic acid derivative 79 of the benzophenone has been synthesised by the Jones 
group (Scheme 1.24).
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Scheme 1.24 
However, the potential of this compound was not demonstrated in a Pd cross-
coupling reaction. Instead, 79 was used to label the active site of a chemically 
modified enzyme. Nevertheless, the application of the benzophenone boronic acid in 
cross-coupling reactions has since been capitalised on by several research groups.
141-
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145
 In 2010, the Houpis group demonstrated the Pd-mediated coupling of an aryl 
chloride 80 with boronic acid 79 to give pyridine 81 (Scheme 1.25).
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Scheme 1.25 
Benzophenone 79 has also been utilised in copper(II)-mediated cross-coupling 
reactions for the synthesis of enterovirus inhibitors. Aguado et al. were able to 
synthesise arylpurine 83 through the Cu-catalysed reaction of purine 82 and 
benzophenone 79 (Scheme 1.26). The photoaffinity labelled nature of inhibitor 83 
was not further explored, but such an inhibitor could be used for mapping novel 
binding sites.
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Scheme 1.26 
1.2.4 Aryl Diazirines 
Aryl diazirines are the final class of photoaffinity labels discussed in this chapter. 
Aryl diazirines 84 can be photoactivated to a reactive carbene 85 by wavelengths 
around 360 nm and like the aryl azide photoaffinity label, upon photoactivation these 
labels lose dinitrogen (Scheme 1.27).
147
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Scheme 1.27 
The generated carbenes 85 will insert into any C-H bond in the vicinity. The reactive 
intermediate is able to form cross-links to biomolecules with rapid photoirradiation 
times. However, the photolysis of 3-aryl diazirines can result in diazo isomerisation, 
presenting unwanted intermediates.
103
 This unfortunate circumstance can be quelled 
by the attachment of a flanking trifluoromethyl group, resulting in the 
trifluoromethylaryl diazirine 86 (Scheme 1.28).
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Scheme 1.28 
The presence of the adjacent trifluoromethyl group prevents the conversion of the 
active carbene 87 to undesired intermediates. The trifluoromethylaryl diazirine has 
been reported to have a remarkably high insertion efficiency, with insertion yields of 
more than 70 %.
149
 
The conversions of carbene 88 with a selection of simple organic molecules are 
depicted in Scheme 1.29. Reaction of 88 with alkanes leads to compounds 89, whilst 
exposure of 88 to alcohols leads to ethers 90. Reaction with alkenes leads to 
cyclopropanes 91.
103
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Scheme 1.29 
Although this photoaffinity label carries many advantages over those discussed 
already, use of the trifluoromethylaryl diazirine is fairly limited. A plausible reason 
for this could be the laborious synthesis required to install the photoaffinity label.
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Most syntheses of the three-membered diazirinyl ring entail a five-step synthesis 
from the corresponding aryl halide derivative (Scheme 1.30). 
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Scheme 1.30 
Lithium-halogen exchange of an aryl iodide 92 with ethyl trifluoroacetate or a 
Grignard reaction between an aryl bromide 93 and ethyl trifluoroacetate furnishes 
trifluoroacetophenone 94.
150,151
 Reaction with hydroxylamine hydrochloride and a 
base gives oxime 95. After tosylation to give 96, reaction with ammonia gives 
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diaziridine 97, which can be oxidised using iodine and a base to the desired 
photoaffinity label 98.
101
 
Work by Bender et al. details the synthesis to diazirinylbenzoic acid 106 (Scheme 
1.31).
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Scheme 1.31 
In this instance, 1,4-dibromobenzene 99 is the aryl halide precursor, and the 
synthesis of the diaziridine 100 is achieved in four steps in a manner similar to that 
described in Scheme 1.30. Following oxidation to diazirine 101, the diazirine does 
not undergo a metal-halogen exchange to the transmetallated species 102. n-BuLi 
results in nucleophilic attack on the diazirine ring, whilst no reaction is seen with 
freshly prepared magnesium. It has been suggested that this inactivity may be due to 
the diazirinyl nitrogens coordinating to an activated metal surface. Subsequently, it 
was found that treating the aryl diaziridine 100 with trimethylsilyl triflate gave the 
silylated diaziridine 103. Treating 103 with n-BuLi provides the lithiated 
intermediate 104, which can be reacted with excess carbon dioxide to give 
diaziridine 105. A final oxidation step gives the diazirinylbenzoic acid 106.
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Radiolabelled diazirinylbenzoic acid 108 can be created by reacting 103 with 
radiolabelled barium carbonate (a source of 
14
CO2). Diaziridinylbenzoic acid 107 can 
be readily oxidised to furnish 108 (Scheme 1.32).
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Scheme 1.32 
Synthetic routes have been described to a multitude of functionalised aryl diazirines 
but an accepted pitfall of this label is that a functional handle has to be incorporated 
very early in a synthesis. In 1994 however, Hatanaka et al. showed that the 3-
trifluoromethyldiazirinyl moiety was stable to a plethora of organic conversions. By 
creating a meta-methoxy substituted aryl diazirine 109, electrophilic aromatic 
substitution is greatly favoured at the 6-position, as a result of both the directing 
effects of the methoxy-group and the steric bulk of the trifluoromethyldiazirinyl 
group (Figure 1.23).
153
 In addition, the methoxy-group could be deprotected using 
boron tribromide to reveal the phenol. Transformations of 109 include Friedel-Crafts 
acylations and subsequent alkylations. Aryl diazirines can also be radioiodinated and 
tritiated via this method.
154
 
N CF3
N
O
Electrophilic aromatic substitution
Deprotection by BBr3 leaves 
site for functional handle
109
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In 2006, Nakashima et al. reported the direct formylation of the unsubstituted aryl 
diazirine 110 to give the formylated aryl diazirine 111 (Scheme 1.33). This can be 
further elaborated to the corresponding ester 112 with methanol and a strong acid, or 
reduced to the benzylic alcohol 113 by sodium borohydride. Benzylic alcohol 113 
can be easily converted to the benzyl bromide 114 via the Appel reaction.
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Scheme 1.33 
Flexibility can be introduced from the formylated aryl diazirine 111, through a 
Wittig reaction to give alkene 115. The alkene can then be reduced using 
Wilkinson’s catalyst to give 116 (Scheme 1.34).
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Scheme 1.34 
1.2.4.1 Aryl diazirines in biological probes 
Diazirine 108 has been used in studies to locate binding sites on various ATPases. 
Malfunctioning ATPases are implicated in a variety of disorders including 
osteoporosis and male infertility. Bender et al. developed a simple coupling reaction 
between the acidic moiety on photoaffinity label 108 and an alcohol group on the V-
ATPase inhibitor Bafilomycin A1 117 to create probe 118 (Scheme 1.35).
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Scheme 1.35 
Bentz and co-workers were able to create an aryl diazirine-labelled pyroglutamate 
120 for the purpose of amassing binding site information on excitatory amino acid 
receptors. Employing the methods hitherto described by Hatanaka et al., the group 
used a para-methoxy moiety on aryl diazirine 109 as a directing group to introduce 
the benzyl bromide functionality in aryl diazirine 119 (Scheme 1.36).
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Scheme 1.36 
It has been suggested in the literature that diazirines might be sensitive to palladium 
catalysis.
158, 159
 Nonetheless, an iodide derivative 121 has been utilised in some Pd-
mediated conversions. In 1998, Topin et al. reported the use of aryl diazirine 121 in a 
cross-coupling reaction to give a labelled nucleoside analogue 122 (Scheme 1.37). 
One of the drawbacks of this reaction is that a stoichiometric amount of catalyst was 
used.
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Scheme 1.37 
More recently, aryl diazirine 121 was employed in a Heck reaction to give another 
labelled nucleoside analogue 124.
161
 By incorporating the aryl diazirine directly onto 
the ribose, DNA was effectively labelled intrahelically (Scheme 1.38), whereas other 
research groups had only managed to label DNA extrahelically using diazirines.
162-
164
 The reaction conditions suggest the diazirine motif is able to withstand mild 
heating for prolonged periods, without undergoing degradation. Ribose 123 is 
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deprotected by TBAF before reduction by Na(OAc)3BH, exhibiting the resistance of 
the diazirine to mild reducing conditions. 
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Scheme 1.38 
In 2007, Luo et al. used diazirine 121 in a Suzuki-Miyaura cross-coupling reaction to 
create a photoaffinity labelled ATP competitive inhibitor 125 possessing low 
nanomolar affinity (Scheme 1.39).
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Scheme 1.39 
Although no boronic acid analogue of the aryl diazirine has been reported, many of 
these reactions show that aryl diazirines are stable to metal-mediated catalysis.  
1.2.5 Photoaffinity based probes for the GABAA receptor 
Multiple photoaffinity-based probes have been synthesised in order to locate various 
binding sites on the GABAA receptor. In 2003, Sammelson and Casida were able to 
create a diazirine labelled probe 127 based on the insecticide Fipronil 126 (Figure 
1.24). The probe non-competitively blocks the GABAA receptor by binding to an 
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allosteric site. Neither 126 nor 127 are selective, and both also bind to glutamate-
gated Cl
-
 channels, limiting their use as research tools with the sole purpose of 
blocking the GABAA receptor.
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Figure 1.24 
Husain et al. synthesised photoaffinity based probes in order to locate an anaesthetic 
binding site on the GABAA receptor. Etomidate 128 is a modulator of the GABAA 
receptor and an enhanced GABA-induced current is observed at receptors carrying 
either a $2 or $3 subunit.
167, 168
 Despite the incorporation of a photoaffinity label in 
probes 129 and 130 resulting in more sizeable analogues, both analogues remain 
potent general anaesthetics (Figure 1.25). 
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Figure 1.25 
An esoteric instance of photoaffinity labelling is observed with two hitherto 
discussed agonists. Muscimol 4 and thiomuscimol 5 have both been exploited as a 
photoaffinity labelled agonists with moderate success.
169
 When 4 is irradiated with 
ultraviolet radiation, N-O bond cleavage results in the formation of a reactive 
intermediate 131, which is able to irreversibly bind to the receptor (Scheme 1.40). 
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Thiomuscimol is regarded more useful as a photoaffinity labelled agonist, since it 
absorbs UV light at a higher wavelength than muscimol, desirable for in vivo systems 
where high energy irradiation damages cells and proteins.
170, 171
 Tritiated analogues 
of thiomuscimol may also be useful for studying the localisation of receptors.
170, 172
 
1.2.6 Photochemically inactivating receptors using photoactivatable 
antagonists 
While the principal use of photoaffinity labelling has traditionally been to acquire 
structural information about a particular binding site, some groups have used the 
concept as a way of blocking certain biological processes. Chambers and co-workers 
for example, pioneered a novel method of tracking receptors in vivo. Populations of 
glutamate receptors can be deactivated by the addition of photochemically reactive 
antagonists. AMPA receptors are a major type of ionotropic glutamate receptor 
found in the brain, where they are responsible for fast excitatory neurotransmission. 
The method of deactivation involves the modification of a known antagonist, DNQX 
132, by the substitution of a nitro group for an azide moiety, forming ANQX 133 
(Figure 1.26).  
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Figure 1.26 
Upon photoactivation, an active nitrene is formed, which is able to insert into the 
amino acid side chains of the protein to which it is bound. Since 133 is a competitive 
antagonist at the AMPA receptor, when irradiated the compound binds to the 
receptor irreversibly and renders the receptor inactive.
44
 Synaptic currents can be 
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recorded to measure the rate of AMPA receptor insertion at the cell membrane in 
tandem with the photoactivation of 133. By electrophysiological patch-clamp 
recording, receptors that have been inactivated can be distinguished from those that 
remain active. Recording of synaptic currents requires a patch-clamp configuration 
with a UV light source as described by England.
45
 
Furthermore, photoaffinity labelling has been used to probe the localisation and 
function of GABAB receptors. In this instance, an aryl diazirine is linked to a known 
antagonist. A fluorophore, BODIPY, is then installed by virtue of a copper-catalysed 
[3+2] azide-alkyne cycloaddition, to give a photoaffinity and fluorophore labelled 
probe 134 (Figure 1.27).
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Figure 1.27 – Photoaffinity probe for the GABAB receptor 
1.3 Summary 
A brief overview of the GABAA receptor and photoaffinity labelling has been given 
in this chapter.  
Firstly, the concept of neurotransmission was introduced and an overview of the 
neurotransmitter GABA and its role in the mammalian CNS was given. Along with 
this, several classes of compounds have been discussed, demonstrating the vast array 
of compounds able to interact with the receptor.  
Secondly, a number of commonly used photoaffinity labels have been discussed in 
detail, stating their respective advantages and disadvantages. Each photoaffinity label 
was then linked to examples in the literature, highlighting the ease of incorporation 
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of various photoaffinity labels into a multitude of ligands, including natural products. 
Additionally, some examples have described a photoaffinity label incorporated 
directly onto a known antagonist. 
Leading on from observations made in the literature, chapter two discusses our 
efforts to create a lead compound for the GABAA receptor, and also our efforts to 
incorporate a photoaffinity label into the core antagonist structure. Using the 
methodology developed by Chambers et al. we eventually hope to be able to knock 
out GABAA receptors in vivo, using a suitably labelled antagonist. As mentioned, the 
cycling of receptors is thought to be significant for the efficacy of synaptic 
inhibition. To extract further information regarding the mobility of GABAA receptor 
subunits and their life cycle requires the development of a traceable molecule that 
will affect function irreversibly. This project aims to create several gabazine 
analogues to probe the mobility of GABAA receptors in the mammalian CNS. 
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2 Results and Discussion 
2.1 Aim 
This project aims to create gabazine analogues to probe the mobility of GABAA 
receptors in the mammalian CNS. In order to track the movement of native receptors, 
a tag such as a photoaffinity labelled antagonist is required to covalently bind to the 
receptor in situ, thereby affecting its function. By using a set-up similar to that 
described by England in section 1.2.6, we hope to be able to track the movement of 
GABAA receptors in neurons.
44, 45
 As mentioned, gabazine 18 (Figure 2.1) is a 
selective, potent competitive antagonist for the GABAA receptor, making it an ideal 
candidate for the template molecule of our project. 
N N
O NH.HBr
O
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Gabazine 18
 
Figure 2.1 
Gabazine binds to the GABA binding site, thus preventing GABA from binding. It 
has been shown that the arylpyridazine core can be functionalised without causing a 
loss in selectivity, discussed in section 1.1.5.5.
70, 72
 By incorporating a photoaffinity 
label onto the core structure, we hope to create photoactivatable antagonists that 
upon irradiation irreversibly bind to the receptor, thus blocking its function (Figure 
2.2). 
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Figure 2.2 
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It was not known whether the addition of a photoaffinity label to the gabazine 
skeleton would diminish or enhance the potency and selectivity for the GABAA 
receptor. Our initial efforts focussed on the development of a lead compound, 
outlined in section 2.2.  
This lead compound replaced the photoaffinity label with a surrogate phenyl group, 
since the synthesis of some photolabels can be time consuming and expensive. Such 
an analogue would also help determine whether making a photolabelled derivative of 
the same compound would be worthwhile; we first wanted to check that the binding 
of new antagonists were retained through the incorporation of new aromatic groups. 
Any successful synthetic route to a lead compound would also be applicable to the 
syntheses of photolabelled derivatives. 
2.2 Lead compound synthesis 
2.2.1 Benzoyl ester antagonist 
We initially attempted to create the benzoyl ester antagonist 135 (Figure 2.3).  
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Figure 2.3 
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The retrosynthetic route to compound 135 is outlined in Scheme 2.1.  
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Scheme 2.1 
As shown in the retrosynthesis, 135 could be formed through the deprotection of 
ester 136. A potential site for a photoaffinity label could be introduced through the 
coupling of a benzoyl chloride and alcohol 137. N-Alkylation of arylpyridazines has 
been documented in the literature, and we felt that it was possible to follow the 
methods outlined previously for conversion of arylpyridazine 138 to 137. We 
planned the construction of the arylpyridazine core through the Suzuki-Miyaura 
coupling of chloropyridazine 32 and boronic acid 139. 
Our synthesis began by testing the feasibility of the Pd-mediated conversion of 
pyridazine 32 and boronic acid 140 (Scheme 2.2), replicating a reaction that had 
been documented in the literature.
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Scheme 2.2 
We initially chose to use conditions employed by Maes et al., but were disappointed 
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with the low yield of arylpyridazine 141 achieved from the reaction.
174
 An increase 
in catalyst loading and slight adjustment with the delicate ratio of the reagents 
however, led to a vast improvement in yield (Table 2.1).  
Entry Ratio of reagents (140 : 32) Catalyst/ mol % Duration/ h Yield 
i 1.5 : 1 3 20 26 % 
ii 1.1 : 1 5 8 35 % 
iii 1.5 : 1 5 10 76 % 
Table 2.1 
With these results, we proceeded to use our best conditions in our system (Scheme 
2.3). However, we were disappointed to find low yields, perhaps attributable to the 
naked alcohol of boronic acid 139. At this juncture, we investigated the use of 
microwave irradiation to see if we could enhance the poor yields. No change was 
observed when using our previous optimised conditions, but upon adopting 
microwave conditions employed by the Lin group, we observed a dramatic increase 
in yield (Table 2.2).
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Scheme 2.3 
Entry Ratio of reagents  
(139 : 32) 
Catalyst (mol %) Conditions Yield 
i 1.5 : 1 Pd(PPh3)4 (5) 10 h, 110 °C, toluene 33 % 
ii 1.5 : 1 Pd(PPh3)4 (5) 10 min, m/w irradiation, 
120 °C, toluene 
33 % 
iii 1.2 : 1 Pd(PPh3)2Cl2 (3) 10 min, m/w irradiation, 
120 °C, CH3CN/water 
(3:2) 
71 % 
Table 2.2 
2. Results and Discussion 
48 
 
Possible reasons for the observed increase in yield could be due to the use of an air 
stable catalyst or due to the increased polarity of the solvent system. A boronic acid 
possessing a polar substituent such as a methoxy- or hydroxy- group, such as 139, 
may benefit from a reaction conducted in a more polar medium, such as this. Lin et 
al. reported that a similar reaction conducted in a toluene/DMF mix severely 
diminishes the yield.
98
  
Since compound 136 includes two ester linkages, we thought it important to employ 
a mild method to facilitate the selective deprotection of just one ester. In addition, it 
was felt that upon eventual replacement of the phenyl group for a photoaffinity label 
such as an aryl diazirine, it would be unable to tolerate the strongly acidic 
deprotection conditions required to cleave an ethyl ester, as previously employed by 
Wermuth.
72
 Accordingly, two bromoesters with mild deprotection conditions were 
synthesised for use in our syntheses. We considered the formation of a tert-butyl 
ester and an allyl ester as being the most useful for our syntheses. The tert-butyl 
group can be deprotected using a mild acid at approximately pH 4, whilst an allyl 
group can be cleaved using a Pd catalyst and appropriate scavenger.  
The synthesis of ester 143 from acid 142 was achieved following methods described 
by Patel et al. (Scheme 2.4), through the synthesis of the mixed anhydride in situ, 
followed by displacement using tert-butanol.
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Scheme 2.4 
Similarly, the synthesis of allyl ester 145 was achieved following a procedure 
outlined by Gellerman and co-workers (Scheme 2.5), by reaction of the 
commercially available acyl chloride 144 with allyl alcohol.
177
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Scheme 2.5 
Attempted N-alkylation of 138 using the tert-butyl ester 143 was unsuccessful 
resulting in full recovery of both starting materials. N-Alkylation using the allyl ester 
145 gave the product 147, isolable by the precipitation of the reaction mixture 
(Scheme 2.6). It remains unclear as to why reaction with tert-butyl ester 143 does 
not lead to compound 146, but we did not dwell on the result due to the successful 
nature of the reaction with allyl ester 145. 
N N
NH2
HO
138
N N
NH.HBr
HO
146
O
O
N N
NH.HBr
HO
147
O
O
a b
Reagents and conditions: a) 143, DMF (8 h, 80 oC); b) 145, DMF (8 h, 80 oC), 76 %.  
Scheme 2.6 
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A mechanism for the N(2)-alkylation of arylpyridazines with bromoesters is outlined 
in Scheme 2.7. The neighbouring amine aids substitution of the pyridazine at the 
N(2) position. In systems that lack a neighbouring aromatic group, N(1)-alkylation 
sometimes results.
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Scheme 2.7 
Subsequent treatment of 147 with benzoyl chloride gave the protected target 
molecule 148 (Scheme 2.8). Despite isolation of the desired product, the reaction 
was particularly unreliable. We observed a mixture of products potentially 
originating through cross-reactivity of benzoyl chloride with the pyridazine moiety. 
Several recrystallisations were necessary in order to separate the desired product 
from unwanted side products. 
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Reagents and conditions: a) Benzoyl chloride, pyridine, DMF (5 h, 80 oC), 60 %.  
Scheme 2.8 
In an attempt to selectively deprotect the allyl ester 148, we adapted a method 
highlighted by Seki et al. using Pd(OAc)2 and triethylphosphite, with dimedone as a 
nucleophilic scavenger.
178
 A general mechanism for allyl ester deprotections 
mediated by palladium and a nucleophilic allyl scavenger are shown in Scheme 2.9.  
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Scheme 2.9 
Unfortunately, the allyl deprotection of compound 148 did not furnish the desired 
acid 135, but instead furnished compound 149 as both esters were cleaved (Scheme 
2.10).  
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Reagents and conditions: a) Pd(OAc)2, P(OEt)3, dimedone, 
NaHCO3, THF/H2O (1:1) (15 h, 35 
oC), 53%.  
Scheme 2.10 
Ultimately, our desire was to retry the reaction under anhydrous conditions as we felt 
that water may have acted as a nucleophile in the collapse of the benzoate fragment. 
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Another possible explanation for the loss of the benzoate group may be that it is also 
prone to deprotection by the conditions necessitated for the allyl deprotection. 
Alternatively, transesterification of acid 135 could also result in the formation of the 
acid 149.  
Attempts were made to reform allyl ester 148 using the methods outlined in Scheme 
2.8; however, these proved to be unreliable and temperamental in nature. As a result, 
we considered an alternative method to create allyl ester 148. Our subsequent efforts 
focussed on the synthesis of the pyridazine 150, which could consequently be N-
alkylated (Scheme 2.11).  
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Scheme 2.11 
Boronate ester 151 was prepared by protection of boronic acid 152 as the pinacol 
ester 153 followed by reaction with benzoyl chloride (Scheme 2.12). We believe that 
the relatively low yields in these reactions stem from the relative insolubility of 152 
and 153 in the solvent media. 
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Scheme 2.12 
Attempts were made to make the triaryl 150 via a Pd-mediated method (Scheme 
2.13). Unfortunately, preparation of the desired triaryl proved unsuccessful under 
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either standard Pd catalysis conditions, or our previously optimised conditions, 
resulting in complex reaction mixtures, possibly from transesterification of the 
boronate ester 151. 
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Reagents and conditions: a) 32, Pd(PPh3)4, Na2CO3, toluene, reflux; 
b) 32, Pd(PPh3)2Cl2, K2CO3, CH3CN/H2O (3:2), microwave (10 min, 120 
oC).  
Scheme 2.13 
Due to the capricious nature of the reactions undertaken and the challenges faced in 
selectively deprotecting an allylic ester in preference to a benzylic ester, an 
alternative target was pursued and efforts to form the benzoyl ester antagonist 135 
were abandoned. It was felt that the synthesis of an antagonist containing two ester 
functionalities was problematic, so following careful consideration we decided to 
pursue a revised target compound in order that this could be avoided. 
2.2.2 Benzyl ether antagonist  
Our revised target was the benzyl ether antagonist 154 shown in Figure 2.4.  
N N
O NH.HBr
O
OH
154
 
Figure 2.4 
We were intrigued by adopting a phenolic system, since we felt that a phenoxide 
system would be easier to functionalise than a benzylic alcohol, as in arylpyridazine 
138. In order to circumvent the problems encountered with selective ester 
deprotection, we decided that a possible site for incorporation of a photoaffinity label 
could be introduced through a Williamson ether synthesis with an appropriate benzyl 
iodide or bromide. Syntheses of photoaffinity labels containing such functionalities 
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has been reported and therefore, it was felt that the benzyl ether antagonist 154 
would be a suitable target. 
The retrosynthetic route to antagonist 154 is outlined in Scheme 2.14. 
N N
O NH.HBr
O
OH
N N
O NH.HBr
O
O
155
N N
O NH2
N N
ClB(OH)2HO NH2
154
156
158 32
Allyl deprotection
Williamson 
ether synthesis
N-alkylation
N N
HO NH2
Pd-mediated
Suzuki coupling
157
 
Scheme 2.14 
In the revised retrosynthesis, antagonist 154 could be formed through the 
deprotection of the allyl ester 155. The requisite site for a photoaffinity label on 
triaryl 156 could be introduced through the coupling of a benzyl bromide and 
arylpyridazine 157 via a Williamson ether synthesis. We planned to achieve the 
synthesis of arylpyridazine 157 through the optimised Suzuki-Miyaura coupling 
conditions obtained thus far. 
Optimised conditions were applied to the microwave coupling of chloropyridazine 
32 to boronic acid 158 (Scheme 2.15).  
B(OH)2HO +
N N
Cl NH2
32158
a
N N
HO NH2
Reagents and conditions: a) Pd(PPh3)2Cl2, K2CO3, CH3CN/H2O (3:2), 
microwave (10 min, 120 oC), 72 %.
157
 
Scheme 2.15 
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We were delighted with the high yield of the reaction. Interestingly, replicating the 
reaction thermally with analogous conditions failed to furnish any of the product.  
With arylpyridazine 157 in hand, our focus turned to the Williamson ether synthesis. 
It was anticipated that the nucleophilicity of the pyridazine amine might lead to a 
mixture of regioisomers, so with this in mind, we wanted to cleave the phenolic 
proton of arylpyridazine 157 to favour reaction at the resulting phenoxide. 
The coupling was attempted with two bases, caesium carbonate and sodium hydride 
(Scheme 2.16). Caesium carbonate can be an effective base for the reaction, but as 
noted, the reaction does not tolerate prolonged heating. With these promising initial 
results, we pursued the influence of using a stronger base in the reaction to remove 
the phenolic proton prior to reaction with benzyl bromide. Gratifyingly, we found 
that using sodium hydride enabled us to access pyridazine 156 in acceptable yield. 
Pyridazine 156 was isolated via both methods as summarised in Table 2.3.  
N N
HO NH2
157
various 
conditions
N N
O NH2
156
Reagents and conditions: a) Benzyl bromide, CsCO3 or NaH, DMF.  
Scheme 2.16 
Entry Base (eq.) Conditions Yield 
i Cs2CO3 (3) DMF, 50°C, 4 h 23% 
ii Cs2CO3 (3) DMF, 50°C, 8 h - 
iii NaH (1) DMF, 0°C, 2 h 41% 
Table 2.3 
N(2)-Alkylation of pyridazine 156 was achieved in good yield using the previously 
synthesised allyl-4-bromobutyrate 145 (Scheme 2.17). No other products were 
observed by TLC and no N(1)-alkylated product was isolated.  
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N N
O NH2
156
a
N N
O NH.HBr
155
O
O
Reagents and conditions: a) 145, DMF (16 h, 80 oC), 59 %.  
Scheme 2.17 
Finally, an allyl deprotection was necessary to remove the allyl group from 155 thus 
furnishing the desired model antagonist 154 (Scheme 2.18). We adopted conditions 
used by Seki et al., as detailed previously.  
N N
O NH.HBr
155
O
O
a
N N
O NH.HBr
154
O
OH
Reagents and conditions: a) Pd(OAc)2, P(OEt)3, THF/H2O (1:1) (17 h, 35 
oC), 56 %.  
Scheme 2.18 
We were delighted to note that the deprotection of the allyl ester proceeded without 
incident, thus affording the lead compound 154 in just four steps. NMR 
characterisation of the product proved difficult due to the insolubility of 154 in d6--
DMSO, d6-acetone, D2O, CD3OD, CD3CN and CDCl3. However, a 1:1 mix of CDCl3 
and CD3OD dissolved the compound. 
2.2.3 Biological Evaluation 
The potency of compound 154 was examined by our collaborators in the Smart 
group, using whole-cell patch clamp electrophysiology with recombinant "1$2%2S 
GABAA receptors transiently expressed in HEK293 cells.
182, 183
  
Patch clamp electrophysiology is a technique which allows the direct study of ion 
channels in cells.
184
 In our system, recombinant "1$2%2S GABAA receptors are 
expressed as they are the most abundant isoform of the receptor, and exist throughout 
the brain. Receptors are expressed in Human Embyronic Kidney 293 (HEK293) cells 
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which are widely used in receptor studies since they are readily transfected, simple to 
culture and lack innate GABAA receptors.
185-187
 Patch clamping can be used to record 
an electrophysiological output from single or multiple ion channels. For the 
construction of potency data of an antagonist, multiple ion channels are required and 
for this purpose, patch clamping is carried out on a whole cell. Typically, the potency 
of a compound can be expressed as the half maximal inhibitory concentration (IC50), 
which is described as the concentration of an antagonist required to inhibit a 
biological process by half. In order to work out the IC50 of compound 154 by patch 
clamp electrophysiology, one must first work out the half maximal effective 
concentration (EC50) of the endogenous ligand on a specific receptor isoform, in this 
case GABA. 
Through constructing concentration inhibition curves for antagonism of the response 
to EC50 GABA, the lower IC50 for 154 (IC50 = 11 nM) indicated a 32-fold increase in 
antagonist potency compared to gabazine 18 (IC50 = 349 nM), which is in accordance 
to literature values (Figure 2.5).  
N N
O NH.HBr
O
OH
N N
O NH.HBr
O
OH
Gabazine 18
IC50 = 349 nM IC50 = 11 nM
154
 
Figure 2.5 
While this project aimed to retain focus on creating photoaffinity labelled 
antagonists, further work was conducted by a Masters student, Ryan Ellwood, who 
concentrated on creating analogues of the benzyl ether antagonist 154. To this end, 
the meta-methoxy analogue 159 was synthesised. The relative potency of this 
compound was increased further (IC50 = 7 nM) compared to gabazine (Figure 2.6). 
Interestingly, installing an electron-withdrawing nitro-group in 160 even further 
enhanced antagonist potency (IC50 = 3 nM) (Figure 2.6).
188
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IC50 = 7 nM
159
N N
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O
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IC50 = 3 nM
160
O NO2
 
Figure 2.6 
The structure-activity relationships of these compounds are outlined in Table 2.4.  
N N
RO NH.HBr
O
OH
 
Figure 2.7 
Entry Compound IC50 /nM  Relative Potency 
i Gabazine 18 (R = CH3) 349 1 
ii 154 (R = C6H5CH2) 11 32 
iii 159 (R = m-MeOC6H4CH2) 7 50 
iv 160 (R = m-NO2C6H4CH2) 3 116 
Table 2.4 
Our findings indicate that there is significant scope to modify the gabazine skeleton 
on the alkoxy substituent and considerably enhance antagonist potency at the 
GABAA receptor (Figure 2.8). 
188
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Figure 2.8 – Concentration inhibition curves for analogues 154, 159 and 160. 
In another analogue 161 (Scheme 2.19), we were able to install a propargyloxy 
group in place of the methoxy group on 18, thereby creating an alternative diverse 
point of attachment for prospective labelling groups. 161 again showed an increased 
potency (IC50 = 40 nM; n=6) compared to gabazine.
188
 
N N
O NH.HBr
O
OH
IC50 = 40 nM
161
N N
HO NH2
Reagents and conditions: a) Propargyl bromide, sodium hydride, DMF (3 h, 0 °C), 71 %; 
b) allyl-4-bromobutyrate, DMF (5 h, 80 °C), 88 %; (c) Pd(PPh3)4, morpholine, 86 %.
157
a, b, c
 
Scheme 2.19 
We were able to demonstrate that alkyne 161 can be further elaborated via click 
chemistry. 161 was further converted into the triazole-containing antagonist 162 
through the Cu-mediated azide-alkyne Huisgen cycloaddition. Due to a low purity of 
the resultant compound, we did not obtain potency data on compound 162 (Scheme 
2.20).  
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N N
O NH.HBr
O
OH
161
N N
O NH.HBr
O
OH
162
Reagents and conditions: a) CuI, TMS-N3, DMF/CH3OH (9:1) (7 h, 100 °C), 22 %.
a
N
N
NH
 
Scheme 2.20 
In conclusion, we have demonstrated that by the simple addition of a benzyl group, 
the antagonist potency of arylpyridazine analogues of GABA can be greatly 
increased. This is exemplified by antagonist 154, where we observed a 32-fold 
increase in potency compared to gabazine. 
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2.3 Photoaffinity labelled antagonists 
Having developed the potent benzyl ether antagonist 154, we pursued the synthesis 
of benzyl ether antagonists 163. We were interested in creating photoaffinity labelled 
analogues that could block the function of the GABAA receptor permanently upon 
irradiation. Since each photoaffinity label possesses a different reactivity profile, we 
chose to create several analogues incorporating the three predominately used 
photolabels (aryl azide, benzophenone and aryl diazirine), discussed in section 1.2. 
Further to this, our desire was to establish which photoaffinity labelled analogue was 
able to block the function of the GABAA receptor most efficiently. 
We were also interested in targeting a set of directly labelled analogues 164. Other 
research groups have modified the methoxy- group of gabazine without observing a 
fluctuation in selectivity for the receptor.
72
 We felt that directly labelled analogues 
164 bore a significant structural resemblance to reported potent gabazine analogues, 
and thus we hoped that the synthesis of these additional photolabelled analogues 
would offer us the best chance of blocking the function of the GABAA receptor upon 
irradiation. Directly labelled analogues were also of methodological interest to us, as 
their syntheses would entail the synthesis of novel building blocks for photoaffinity 
label synthesis. Our general targets are illustrated in Figure 2.9. 
N N
O NH.HBr
O
OH
163
R
N N
R NH.HBr
O
OH
164
Benzyl ether analogues
Directly 
labelled analogues
(where R = N3 (azide), COPh (benzophenone), C(N)2CF3
 (diazirine))  
Figure 2.9 
2.3.1 Benzyl ether analogues 
This section outlines the strategies taken to synthesise photoaffinity labelled 
compounds based on the antagonist 154. Retrosyntheses of these compounds follow 
the same strategy outlined previously in Scheme 2.14. Our plan was to try and 
incorporate photoaffinity labels on the para-position of the benzyl group, since the 
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synthesis of para-substituted photoaffinity labels are thoroughly documented in the 
literature.
101, 123, 138, 152
 
2.3.1.1 Azide analogue 
We first addressed the synthesis of azide labelled antagonist 165 (Figure 2.10), due 
to the relatively straightforward synthesis of the azide component compared with an 
analogous diazirine constituent, and the relative small size of the photoaffinity label 
compared to a benzophenone.  
N N
O NH.HBr
O
OH
165
N3
 
Figure 2.10 
A straightforward synthesis of the appropriate benzyl bromide 166 was completed in 
two steps from commercially available para-toluidine 49. This was achieved through 
formation of the diazonium salt, followed by displacement with sodium azide to give 
intermediate 50, which was subjected to radical bromination by AIBN and N-
bromosuccinimide (Scheme 2.21).
189
 
NH2 N3 N3
Br
Reagents and conditions: a) NaNO2, HCl (2M, 5 min, -5 
oC); b) NaN3, NaOAc, 
H2O (2 h, 0 
oC), 86 % across two steps; c) AIBN, N-bromosuccinimide, 
benzene (8 h, 80 oC), 44 %.
a, b c
49 50 166
 
Scheme 2.21 
We proceeded to couple bromide 166 with arylpyridazine 157 in a Williamson ether 
synthesis. However, the product obtained appeared to be a multi-alkylated 
compound, isolation of which was not achieved, despite numerous attempts at 
purification by column chromatography (Scheme 2.22).  
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N N
HO NH2
157
a
Reagents and conditions: a) 166, NaH, DMF (2 h, 0 oC).
Complex mixture
 
Scheme 2.22 
We felt that a strong base was required in order to fully deprotonate the phenolic 
proton of the arylpyridazine prior to Williamson ether synthesis in order to ensure 
that reaction took place at the phenoxide rather than the nucleophilic amine. Due to 
the problems encountered with the use of sodium hydride, we investigated the use of 
potassium tert-butoxide. We were able to isolate the desired pyridazine 167, through 
a Williamson ether synthesis conducted under anhydrous conditions, in acceptable 
yield (Scheme 2.23). 
N N
HO NH2
157
a
N N
O NH2
167
Reagents and conditions: a) 166, potassium tert-butoxide, DMF (3 h, 0 oC), 38 %.
N3
 
Scheme 2.23 
Extraction of 167 during work-up was particularly difficult in this case, due to poor 
organic solubility of pyridazine 167. It should also be noted that longer reaction 
times led to the formation of further products, as observed by TLC. The best results 
were obtained through the slow addition of one equivalent of benzyl bromide 166 to 
a DMF solution of arylpyridazine 157 that had been deprotonated in situ at 0 °C by 
potassium tert-butoxide. 
Treatment of pyridazine 167 with allyl-4-bromobutyrate led to an unexpected result. 
We replicated reaction conditions used for the formation of ester 155, by heating the 
reaction mixture for 18 h in DMF. However, the prolonged heating was not tolerated 
well in this instance, and unexpectedly, we isolated the debenzylated compound 168 
(Scheme 2.24).  
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N N
O NH2
167
N3
a
N N
HO NH.HBr
O
O
168
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (18 h, 80 oC), 28 %.  
Scheme 2.24 
It is thought that the debenzylated compound 168 could have been formed through 
the elimination of the benzyl bromide. Cleavage of benzyl ethers has been reported 
in the presence of strong acids, and it is possible that a small amount of nucleophilic 
bromide is present in the reaction mixture. Figure 2.11 also demonstrates the 
influence that the para-substituted azide may have in the observed debenzylation.  
OR
N
N
N  
Figure 2.11 
 
Undeterred, we repeated the reaction with a decreased reaction time, hoping to avoid 
the undesired formation of 168. Pleasingly, ester 169 was isolated as the sole product 
from the reaction, in satisfactory yield (Scheme 2.25). 
N N
O NH2
167
N3
a
N N
O NH.HBr
O
O
169
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (6 h, 80 oC), 37 %.
N3
 
Scheme 2.25 
Finally, given the success of the Pd-mediated deprotection of the allyl ester in the 
synthesis of the lead compound 154, we chose to employ identical reaction 
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conditions for the conversion. However, we found that the parent ester 154 gave a 
complex mixture of inseparable products when subjected to these reaction conditions 
(Scheme 2.26). 
N N
O NH.HBr
O
O
169
N3
a
Complex mixture
Reagents and conditions: a) Pd(OAc)2, P(OEt)3, dimedone,
 THF/H2O (1:1) (17 h, 35 
oC).  
Scheme 2.26 
We sought to use an alternative protocol for the allyl deprotection as we felt that 
some of the problems may be attributable to lengthy reaction times, having observed 
debenzylation in the previously extended reaction. Through an alternative rapid 
protocol using Pd(PPh3)4 and morpholine as an allyl scavenger, the desired azide 
analogue 165 was cleanly afforded in excellent yield (Scheme 2.27).
190, 191
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O NH.HBr
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O
169
N3
a
N N
O NH.HBr
O
OH
165
N3
Reagents and conditions: a) Pd(PPh3)4, morpholine, THF/CH3OH (4:1) (30 min, rt), 94 %.  
Scheme 2.27 
In summary, the synthesis of the azide analogue 165 was concluded in six steps from 
commercially available para-toluidine 49. 
2.3.1.2 Benzophenone analogue 
We next chose to tackle the synthesis of a benzophenone labelled antagonist 170 
(Figure 2.12), due to its relatively facile preparation compared to the analogous 
diazirine labelled antagonist. Furthermore, the required benzophenone bromide is 
commercially available. 
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Figure 2.12 
 
Making use of the optimised conditions from the synthesis of the azide analogue, we 
employed potassium tert-butoxide as the base for the Williamson ether synthesis. 
Although low yielding, pyridazine 171 was cleanly isolated by column 
chromatography (Scheme 2.28). 
N N
HO NH2
157
a
N N
O NH2
171
Reagents and conditions: a) 4-(Bromomethyl)benzophenone, 
potassium tert-butoxide, DMF (3 h, 0 oC), 31 %.
O
 
Scheme 2.28 
We attempted to alkylate pyridazine 171 with allyl-4-bromobutyrate. Pleasingly, the 
desired ester 172 was isolated in a good yield as a single product from the reaction 
(Scheme 2.29). In this instance we observed no debenzylation, despite prolonged 
heating. 
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N N
O NH2
171O
a
N N
O NH.HBr
172O
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O
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (18 h, 80 oC), 60 %.  
Scheme 2.29 
Finally, the allyl group on ester 172 was successfully deprotected using Pd(PPh3)4 
and morpholine as described previously, to leave the desired benzophenone 
derivative 170 (Scheme 2.30).  
N N
O NH.HBr
172O
O
O
N N
O NH.HBr
170O
O
OH
a
Reagents and conditions: a) Pd(PPh3)4, morpholine, THF/CH3OH (4:1) (30 min, rt), 65 %.  
Scheme 2.30 
In summary, the synthesis of the benzophenone analogue 170 was conveniently 
completed in three steps from the commercially available 4-
(bromomethyl)benzophenone. 
2.3.1.3 Diazirine analogue 
In our final benzyl ether analogue, we hoped to attach a diazirine photolabel to form 
analogue 173 (Figure 2.13). However, the diazirine benzyl bromide component 114 
is not commercially available and demands a lengthy synthesis. 
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Figure 2.13 
Synthesis of the appropriate benzyl bromide required six steps from commercially 
available 4-bromotoluene 174. We embarked on the first four steps (Scheme 2.31), 
culminating in the synthesis of diaziridine 178. 
Br
O CF3 N CF3
HO
N CF3 CF3HN
NH
TsO
a b c d
Reagents and conditions: a) n-BuLi, ethyl trifluoroacetate, Et2O (5 h, -78 
oC), 38 %; 
b) hydroxylamine hydrochloride, pyridine (3 h, 70 oC), 99 %; c) p-TsCl, 
pyridine (18 h, 110 oC), 75 %; d) NH3, Et2O (8 h, -78 
oC), 88 %.
174 175 176 177 178
 
Scheme 2.31 
4–Bromotoluene undergoes a straightforward lithium-halogen exchange before 
conversion to the ketone 175. Accounts in the literature often purify this compound 
via distillation, however it was found that the reaction could be suitably purified by 
column chromatography.
150
 A mixture of oximes 176 resulted, as expected from 
literature precedent, when the parent ketone 175 was reacted with hydroxylamine 
hydrochloride. We continued to the next step with a 1:1 mixture of isomers where 
176 was reacted with para-toluenesulfonyl chloride to furnish the corresponding 
tosylate 177 in good yield. Finally, diaziridine 178 is formed through a low 
temperature reaction with ammonia, condensed into a sealed vessel at -78 °C, 
furnishing diaziridine 178 in excellent yield.  
Our attention then turned to forming the diazirine. Frustratingly, several attempts to 
oxidise diaziridine 178 to diazirine 179, following literature methods in methanol or 
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ethanol were unsuccessful. Diaziridine 178 was recovered in each case, despite the 
use of several freshly prepared oxidizing agents (Scheme 2.32).
101, 152, 160
 
CF3HN
NH
CF3N
N
a or b or c
Reagents and conditions: a) tert-Butyl hypochlorite, NEt3, EtOH (2 h, 0 
oC); b) I2, NEt3, 
MeOH (2 h, 0 oC); c) Ag2O, NEt3, MeOH (2 h, 0 
oC)
178 179
 
Scheme 2.32 
We then investigated a method used by Strømgaard and co-workers, which employed 
iodine in an aprotic chlorinated solvent to mediate the conversion.
123
 Using their 
procedure, diazirine 179 was isolated in good yield (Scheme 2.33).  
CF3HN
NH
CF3N
N
a
Reagents and conditions: a) I2, NEt3, CH2Cl2 (5 min, 0 
oC), 61 %.
178 179
 
Scheme 2.33 
We next attempted to brominate the tolyl position of diazirine 179 via radical 
bromination using AIBN and N-bromosuccinimide in CCl4.
123
 We successfully 
isolated bromide 114 in good yield (Scheme 2.34).  
CF3N
N
CF3N
N
a
Reagents and conditions: a) AIBN, N-bromosuccinimide, CCl4 (4 h, 70 
oC), 65 %.
Br
179 114
 
Scheme 2.34 
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One interesting point, which is rarely commented upon in the literature, is the 
volatility of both diazirine 179 and bromide 114 in this reaction. The volatility of 
both products necessitated that any concentration in vacuo must be conducted at low 
temperature, otherwise loss of bromide 114 under reduced pressure was observed. 
This may have led to the suppressed yields in reactions involving these reagents. 
Owing to the precious nature of the bromide we chose to react the compound with an 
excess of arylpyridazine 157. Additionally, we felt that it might be beneficial to add a 
crown ether to the reaction mixture to facilitate clean removal of the acidic proton 
prior to reaction. Crown ethers are often used in conjunction with bases in order to 
coordinate metal cations to the central cavity of a crown ether. For potassium bases, 
18-crown-6 is commonly used.
192-194
 To our delight, pyridazine 180 was afforded in 
good yield through using this adapted procedure (Scheme 2.35). 
N N
HO NH2
157
a
N N
O NH2
180
Reagents and conditions: a) 114, potassium tert-butoxide, 18-crown-6, 
DMF (3 h, 0 oC), 62 %.
CF3
N
N
 
Scheme 2.35 
Following on from this we attempted to N-alkylate the compound as previously 
described. However, under the strain of extended heating, we again isolated the 
debenzylated compound 168 (Scheme 2.36).  
N N
O NH2
180
a
N N
HO NH.HBr
O
O
168
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (19 h, 80 oC), 21 %.
CF3
N
N
 
Scheme 2.36 
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We predicted the conversion to ester 168 could again be alleviated through 
decreasing the exposure of reaction mixture to heating for long periods. As a 
compromise, we sacrificed the yield of the reaction for the purity of ester 181, which 
was isolated in moderate yield (Scheme 2.37). 
N N
O NH2
180
a
N N
O NH.HBr
O
O
181
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (5 h, 80 oC), 41 %.
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Scheme 2.37 
Our preferred method of deprotection using Pd(PPh3)4 and morpholine gave 
unfortunate results. After conducting the reaction, the desired compound could not 
be seen on TLC. This was a result of the excess morpholine used as the scavenger 
ligand. We postulated that the compound was left as the carboxylate species, which 
could not pass through the column without elution with acetic acid. An attempt to re-
acidify the compound with HCl in methanol, followed by a trituration with water to 
remove the morpholide salts was promising; however, instead of the desired 
antagonist we isolated the methyl ester 182 (Scheme 2.38). 
N N
O NH.HBr
O
O
181
Reagents and conditions: a) Pd(PPh3)4, morpholine, THF/CH3OH (4:1) (30 min, rt); 
b) HCl in MeOH (2M) (2 h, rt), 45 % over two steps.
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N
N
a, b
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Scheme 2.38 
Given this result, it was felt that the desired acid 173 could be isolated with work-up 
with either aqueous HCl or HCl in diethyl ether after Pd deprotection in order to 
avoid the esterification observed with methanol. However, we found that the 
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compound could not be isolated with either protocol and instead led to a complex 
mixture by NMR. (Scheme 2.39). 
N N
O NH.HBr
O
O
181
Reagents and conditions: a) Pd(PPh3)4, morpholine, THF/CH3OH (4:1) (30 min, rt); 
b) HCl in H2O (2M) (2 h, rt); c) HCl in Et2O (2M) (2 h, rt).
CF3
N
N
a,
 then b or c
Complex mixture
 
Scheme 2.39 
Deprotection of the allyl ester was also attempted using a classical acidic hydrolysis 
method outlined by the Wermuth group.
72
 While this led to removal of the allyl 
group, debenzylation of 181 also occurred to give acid 183 (Scheme 2.40). 
N N
O NH.HBr
O
O
181
Reagents and conditions: a) HBr, AcOH (18 h, 100 oC), 74 %.
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Scheme 2.40 
Since many of the problems with the allyl deprotection originated from the basic 
nature of the morpholine scavenger, we examined the literature for examples where 
acidic allyl scavengers had been used in allyl deprotections. In one report, acetic acid 
was used but when this protocol was adapted, only starting material was observed 
(Scheme 2.41).
195
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Scheme 2.41 
Finally, we tried 1,3-dimethylbarbituric acid, an alternative acidic scavenger that is 
commonly employed in allyl deprotections.
196-198
 To our delight, the synthesis of the 
diazirine analogue 173 was concluded in this way, with the final step achieved in 
good yield (Scheme 2.42). 
N N
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O
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Reagents and conditions: a) Pd(PPh3)4, 1,3-dimethylbarbituric acid, 
THF/CH3OH, (3 h, rt), 59 %.
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Scheme 2.42 
No degradation or reduction to an inactive diaziridine form was observed, hence we 
were able to demonstrate the stability of the diazirine moiety to palladium. The 
diazirine labelled antagonist 173 was therefore synthesised in nine steps from 
commercially available 4-bromotoluene 174.  
2.3.2 Directly labelled analogues 
Our efforts to create directly labelled analogues are discussed in this section. Directly 
labelled analogues 164 are depicted in Figure 2.14. We chose to target such 
compounds for two main reasons; firstly because other research groups have 
modified the methoxy- group of gabazine without observing a drop in selectivity
72
; 
and secondly, these targets are methodologically interesting, as they could entail the 
synthesis of novel building blocks for photoaffinity labelling.  
2. Results and Discussion 
74 
 
N N
R NH.HBr
O
OH
164
Directly 
labelled analogues
(where R = COPh (benzophenone), C(N)2CF3
 (diazirine))  
Figure 2.14 
Our general retrosynthetic route to compounds 164 is outlined in Scheme 2.43.  
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R NH.HBr
O
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Allyl deprotection
N-alkylation
Pd-mediated
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Scheme 2.43 
Acid 164 could be formed through the deprotection of ester 184. Ester 184 is formed 
through the reaction of arylpyridazine 185 and allyl-4-bromobutyrate. Synthesis of 
arylpyridazine 185 could be achieved through a Pd-mediated Suzuki-Miyaura 
coupling of chloropyridazine 32 and boronic acid 186. We believed that it would be 
possible to incorporate a photoaffinity label via a boronic acid. The benzophenone 
boronic acid already exists140, but an analogous diazirine analogue would demand 
formation of a novel diazirinyl boronic acid. We decided to abandon efforts to create 
an analogous azide analogue, due to our concerns over the high-energy irradiation 
required to activate such an analogue. Conditions such as these have been reported as 
being deleterious to cells.199 
2.3.2.1 Benzophenone analogue 
For our first analogue 187, we hoped to attach a benzophenone photolabel (Figure 
2.15).  
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Figure 2.15 
We intended to introduce the photoaffinity label via a Suzuki-Miyaura coupling 
between commercially available benzophenone boronic acid 188 and 
chloropyridazine 32. Our previously optimised conditions were applied to coupling 
(Scheme 2.44). We isolated the desired pyridazine 189 in good yield. 
O
B(OH)2
a
O
N N
NH2
Reagents and conditions: a) 32, Pd(PPh3)2Cl2, K2CO3, CH3CN/H2O (3:2), 
microwave (10 min, 120 oC), 61 %.
188 189
 
Scheme 2.44 
N-Alkylation was then carried out on pyridazine 189, following similar protocols to 
those described previously. We were able to isolate ester 190 as a single product 
from the reaction in excellent yield (Scheme 2.45). 
O
N N
NH2
189
a
O
N N
NH.HBr
190 O
O
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (18 h, 80 oC), 76 %.  
Scheme 2.45 
Finally, deprotection of the ester was carried out using similar conditions to those 
previously employed, culminating in excellent yield (Scheme 2.46). 
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Reagents and conditions: a) Pd(PPh3)4, morpholine, THF/CH3OH (4:1) (30 min, rt), 92 %.  
Scheme 2.46 
Gratifyingly, we were able to isolate the desired photoaffinity labelled antagonist 187 
in three steps. 
2.3.2.2 Diazirine analogue 
Our focus then shifted towards creating diazirine analogue 191 (Figure 2.16).  
N N
NH.HBr
191
OH
O
F3C
N
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Figure 2.16 
It was envisaged that the synthesis of 191 would require the creation of a novel 
diazirinyl boronic acid. We felt that such a chemical segment is missing from the 
chemist’s armoury, so in an effort to develop a new and unique way to incorporate 
the photoaffinity label, we sought to explore the synthesis of the boronic acid. 
Boronic acids possess many qualities that render them useful reagents in organic 
chemistry; in this case they could aid facile insertion of a complicated photoaffinity 
label via a relatively simple C-C bond forming reaction through a Pd-mediated 
procedure.  
Our planned synthesis of the boronic acid would necessitate the formation of 
diazirinyl aryl iodide 121, which could itself be synthesised from commercially 
available 1,4-diiodobenzene 192. We carried out the synthesis of iodide 192 
following a procedure outlined by Topin et al. (Scheme 2.47), which follows similar 
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methods to those described previously for the synthesis of the diazirine 179 (Scheme 
2.31 and Scheme 2.33).
160
 
I
I I I I I
O CF3 N CF3
HO
N CF3 CF3HN
NH
TsO
a b c d
Reagents and conditions: a) n-BuLi, ethyl trifluoroacetate, Et2O (18 h, -78 
oC), 41 %; 
b) hydroxylamine hydrochloride, pyridine, EtOH (4 h, 60 oC), 82 %; c) p-TsCl,
pyridine (18 h, 110 oC), 59 %; d) NH3, Et2O (8 h, -78 
oC), 48 %; 
e) I2, NEt3, CH2Cl2 (5 min, 0 
oC), 64 %.
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Scheme 2.47 
With iodide 121 in hand, we attempted to form the boronic acid 197. Our initial 
attempts focussed on the Pd-mediated substitution of a boronate ester prior to 
cleavage using acid. However all our initial attempts to create the boronate ester lead 
to complex mixtures by NMR and we were unable to retrieve any of the desired 
boronate ester. Nevertheless, we did observe small amounts of the homocoupled 
product 198, leading us to believe that we were forming the boronate ester (Scheme 
2.48).  
I
CF3N
N
121
CF3N
N
NF3C
N
B
CF3N
N
O O
a a
Reagents and conditions: a) Pd(dppf)Cl2, B2pin2, KOAc, DMSO (4 h, 80 
oC), 12 %.
198197
 
Scheme 2.48 
One explanation for the observation of the homocoupled product 198 is that as soon 
as the boronate ester 197 is formed, it couples to the aryl iodide 121 and undergoes a 
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Pd-mediated Suzuki-Miyaura coupling. It is possible that the labile nature of the 
iodide atom makes aryl iodide 121 an attractive partner for coupling to proceed with, 
in the presence of a Pd catalyst and base. Homocoupling of aryl bromides and aryl 
iodides has been reported in the literature upon when attempting to mediate the 
formation of the boronate ester with palladium.
200
 
Further attempts were made to create the boronic acid through a direct borylation of  
iodide 121. We had concerns about using this method, due to reports in the literature 
of the high sensitivity of the diazirinyl nitrogens to n-BuLi.
152
 Unfortunately, we 
observed a complex NMR profile suggesting that degradation of the parent iodide 
had indeed occurred (Scheme 2.49).  
I
CF3N
N
121
a
Complex mixture
Reagents and conditions: a) n-BuLi, B(OMe)3, THF (3 h, -78 
oC), then HCl (2M) (1 h, rt).  
Scheme 2.49 
At this point, due to promising results from our other analogues and the long route to 
creating the aryl bromide and aryl chloride diazirine derivatives, we halted our work 
on diazirine analogue 191. Literature reports do indicate that aryl chloride substrates 
may be superior precursors for boronic acids, in some cases circumventing the 
formation of homocoupled compounds.
201, 202
 We feel that the creation of a boronic 
acid is viable and our pertinent results thus far indicate a platform upon which to 
base future work in this area. 
2.3.3 Biological Evaluation 
The potency of compounds 165, 170, 173 and 187 (Figure 2.17) were examined by 
our collaborators using patch clamp electrophysiology with recombinant "1$2%2S 
GABAA receptors transiently expressed in HEK293 cells.
182, 183
 The potencies from 
inhibition curves and affinities from Schild analysis of these compounds are shown 
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in Table 2.5. 
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N N
NH.HBr
OH
O
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N N
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R
Benzophenone 
analogue 187
Benzyl ether analogues
 (R = N3 (165), COPh (170) 
or C(N)2CF3
 (173))  
Figure 2.17 
Entry GABA
A
 antagonist
 
IC
50
 /nM
 
K
i
 /nM
 
i 165 (R = N
3
) 28 ± 7 44 [34;57] 
ii 170 (R = COPh) 171 ± 34 153 [93;230] 
iii 173 (R = C(N)
2
CF
3
)
 
59 ± 5 132 [69;254] 
iv 187 233 ± 33 318 [190;475] 
Table 2.5 
As can be seen, the effect of a small photoaffinity label such as an azide in 165 
(Entry i, Table 2.5) or a diazirine in 173 (Entry iii, Table 2.5) has a slight effect on 
the potency of the respective compound, which could be attributed to the subtle 
changes in electronics of the compound as well as the additional steric bulk. 
Benzophenone analogue 170 (Entry ii, Table 2.5) was found to be less potent that 
any of the other analogues, but this could once again be attributed to a more 
significant steric bulk, or to the electron withdrawing nature of the arylketone. A 
significant drop in potency is observed with benzophenone analogue 187 (Entry iv, 
Table 2.5), which could arise from the loss of the ether functionality and 
introduction of an electron withdrawing ketone moiety. Reports in the literature have 
highlighted the importance of the electron donating oxygen atom in the structures of 
gabazine and another competitive antagonist bicuculline, and by removing this atom, 
it is possible that a reduction in affinity is induced.
81
 Nevertheless, it should be noted 
that benzophenone analogue 173 still possesses a greater affinity than the parent 
compound gabazine, adding gravitas to the notion that the presence of the ether 
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functionality is not the only way of creating a potent analogue. It is possible that the 
presence of an additional phenyl group may facilitate an increase in potency, as 
exemplified by the elevated potency of our compounds when compared to gabazine. 
Our collaborators then further investigated whether our photolabelled antagonists 
would effectively block the function of GABAA receptors in vitro. By irradiating 
each photoactivatable analogue in the presence of GABAA receptors, the synaptic 
block of receptors could be measured using patch-clamp electrophysiology. 
Irradiation was achieved using a Rapp Optoelectronic JML-C2 Xenon flashlamp 
system, with a 240-395 nm band-pass filter. The findings from these experiments are 
summarised in Table 2.6.  
Entry GABA
A
 antagonist
 
&max /nm Photolytic Block 
 
i 165 (R = N
3
) 313 29 ± 7% 
ii 170 (R = COPh) 303 49 ± 2% 
iii 173 (R = C(N)
2
CF
3
)
 
335 21 ± 5% 
iv 187 306 2 ± 4% 
Table 2.6 
In these experiments, patch clamp electrophysiology is used to record the membrane 
current from multiple ion channels on a whole cell. An EC50 concentration of GABA 
(10 µM) is applied to the cell and the postsynaptic current is measured, before the 
agonist is washed away. A high concentration of antagonist (10 µM) is then applied 
to the cell. UV radiation is then exposed to the cell via an optic fibre as 10 brief 
flashes (0.6 ms) every 20 seconds. Subsequent to this, any antagonist that has not 
covalently bound to the receptor is washed away for 5 minutes. The original 
concentration of GABA (10 µM) is then applied to the cell and the GABA current is 
recorded. The difference in GABA current prior to and after irradiation is referred to 
as the photolytic block, and this denotes the total percentage of GABAA receptors 
that have been inactivated on a whole cell following irradiation in the presence of a 
photoaffinity labelled antagonist.  
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As can be seen, no block of GABAA receptors is observed with benzophenone 
analogue 187 (Entry iv, Table 2.6) and a moderate block is observed from both the 
azide analogue 165 (Entry i, Table 2.6) and diazirine analogue 173 (Entry iii, Table 
2.6) analogues, whereas benzophenone analogue 170 (Entry ii, Table 2.6) blocks the 
receptor significantly, accounting for a 49% block of GABAA receptors (Figure 
2.18). No irreversible block is observed after UV exposure with gabazine 18, which 
lacks a photoaffinity label, shown in Figure 2.18.  
 
Figure 2.18 – Photoirradiation of 170 and Gabazine on GABAA receptors 
In this recombinant in vitro system, there is no mechanism by which the receptors 
can be replenished from an intracellular pool of GABAA receptors.
39
 If the GABA 
current is recorded over time, we observe no recovery to the pre-irradiation GABA 
current (Figure 2.19).  
 
Figure 2.19 – GABA activated current pre- and post-photoirradiation 
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Work is currently underway to test for photoinhibition of GABA currents in 
hippocampal neurons, where replenishment of receptors is believed to occur.
39
 In 
such a system, we could expect to see recovery of the GABA current following 
GABAA receptor block.  
In collaboration with the Topf group, computational studies have been used to give 
insights into how benzophenone analogue 170 binds to the GABAA receptor. 
Unfortunately, the crystal structure of the GABAA receptor has not been solved, so 
molecular modelling and docking studies rely heavily on sequence homology with 
the structurally similar nicotinic acetylcholine receptor (nAChR). With this in mind, 
we feel that key interactions indicated by docking experiments would need to be 
scrutinised further by mutagenesis. To this end, mutagenesis studies have 
commenced to investigate the pertinence of several key residues in binding as 
presented by the docking studies.  
Molecular modelling revealed that the benzophenone label of benzophenone 
analogue 170 could lie in a hydrophobic pocket between " and $ subunits in "1$2%2 
WT receptors, where the label can be excited (Figure 2.20). 
 
Figure 2.20 – Homology model of 170 within "1 and $2 subunits 
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We propose that the "1R84 and "1R119 residues may be involved in cation-# 
stacking interaction between the benzophenone and receptor. Both residues could 
also be involved in allowing radical recombination to occur after photoirradiation. 
Substitution of a less polar residue by mutagenesis may lead to a loss of this 
interaction, which in turn could lead the benzophenone analogue not being held as 
tightly in the binding site of the receptor. These considerations are currently under 
exploration by our collaborators in the Smart group. 
With this result in hand, the next step in our research was to track native receptors 
microscopically by labelling them with a fluorescent marker such as a quantum dot. 
In the following section, we describe our efforts towards creating an analogue for 
this goal. 
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2.4 Photoaffinity labelled probes for following receptor mobility 
The denouement of our research concerned efforts to create a gabazine analogue 
incorporating the most effective blocking photoaffinity label, i.e. a benzophenone, in 
addition to a fluorescent marker, enabling the tracing of receptor mobility 
microscopically. Quantum dots (QDs) are intensely fluorescent nanoparticles usually 
made from CdSe, encased in zinc sulfide. They hold many advantages over 
traditional dye molecules; principally that they do not suffer photobleaching, whilst 
possessing wide absorption bands yet narrow and distinct emission spectra.
203
 The 
attachment of a QD to a biomolecule is however problematic.
204
 To our knowledge, 
there are no instances where a QD has been used in tandem with photoaffinity 
labelling. Nevertheless, we felt that various approaches could be attempted in order 
to label the GABAA receptor. Three of the most relevant methods are outlined below. 
2.4.1 Methods of QD conjugation 
2.4.1.1 Direct attachment 
A direct link could be made between a given biomolecule and a QD. This approach 
has been applied to the tracking of GABAC receptors, where muscimol was directly 
tethered to a quantum dot via a polyethylene glycol (PEG) linker.
205, 206
 Through this 
method however, there is little control over the number of muscimol units per 
quantum dot, with some estimations suggesting that as many as 150 muscimol units 
may be bound to each QD. Therefore, a substantial concern of this method is that 
receptors are labelled non-specifically, and many receptors may be tethered to a 
single QD. 
2.4.1.2 Indirect attachment - Strain-promoted azide-alkyne coupling 
The Cu-mediated azide-alkyne Huisgen cycloaddition is widely used in 
bioconjugation but QD fluorescence is quenched in the presence of Cu.
207
 This 
outcome can be circumvented by reacting a strained alkyne with an azide (Scheme 
2.50).
208-211
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Scheme 2.50 
This method is essentially a two-step approach. One element could contain the 
reactive alkyne (usually the biomolecule), while a QD could be functionalised with 
azides. Azide-coated QD’s are not commercially available, however these could be 
synthesised from an amine-coated QD precursor. A significant drawback of this 
approach is that the reaction between azide and alkyne takes place over several 
hours, and for the tracking of GABAA receptors this would therefore be unsuitable. 
2.4.1.3 Indirect attachment - Streptavidin-biotin coupling 
The streptavidin-biotin non-covalent interaction is one of the most powerful non-
covalent interactions in nature. Streptavidin coated QD’s have been used by other 
groups for receptor mobility and are commercially available.
212, 213
 With this method, 
a biotinylated photoaffinity labelled ligand could be synthesised, and subsequently 
conjugated to a streptavidin coated QD. Compared to the strain-promoted azide-
alkyne coupling, the streptavidin-biotin coupling would be more suitable for the 
tracking of receptors, due to the accelerated rate of coupling between the two 
components and the rate of receptor mobility. 
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2.4.2 Photoaffinity probe design 
We felt that the streptavidin-biotin coupling was the strongest method to achieve 
specific labelling of GABAA receptors, due to the strong and expedient nature of the 
coupling between streptavidin and biotin. Moreover, the commercial availability of 
streptavidin-coated QDs meant that we could concentrate on creating a 
benzophenone analogue that would incorporate a biotin moiety. However, the 
attachment of biotin to the core antagonist structure necessitated a thorough 
investigation of the factors that could affect the compound’s labelling efficiency 
(Figure 2.21). 
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Figure 2.21 
Previous reports indicate that functionalisation on the pyridazine is poorly tolerated 
and significantly affects the high potency of gabazine related compounds.
72, 81, 83
 We 
were thus keen to avoid disturbing the two available positions on the pyridazine.
72
 
The ether functionality also plays a dual role; for the attachment of the 
benzophenone photoaffinity label, and as a hydrogen bond donor.
81
 Furthermore, 
from collaborative computational work, we were able to theorise that the bulk of the 
benzophenone photoaffinity label in analogue 170 lies in a hydrophobic pocket 
between " and $ subunits on the GABAA receptor (Figure 2.22).  
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Figure 2.22 – Proposed orientation of 170 within GABAA receptor binding site 
We were keen not to perturb the orientation of the photoaffinity label within this 
location, though a potential point of attachment for a biotin moiety was a position on 
the internal phenyl of the benzophenone. 
Given these considerations, we considered synthesising the photoaffinity probe 199 
shown in Figure 2.23. 
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Figure 2.23 
The biotin moiety would need to be placed sufficiently away from the receptor to 
facilitate coupling to streptavidin and we therefore envisioned that a spacer from the 
core antagonist structure to biotin would be required. It was envisaged that an 
ethylene glycol linker could be used for this purpose. An alkyne was chosen as the 
most appropriate way of attaching a linker for several reasons. Firstly, our 
computational modelling studies had shown that space exists for a linear linker at 
this location on the benzophenone (Figure 2.22). Secondly, alkyne-substituted 
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benzophenones have previously been used as effectively as photoaffinity labels 
without any detrimental effect on the cross-linking ability originating from the 
presence of a conjugated alkyne.
139
  
The preliminary retrosynthetic route to 199 is outlined in Scheme 2.51.  
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Scheme 2.51 
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We believed that acid 199 could be synthesised through the alkylation and 
subsequent deprotection of pyridazine 200, using identical procedures to those used 
for analogues previously described. Pyridazine 200 could be made by a coupling 
reaction between acid 201 and amine 202. Synthesis of the amine fragment 202 has 
been thoroughly documented in the literature
214-216
, whereas acid fragment 201 
required a novel synthetic route. Outlined below in Scheme 2.52 was our proposed 
path for creating acid 201. 
N N
NH2O
O
O
OH
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Williamson ether 
synthesis
O O
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Br
Pd-mediated 
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O
Br
Br
O
Br
Radical Bromination
Friedel-Crafts
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O
Cl
Br
O
HO
Br
203
204
205206207  
Scheme 2.52 
We proposed that acid 201 could be formed through a Williamson ether synthesis 
between bromide 203 and arylpyridazine 157, as routinely conducted in the 
syntheses of other analogues. The acid functionality can be introduced through a 
selective Sonogashira coupling between bromide 204 and 5-hexynoic acid. Bromide 
204 could be created through the radical bromination of the tolyl position on 
benzophenone 205. Benzophenone 205 is not commercially available, but its 
synthesis has been documented.
217
 Thus, we anticipated that benzophenone 205 
could be created through a Friedel-Crafts acylation of the corresponding acid 
chloride 206, itself easily synthesised from the acid 207. 
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We embarked upon the synthesis of benzophenone 205. Following conditions 
described by Ding et al. we were delighted to obtain benzophenone 205 in excellent 
yield. This was achieved through chlorination of acid 207 in refluxing SOCl2, 
followed immediately by Friedel-Crafts acylation of the resulting acid chloride 206 
in refluxing benzene, mediated by a catalytic amount of AlCl3 (Scheme 2.53).
217
 
O
Br
O
Cl
Br
O
HO
Br
205206207
a b
Reagents and conditions: a) SOCl2 (2 h, 80 
oC), quant.; 
b) AlCl3, benzene (2 h, 50 
oC), 98 %.  
Scheme 2.53 
The bromide 204 is formed through radical bromination of benzophenone 205 with 
N-bromosuccinimide and AIBN as a radical initiator. The low yield is in part a result 
of multiple bromination of the tolyl position, as well as difficulties encountered with 
purification by column chromatography due to benzophenones 204 and 205 
possessing similar retention factors (Scheme 2.54).
217
 
O
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O
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Br
Reagents and conditions: a) AIBN, N-Bromosuccinimide, CCl4 (17 h, 70 
oC), 27 %.  
Scheme 2.54 
Following this, we attempted to proceed with a Sonogashira coupling of bromide 204 
with 5-hexynoic acid. Unfortunately we were unable to isolate any of the desired 
acid 203 and instead obtained the amine 208. This was formed through the SN2 
displacement of the bromide on benzophenone 204, by diethylamine (Scheme 2.55). 
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Scheme 2.55 
We considered that the reaction would proceed cleanly in triethylamine, so attempted 
the Sonogashira coupling using this approach. Synthesis of the desired compound 
however was not achieved, instead isolating the alkyne 209 and the aldehyde 210 
(Scheme 2.56).  
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a
O
Br
O
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O
Reagents and conditions: a) 5-Hexynoic acid, Pd(PPh3)2Cl2, CuI, 
NEt3 (48 h, rt), 209, 31 %; 210, 9.5 %.
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Scheme 2.56 
Alkyne 209 is formed through the in situ deprotonation of 5-hexynoic acid, followed 
by the SN2 displacement of the bromide on benzophenone 204. Nevertheless, the 
isolation of aldehyde 210 is unusual. We propose that the triethylamine used may 
have been wet, in which case it is possible that the benzyl bromide could have been 
converted to the benzyl alcohol 211. Several reports have detailed the Pd
II
-catalysed 
formation of benzaldehydes from benzyl alcohols, and we believe that aldehyde 210 
may have been formed in this way (Scheme 2.57).
218, 219
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Scheme 2.57 
We hoped that the formation of alkyne 209 could be abated through the Sonogashira 
coupling of bromide 204 with an ester, which could subsequently be deprotected. 
Hence, we synthesised a tert-butyl ester, which can be deprotected using a mild acid 
at approximately pH 4.  
The synthesis of ester 213 was achieved via the synthesis of the mixed anhydride of 
5-hexynoic acid 212 in situ, followed by displacement using tert-butanol. However, 
the synthesis culminated in a very low yield, which we thought was due to the high 
volatility of the ester 213 (Scheme 2.58). 
O
O
OH
O
a
Reagents and conditions: a) t-BuOH, (CF3CO)2O, 
THF (16 h, -40 oC to rt), 6 %.
212 213
 
Scheme 2.58 
We considered that the volatility of ester 213 might be problematic in our planned 
Sonogashira coupling and envisaged that a bulkier ester might be beneficial for our 
syntheses. Accordingly, we synthesised the phenacyl ester, which is deprotected 
using copper in the presence of acetic acid.  
The synthesis of ester 214 was achieved via the in situ formation of phenacyl iodide 
from phenacyl chloride with tetrabutylammonium iodide, followed by SN2 
displacement of the iodide by 5-hexynoic acid. Ester 214 was isolated in acceptable 
yield (Scheme 2.59). 
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Scheme 2.59 
The Sonogashira coupling of ester 214 to bromide 204 was attempted. Unfortunately 
however, we obtained a complex mixture by NMR, containing none of the desired 
adduct (Scheme 2.60). 
O
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Complex mixture
Reagents and conditions: a) 214, Pd(PPh3)2Cl2, CuI, NEt3 (48 h, rt).  
Scheme 2.60 
We believe that the phenacyl ester may have been partially deprotected by the copper 
present in the reaction mixture, which is necessary for the Sonogashira coupling.  
Due to the difficulties encountered towards the synthesis of bromide 204, we altered 
our retrosynthesis so that a Sonogashira coupling could be attempted prior to 
bromide formation, with the aim of creating the ester 216. Outlined in Scheme 2.61 
is our revised retrosynthesis for the formation of bromide 215. 
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Scheme 2.61 
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We postulated that bromide 215 could be synthesised via the radical bromination of 
ester 216 with AIBN and N-bromosuccinimide. We predicted that potential cross-
reactivity of the alkyne with N-bromosuccinimide could be a problem, particularly as 
the formed tolyl radical would be in conjugation with the alkyne. Nevertheless, we 
hoped that we would be able to create bromide 215 in this way. Acid 217 could be 
synthesised via a Sonogashira coupling between 5-hexynoic acid and benzophenone 
205. 
Consequently, Sonogashira coupling of benzophenone 205 to 5-hexynoic acid was 
attempted using our previously favoured conditions. Acid 217 was isolated in 
acceptable yield. We then protected acid 217 with a tert-butyl group, using 
conditions adopted previously, affording ester 216 in reasonable yield (Scheme 
2.62). 
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b
Reagents and conditions: a) 5-Hexynoic acid, Pd(PPh3)2Cl2, CuI, 
HNEt2 (48 h, rt), 45 %; b) t-BuOH, (CF3CO)2O, THF (3 h, -40 
oC to rt), 47 %.  
Scheme 2.62 
Following from this, we attempted a radical bromination of ester 216, hoping to 
brominate on the tolyl position. However, the only product isolated from the reaction 
was the dibromoalkene 218 (Scheme 2.63). 
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Scheme 2.63 
The undesired product is likely to be the result of the displacement of a bromonium 
ion by nucleophilic bromide in the reaction mixture. (Scheme 2.64)  
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Scheme 2.64 
Unfortunately, we were not able to create the desired bromide 215 in this way. An 
alternative plan of action was then devised due to the complexity of trying to create 
bromide 203. We then considered arriving at acid 201 via the retrosynthetic pathway 
outlined in Scheme 2.65. 
N N
NH2O
O
O
OH
201
N N
NH2O
O
219
Br
Pd-mediated 
Sonogashira coupling
O
Br
Br
Williamson ether
synthesis
N N
NH2HO
157204  
Scheme 2.65 
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We proposed that acid 201 could be created through Sonogashira coupling of 
pyridazine 219 with 5-hexynoic acid. Pyridazine 219 could be synthesised via 
Williamson ether synthesis of bromide 204 with the previously synthesised 
arylpyridazine 157.  
Using bromide 204, we attempted a Williamson ether synthesis with arylpyridazine 
157, employing our favoured conditions from previous ether syntheses. We were 
delighted to obtain the desired pyridazine 219 in excellent yield (Scheme 2.66). 
N N
HO NH2
157
a
N N
O NH2
219
Reagents and conditions: a) 204, potassium tert-butoxide, 18-crown-6, 
DMF (3 h, 0 oC), 81 %.
O
Br
 
Scheme 2.66 
Sonogashira coupling of pyridazine 219 was attempted using our preferred 
conditions and the desired acid 201 was isolated in good yield (Scheme 2.67).  
N N
O NH2
219
O
Br
a
N N
O NH2
201
O
O
OH
Reagents and conditions: a) 5-Hexynoic acid, Pd(PPh3)2Cl2, CuI, HNEt2 (48 h, rt), 77 %.  
Scheme 2.67 
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Reproduction of the Sonogashira coupling was ineffectual under our optimised 
conditions, and we were not able to repeat this reaction successfully. Due to time 
constraints, this is an issue that remains to be addressed. Nevertheless, we continued 
our synthesis towards probe 199 with the isolated amount of acid 201. We 
discovered that acid 201 was very insoluble, possibly due to the compound 
preferring to exist as a zwitterion. Consequently, we were unable to obtain either 
1
H 
NMR or 
13
C NMR spectra for this compound, due to its insolubility in common 
deuterated solvents. The correct mass was obtained by mass spectrometry, and in 
order to definitively prove the isolation of acid 201, we decided to derivatise the 
compound with a simple amine, hoping to lower its polarity such that conclusive 
NMR spectra could be obtained.  
Accordingly, an amide coupling was attempted via the in situ generation of the NHS 
ester of acid 201 and 2-methoxyethylamine, mediated by diisopropylcarbodiimide 
hydrochloride. Pyridazine 220 was afforded in good yield (Scheme 2.68). 
N N
O NH2
201
O
O
OH
a
N N
O NH2
220
O
O
NH
O
Reagents and conditions: a) 2-Methoxyethylamine, N-hydroxysuccinimide,
 diisopropylcarbodiimide hydrochloride, DMF (3 h, rt), 60 %.  
Scheme 2.68 
With pyridazine 220 conclusively proven to be the product of the previous reaction, 
we sought to create the amine fragment 202 for coupling to acid 201. Amine 202 has 
been synthesised previously in the literature, so we followed those procedures 
outlined in our synthesis.
214-216
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We began with mono-Boc protection of diamine 221 to furnish the amine 222 in 
moderate yield (Scheme 2.69). 
H2N
O
O
NHBoc
a
H2N
O
O
NH2
Reagents and conditions: a) Di-tert-butyl-dicarbonate, CH2Cl2 (24 h, rt), 56 %.
221 222
 
Scheme 2.69 
We believe that the moderate yield can be accounted for by diamine 221 reacting 
twice with di-tert-butyl dicarbonate, hence leading to some doubly protected amine.  
Amide coupling of amine 222 to biotin, mediated by HBTU and N,N-
diisopropylethylamine (DIPEA) led to amine 223 in excellent yield. Subsequent 
treatment of amine 223 with trifluoroacetic acid led to the removal of the Boc group 
to reveal the desired amine 224, as the trifluoroacetate salt in quantitative yield 
(Scheme 2.70).
214-216
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Reagents and conditions: a) Biotin, HBTU, DIPEA, DMF (2 h, rt), 83 %;
b) TFA/CH2Cl2 (1:1) (3 h, rt), quant..
a
b
 
Scheme 2.70 
With acid fragment 201 and amine fragment 224 in hand, we attempted the coupling 
of the two reagents using standard amide coupling conditions, as previously 
employed. We isolated the desired pyridazine 200, but in a poor yield of 12% 
(Scheme 2.71).  
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Reagents and conditions: a) 224, HBTU, DIPEA, DMF (3 h, rt), 12 %.
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Scheme 2.71 
It is believed that the poor yield was attributable to the compound being sensitive to 
column chromatography, as we were only able to isolate a small amount of the 
desired compound pure.  
Intriguingly, by 
1
H NMR, one aromatic signal was missing in protic deuterated 
solvents. It was found that one pyridazine hydrogen, highlighted in Scheme 2.72, is 
readily exchangeable in this environment. The deuteration is not observed in DMSO.  
N N
O NH2
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O
NH O O NH
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H
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Scheme 2.72 
A tentative explanation for the apparent deuteration of the proton could be that the 
delivery of a deuterium is passed to the enamine by the neighbouring pendant chain.  
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Whilst the poor yield of the previous reaction remains to be addressed, we continued 
to the penultimate step of our synthesis. Treatment of pyridazine 200 with allyl-4-
bromobutyrate in DMF furnished the desired ester 225 through selective N(2)-
alkylation of the pyridazine (Scheme 2.73). 
N N
O NH2
200
O
O
NH O O NH
O
S
HN
NH
O
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H
a N N
O NH.HBr
225
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O
NH O O NH
O
S
HN
NH
O
H
H
O
O
Reagents and conditions: a) Allyl-4-bromobutyrate, DMF (5 h, 80 oC), 43 %.  
Scheme 2.73 
Deprotection of ester 225 was attempted with our favoured conditions for allyl 
deprotection, using Pd(PPh3)4 and 1,3-dimethylbarbituric acid as the allyl scavenger. 
However, treatment of ester 225 with this system led to complete degradation, 
resulting in a complex mixture by NMR. Analyses by LC-MS also failed to reveal 
the desired compound (Scheme 2.74). 
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Complex mixture
Reagents and conditions: a) Pd(PPh3)4, 1,3-dimethylbarbituric acid, 
THF/CH3OH, (3 h, rt).  
Scheme 2.74 
A plausible reason for the failure of the Pd-mediated deprotection method could be 
due to poisoning of the catalyst through the sulfur atom of biotin. Additionally, 
coordination of the ethylene glycol unit to the catalyst may contribute to its 
inactivity.  
Although other metal-mediated allyl deprotections have been reported
220
, we were 
concerned about the potential poisoning of catalysts. As a result, we chose to 
investigate a simple saponification method described by Gavande and co-workers.
100
 
To our delight, we were able to isolate compound 226 as the hydrochloride salt in 
acceptable yield (Scheme 2.75). 
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Reagents and conditions: a) NaOH, THF/H2O (1:1) (3 h, 50 
oC); 
b) HCl (0.1 M in H2O), 52 % over both steps  
Scheme 2.75 
As a result, we were able to isolate a small amount (2.6 mg) of the desired 
photoaffinity probe 226 across eight steps from the commercially available 3-bromo-
4-methylbenzoic acid 207. 
2.4.3 Biological Evaluation 
Our collaborators in the Smart group investigated the potency of compound 226 
using patch clamp electrophysiology with recombinant "1$2%2S GABAA receptors 
transiently expressed in HEK293 cells by our collaborators in the Smart group.
182, 183
 
Through construction of concentration inhibition curves for the response to EC50 
GABA, the IC50 for probe 226 was calculated as 1.49 µM (Figure 2.24), a nine-fold 
decrease in potency compared to the benzophenone analogue 170.  
 
Figure 2.24 – Concentration inhibition curve for probe 226 
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Our collaborators further investigated whether probe 226 would effectively block the 
function of GABAA receptors in vitro. The findings from these initial experiments 
are summarised in Table 2.7. 
Entry GABA
A
 antagonist
 
Photolytic Block 
 
i 226 32 ± 14% 
Table 2.7 
Due to the relatively small quantity of photoaffinity probe 226 synthesised, research 
examining the mobility of the GABAA receptor relies upon further synthesis. We 
have not been able to attempt the QD labelling of receptors due to the small amount 
of compound synthesised, but we have so far demonstrated that probe 226 blocks 
receptors in HEK cells.  
2.5 Conclusions and Future Work 
A number of GABAA antagonists based on the gabazine structure have been made 
for use as research tools for the receptor. We have demonstrated that by the simple 
addition of a benzyl group, the antagonist potency of arylpyridazine analogues of 
GABA can be greatly increased. This is exemplified by antagonist 154, where we 
observed a 32-fold increase in potency compared to gabazine (Figure 2.25). 
N N
O NH.HBr
O
OH
154
 
Figure 2.25 
Our preliminary findings also indicated that the inclusion of an electron-donating 
methoxy- group or an electron-withdrawing nitro- group on the meta-position of the 
benzyl ring (159 and 160 respectively) were not only tolerated but also enabled 
further increases in potency. Furthermore, we demonstrated that the presence of an 
additional benzyl group is not the only means of eliciting an increase in antagonist 
potency. In the case of 161, a propargyloxy group will suffice.
188
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In all, four photoaffinity labelled antagonists were created (Figure 2.26). Of these, 
the benzophenone analogue 170 was shown to block 49% of GABAA receptors in 
cultured HEK cells. Future work in this area will concentrate on the optimization of 
blocking GABAA receptors in vivo. 
O
N N
NH.HBr
OH
O
O
N N
NH.HBr
OH
O
R
Benzophenone 
analogue 187
Benzyl ether analogues
 (R = N3 (165), COPh (170) 
or C(N)2CF3
 (173))  
Figure 2.26 
The tools created are the first with the potential to irreversibly inactivate GABAA 
receptors in vivo, and avoid the need to use mutant receptors expressed in neurons. 
Receptor trafficking could potentially be probed in specific surface areas of a neuron 
with the use of spot illumination methods, whereby photolysis can be limited to 
defined areas of neurons.
221, 222
 It is also possible that some of the antagonists created 
thus far may be subtype specific. If this is the case, then the mobility of particular 
receptor subtypes could also be explored.  
2. Results and Discussion 
105 
 
We were able to create a benzophenone labelled photoaffinity probe 226 for the 
GABAA receptor (Figure 2.27).  
N N
NH.HClO
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NH O O NH
O
S
HN
NHH
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OH
 
Figure 2.27 
It is hoped that such a compound could be useful for exploring the spatial and 
temporal mobility of native GABAA receptors microscopically. Optimisation of 
receptor labelling studies may necessitate the synthesis of further photoaffinity 
probes, with variable tether lengths. Future work will therefore focus on the synthesis 
of analogues with variable PEG lengths.  
Unfortunately, we abandoned plans to create diazirine analogue 191 due to time 
constraints (Figure 2.28). 
N N
NH.HBr
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O
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Figure 2.28 
Attempts to create a diazirinyl boronic acid were fruitless, but we remain hopeful 
that a boronic acid could still be synthesised. If a diazirinyl boronic acid is unstable, 
we may have to consider a method by which to stabilise the compound. One such 
way, is through the creation of an air stable N-methyliminodiacetic acid (MIDA) 
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boronate of the diazirine. MIDA boronates promote the slow release of an unstable 
boronic acid, with impressive isolated cross-coupling yields from a series of unstable 
boronic acid precursors. Hence, the synthesis of a diazirinyl MIDA boronate 227 
could circumvent those problems encountered with the synthesis of the diazirinyl 
boronic acid (Figure 2.29).  
N CF3
N
B
O
O
O
O
MeN
227  
Figure 2.29 
Similarly, trifluoroborate salts have become fashionable as partners in Pd-mediated 
cross-couplings.
223-226
 This is in part due to their easy-to-handle nature and stability 
compared to their analogous boronic acids. Molander et al. recently established a 
one-pot procedure to generate trifluoroborates from their respective aryl chlorides.
201
 
This route could be compatible with a diazirinyl aryl chloride 228, where one could 
create potentially create trifluoroborate salt 229 (Scheme 2.76).  
N CF3
N
Cl
a, b
N CF3
N
BF3K
Reagents and conditions: a) Pd cat., XPhos, sodium tert-butoxide, 
diboronic acid, KOAc, EtOH (18 h, 80 oC); b) KHF2.
228 229
 
Scheme 2.76 
Finally, the synthesis of new photoaffinity labelled antagonists that could be used to 
probe the mobility of GABAA receptors may entail the synthesis of various 
analogues containing a muscimol or thiomuscimol backbone in place of the GABA 
backbone. Muscimol 4 and thiomuscimol 5 have been exploited as photoaffinity 
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labelled agonists, as discussed in section 1.2.5. Antagonists 21 and 22 were created 
by the Wermuth group, yet their use as photoaffinity labelled antagonists remain 
unexplored (Figure 2.30).
83
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Figure 2.30 
Future work in this area will concentrate on the synthesis of lead compound 
analogues such as analogues 230 and 231 depicted in Figure 2.31. 
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Figure 2.31 
If successful, the resulting analogues could be derivatised to furnish other 
photoaffinity probes for the GABAA receptor. 
3. Experimental Section 
108 
 
3 Experimental Section 
3.1 General Methods 
All reactions were carried out at atmospheric pressure with stirring unless otherwise 
stated. All reagents and solvents were purchased from suppliers and used without 
further purification unless otherwise stated. Anhydrous toluene and THF were 
obtained from an Anhydrous Engineering (USA) solvent system after drying over 
alumina granules or pellets. NBS was recrystallised from water prior to use. 
Reactions were monitored by TLC or 
1
H NMR as stated. TLC plates pre-coated with 
silica gel 60 F254 on aluminium (Merck KGaA) were used, being visualized by UV 
(254 or 365 nm) or chemical stain (KMnO4 or vanillin). Normal phase silica gel 
(BDH) was used for flash chromatography. 
1
H NMR and 
13
C NMR spectra were recorded at 500 MHz and 125 MHz 
respectively on a Bruker AMX500 at ambient temperature, unless otherwise stated; 
all chemical shifts were referenced to the residual proton impurity of the deuterated 
solvent. All spectra were recorded at 298 K. The multiplicity of the signal is 
indicated as s (singlet), d (doublet), t (triplet), dd (doublet of doublets), dt (doublet of 
triplets), quint (quintet) and m (multiplet); defined as all multipeak signals where 
overlap or complex coupling of signals makes definitive descriptions of peaks 
difficult. All peaks should be taken as sharp unless otherwise described. Coupling 
constants are defined as J given in Hz. Coupling constants are quoted in Hz to one 
decimal place. For NMR experiments, CDCl3 denotes deuterated (d
3
) chloroform, 
DMSO denotes deuterated (d
6
) dimethylsulfoxide, and CD3OD denotes deuterated 
(d
4
) methanol. Deuterated solvents were chosen according to the position of solvent 
peak in spectra and solubility of substrate. 
High and low resolution mass spectrometry was performed using a VG70 SE 
operating in modes CI, EI, ES and FAB. 
Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer 
operating in ATR mode. Melting points were measured with a Gallenkamp apparatus 
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and are uncorrected. Room temperature (rt) is defined as between 19-22 ºC. In vacuo 
is used to describe solvent removal by Büchi rotary evaporation between 20 ºC and 
60 ºC, at approximately 10 mmHg unless otherwise stated. The term ‘degassed’ 
refers to the process of removing O2 from a solution by bubbling Argon through a 
sealed vessel containing the solution prior to use. Microwave irradiation was carried 
out in a CEM 150W microwave reactor. 
3.2 Experimental Procedures 
6-(4-Methoxyphenyl)-pyridazin-3-ylamine
94
 (141)  
 
To a solution of 3-amino-6-chloropyridazine (50 mg, 0.386 mmol) in toluene (5 mL) 
was added 4-methoxybenzeneboronic acid (88 mg, 0.579 mmol), 
tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.019 mmol) and Na2CO3 (3 mL, 2 
M in H2O) then degassed at rt for 10 min. The reaction mixture was then heated to 
110 °C for 10 h. After cooling to rt, the solvent was removed in vacuo. EtOAc (20 
mL) was added and the mixture placed in an ultrasound bath for 10 min. The mixture 
was filtered, and the residue was washed with EtOAc (2 * 40 mL). The solvent was 
then removed in vacuo and the residue was purified by column chromatography 
(EtOAc) to give the pyridazine 141 (59 mg, 0.293 mmol, 76%) as a white solid. m.p. 
166-168 °C; lit. m.p.
94
 171 °C; Rf = 0.15 (EtOAc); IR +max (film)/cm
-1
 3460, 3104, 
1651, 1610, 1456; 
1
H NMR (DMSO, 500 MHz) ' 3.79 (3 H, s, OCH3), 6.45 (2 H, s, 
NH2), 6.83 (1 H, d, J 9.3, NH2CCH), 7.01 (2 H, d, J 7.3, CH3OCCH), 7.78 (1 H, d, J 
9.3, NH2CCHCH), 7.87 (2 H, d, J 7.3, CH3OCCHCH); 
13
C NMR (DMSO, 125 
MHz) ' 55.2 (CH3), 114.1 (CH), 114.7 (CH), 125.2 (CH), 126.7 (CH), 129.4 (C), 
149.6 (C), 159.2 (C), 159.6 (C); m/z (CI+) 201.0905 (M
+
, C11H11N3O requires 
201.0902). 
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[4-(6-Aminopyridazin-3-yl)-phenyl]-methanol (138) 
 
To a solution of 3-amino-6-chloropyridazine (50 mg, 0.386 mmol) in CH3CN (1.2 
mL) and water (0.8 mL) in a microwave vial was added 4-(hydroxymethyl)-
benzeneboronic acid (70 mg, 0.463 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (8.0 mg, 0.0115 mmol) and K2CO3 (80 mg, 0.579 mmol) consecutively. 
The resulting solution was degassed at rt for 5 min then subjected to microwave 
irradiation for 10 min at 120 °C. The mixture was diluted with water (50 mL) and 
extracted with EtOAc (3 * 100 mL), washed with brine (100 mL), dried (MgSO4) 
and concentrated in vacuo. The residue was subjected to column chromatography 
(EtOAc/CH3OH 19:1) to give the pyridazine 138 (55 mg, 0.273 mmol, 71%) as a 
white solid. m.p. 190-194 °C; Rf = 0.15 (EtOAc); IR +max (film)/cm
-1
 3423, 3133, 
1647, 1611, 1459; 
1
H NMR (CD3OD, 500 MHz) ' 4.65 (2 H, s, HOCH2), 6.45 (2 H, 
s, NH2), 7.00 (1 H, d, J 9.3, NH2CCH), 7.45 (1 H, d, J 7.3, HOCH2CCHCH), 7.78 (1 
H, d, J 9.3, NH2CCHCH), 7.86 (2 H, d, J 7.3, HOCH2CCH); 
13
C NMR (CD3OD, 125 
MHz) ' 64.8 (CH2), 117.4 (CH), 127.1 (CH), 128.3 (CH), 128.4 (CH), 137.0 (C), 
143.6 (C), 152.7 (C), 161.0 (C); m/z (CI+) 201.0911 (M
+
, C11H11N3O requires 
201.0902), 184 (50). 
tert-Butyl-4-bromobutyrate
175, 176
 (143) 
 
Trifluoroacetic anhydride (2.00 g, 9.52 mmol) was slowly added to a solution of 4-
bromobutyric acid (1.71 g, 10.2 mmol) in anhydrous THF (15 mL) at !40 °C and the 
resulting solution was stirred at !40 °C for 30 min. tert-Butyl alcohol (12.5 mL) was 
added to the solution, which was then warmed to rt and stirred for 16 h. The reaction 
mixture was poured onto a mixture of crushed ice and saturated NaHCO3 (25 mL). 
The product was extracted using EtOAc (50 mL) and the organic phase washed with 
water (50 mL), brine (50 mL), and dried (Na2SO4). The filtrate was concentrated in 
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vacuo to obtain an oil, dissolved in methyl tert-butyl ether (50 mL). The resulting 
solution was passed through a short pad of silica gel. The filtrate was concentrated in 
vacuo and dried under high vacuum to yield the ester 143 (1.19 g, 5.34 mmol, 56%) 
as a colourless oil.
 
IR +max (film)/cm
-1 
2995, 1732; 
1
H NMR (CDCl3, 500 MHz) ' 
1.42 (9H, s, CO2C(CH3)3), 2.10 (2 H, tt, J 7.2 and 6.5, BrCH2CH2), 2.37 (2 H, t, J 
7.2, BrCH2CH2CH2), 3.41 (2 H, t, J 6.5, BrCH2); 
13
C NMR (CDCl3, 125 MHz) ' 
28.2 (CH2), 28.3 (CH3), 32.9 (CH2), 33.8 (CH2), 63.7 (C), 172.3 (C=O); m/z (CI+) 
223.0339 (M+H, C8H16O2
79
Br requires 223.0334), 225 (100), 151 (100), 149 (100). 
Allyl-4-bromobutyrate
177
 (145)  
 
4-Bromobutyrylchloride (2.31 g, 12.5 mmol) was added dropwise to allyl alcohol 
(5.85 g, 101 mmol) at 0 °C over 2 h. After stirring at rt for a further 3 h, the solvent 
was removed in vacuo and the residue dissolved in CH2Cl2 (25 mL), washed with 
NaHCO3 (25 mL), brine (25 mL) and dried (Na2SO4). The filtrate was concentrated 
in vacuo and dried under high vacuum to yield the ester 145 (1.99 g, 9.61 mmol, 
77%) as a colourless oil. Rf = 0.75 (petrol/EtOAc 1:1); IR +max (film)/cm
-1
 2983, 
1774, 1737; 
1
H NMR (CDCl3, 500 MHz) ' 2.17 (2 H, tt, J 6.9 and 6.5, BrCH2CH2), 
2.51 (2 H, t, J 6.9, BrCH2CH2CH2), 3.44 (2 H, t, J 6.5, BrCH2), 4.57 (2 H, d, J 12.5, 
CO2CH2CHCH2), 5.21 (1 H, dd, J 10.4 and 1.3, CO2CH2CHCHH), 5.29 (1 H, dd, J 
17.3 and 1.3, CO2CH2CHCHH), 5.88 (1 H, m, CO2CH2CH); 
13
C NMR (CDCl3, 125 
MHz) ' 27.9 (CH2), 32.4 (CH2), 32.7 (CH2), 65.3 (CH2), 118.4 (CH2), 132.1 (CH), 
172.3 (C=O); m/z (CI+) 207.0024 (M+H, C7H12O2
79
Br requires 207.0021), 209 
(100), 151 (60), 149 (60), 127 (75). 
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1-(3-Allyloxycarbonylpropyl)-6-amino-3-(4-hydroxymethylphenyl)-
pyridazinium bromide (147) 
N N
NH.HBr
HO
O
O
 
To a solution of 3-amino-6-(4-hydroxymethylphenyl)pyridazine (100 mg, 0.497 
mmol) in DMF (0.3 mL) was added allyl-4-bromobutyrate (154 mg, 0.743 mmol). 
The solution was heated to 80 °C for 8 h. The hot solution was poured into EtOAc (6 
mL) to yield a solid, which was then isolated by filtration. The product was dried 
under high vacuum to give the ester 147 (155 mg, 0.379 mmol, 76%) as a white 
solid. m.p. degraded > 200 °C; Rf = 0.05 (EtOAc/CH3OH 9:1); IR +max (film)/cm
-1
 
3034, 1726, 1655, 1579, 1534; 
1
H NMR (CD3OD, 500 MHz) ' 2.27 (2 H, m, 
NCH2CH2), 2.62 (2 H, t, J 6.8, NCH2CH2CH2), 4.46-4.48 (4 H, m, NCH2 and 
CO2CH2CHCH2), 4.69 (2 H, s, HOCH2), 5.15 (1 H, dd, J 10.4 and 1.1, 
CO2CH2CHCHH), 5.23 (1 H, dd, J 17.1 and 1.1, CO2CH2CHCHH), 5.82 (1 H, m, 
CO2CH2CH), 7.53 (2 H, d, J 8.2, HOCH2CCHCH), 7.64 (1 H, d, J 9.3, NHCCH), 
7.97 (2 H, d, J 8.2, HOCH2CCH), 8.33 (1 H, d, J 9.3, NHCCHCH); 
13
C NMR 
(CD3OD, 125 MHz) ' 22.5 (CH2), 31.3 (CH2), 57.0 (CH2), 64.9 (CH2), 66.5 (CH2), 
118.6 (CH2), 126.9 (CH), 127.8 (CH), 128.5 (CH), 132.8 (CH), 133.0 (C), 133.4 
(CH), 146.4 (C), 152.1 (C), 154.2 (C), 174.0 (C=O); m/z (ES+) 327.1611 (M+H, 
C18H21N3O3 requires 327.1582), 200 (35). 
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1-(3-Allyloxycarbonylpropyl)-6-amino-3-(4-benzoyloxymethylphenyl)-
pyridazinium bromide (148) 
N N
NH.HBr
O
O
O
O
 
To a solution of 147 (53 mg, 0.130 mmol) and pyridine (10 mg, 0.130 mmol) in 
DMF (0.8 mL) at 80 °C, was added benzoyl chloride (18 mg, 0.130 mmol) and the 
reaction mixture was heated at 80 °C for 3 h. EtOAc (16 mL) was added to the hot 
solution to give a white solid. The solid was recrystallised from ethanol. The product 
was dried under high vacuum to give the ester 148 (40 mg, 0.078 mmol, 60%) as a 
white solid. m.p. degraded > 200 °C; Rf = 0.05 (EtOAc/CH3OH 9:1); IR +max 
(film)/cm
-1
 3030, 1726, 1720, 1647, 1560, 1531; 
1
H NMR (CD3OD, 500 MHz) ' 
2.25-2.28 (2 H, m, NCH2CH2), 2.61-2.63 (2 H, m, NCH2CH2CH2), 4.45-4.48 (4 H, 
m, NCH2 and CO2CH2CHCH2), 4.68 (2 H, s, OCH2), 5.15 (1 H, dd, J 10.2 and 1.3, 
CO2CH2CHCHH), 5.23 (1 H, dd, J 16.7 and 1.3, CO2CH2CHCHH), 5.82 (1 H, m, 
CO2CH2CH), 7.52 (2 H, d, J 8.2, OCH2CCHCH), 7.67 (1 H, d, J 9.3, NHCCH), 7.96 
(2 H, d, J 8.2, OCH2CCH), 8.13-8.15 (2 H, m, CO2CCHCHCH), 8.33 (1 H, d, J 9.3, 
NHCCHCH), 8.69 (1 H, t, J 7.5, CO2CCHCHCH), 8.90 (2 H, d, J 7.7, 
CO2CCHCHCH); 
13
C NMR (CD3OD, 125 MHz) ' 22.6 (CH2), 31.4 (CH2), 57.1 
(CH2), 64.5 (CH2), 66.5 (CH2), 118.8 (CH2), 127.0 (CH), 127.8 (CH), 128.6 (CH), 
128.9 (CH), 132.9 (CH), 133.0 (C), 133.5 (CH), 143.0 (CH), 146.4 (C), 148.1 (C), 
148.5 (CH), 152.0 (C), 154.2 (C), 174.0 (C=O), 174.9 (C=O); m/z (ES+) 431.1795 
(M+H, C25H25N3O4 requires 431.1845), 326 (30), 304 (40). 
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1-(3-Carboxypropyl)-6-amino-3-(4-hydroxymethylphenyl)-pyridazinium 
bromide (149) 
N N
NH.HBr
HO
O
OH
 
To a solution of NaHCO3 (11 mg, 0.130 mmol), and dimedone (11 mg, 0.078 mmol) 
in water (1 mL) was successively added THF (1 mL), triethyl phosphite (7.0 mg, 
0.043 mmol) and palladium(II) acetate (1.5 mg, 0.0089 mmol) under argon. After 
stirring for 3 min, 148 (40 mg, 0.078 mmol) was added and the mixture was stirred at 
35 °C for 15 h. The mixture was diluted with water (5 mL) and washed thoroughly 
with CH2Cl2 (3 * 15 mL). The aqueous phase was separated and evaporated in 
vacuo. The residue was purified by column chromatography (CHCl3/CH3OH 9:1) to 
give the acid 149 (15 mg, 0.042 mmol, 54%) as a white solid. m.p. degraded > 200 
°C; Rf = 0.05 (EtOAc/CH3OH 8:2); IR +max (film)/cm
-1
 3030, 1721, 1660, 1544; 
1
H 
NMR (CD3OD, 500 MHz) ' 2.14 (2 H, m, NCH2CH2), 2.34 (2 H, t, J 6.8, NCH2CH-
2CH2), 4.43 (4 H, t, J 6.8, NCH2), 4.67 (2 H, s, HOCH2), 7.54 (2 H, d, J 8.1, 
HOCH2CCHCH), 7.63 (1 H, d, J 9.1, NHCCH), 7.97 (2 H, d, J 8.1, HOCH2CCH), 
8.28 (1 H, d, J 9.1, NHCCHCH); 
13
C NMR (CD3OD, 125 MHz) ' 22.3 (CH2), 31.1 
(CH2), 56.4 (CH2), 64.9 (CH2), 128.0 (CH), 128.5 (CH), 132.6 (CH), 132.9 (C), 
133.2 (CH), 146.7 (C), 152.0 (C), 153.7 (C), 177.3 (C=O); m/z (ES+) 287.1268 
(M+H, C15H17N3O3 requires 287.1270), 200 (25). 
[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl] methanol (153) 
 
To a solution of 4-(hydroxymethyl)benzeneboronic acid (640 mg, 4.23 mmol) in 
Et2O (25 mL) was added pinacol (499 mg, 4.23 mmol) and stirred at rt for 6 h. The 
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solvent was removed in vacuo and the residue subjected to column chromatography 
(petrol/EtOAc 4:1) to give the boronate ester 153 (388 mg, 1.66 mmol, 39%) as a 
white solid. m.p. 90-93 °C; Rf = 0.80 (EtOAc); IR +max (film)/cm
-1
 3023, 1610; 
1
H 
NMR (DMSO, 500 MHz) ' 1.23 (12 H, s, 4 * CH3), 4.47 (2 H, d, J 5.7, HOCH2), 
5.26 (1 H, t, J 5.7, OH), 7.35 (2 H, d, J 8.0, BCCHCH), 7.65 (2 H, d, J 8.0, BCCH); 
13
C NMR (DMSO, 125 MHz) ' 24.6 (CH3), 62.7 (CH2), 83.5 (C), 125.7 (CH), 126.7 
(C), 134.3 (CH), 146.0 (C); m/z (EI) 234.1419 (M
+
, C13H19O3B requires 234.1422), 
135 (50). 
Benzoic acid 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl ester (151)  
 
To a solution of 153 (100 mg, 0.427 mmol) and pyridine (33 mg, 0.427 mmol) in 
Et2O (1 mL) was added benzoyl chloride (60 mg, 0.427 mmol). The reaction mixture 
was stirred at rt for 4 h. EtOAc (50 mL) was then added and the mixture was washed 
with water (50 mL) and dried (Na2SO4). The solvent was removed in vacuo and the 
residue was subjected to column chromatography (petrol/EtOAc 4:1) to give the 
boronate ester 151 (70 mg, 0.207 mmol, 48%) as a white solid. m.p. 60-63 °C; Rf = 
0.60 (petrol/EtOAc 1:1); IR +max (film)/cm
-1
 3031, 1727, 1603; 
1
H NMR (CDCl3, 
500 MHz) ' 1.23 (12 H, s, 4 * CH3), 5.28 (2 H, s, CO2CH2), 7.52-7.54 (4 H, m, 
CO2CCHCHCH and CO2CCHCHCH), 7.56 (1 H, t, J 7.2, CO2CCHCHCH), 7.83 (2 
H, d, J 7.2, BCCHCH), 8.07 (2 H, d, J 7.2, BCCH); 
13
C NMR (CDCl3, 125 MHz) ' 
24.9 (CH3), 66.7 (CH2), 83.9 (C), 127.4 (CH), 128.5 (CH), 129.3 (C), 129.8 (CH), 
130.2 (C), 133.1 (CH), 135.2 (CH), 139.1 (C), 166.5 (C=O); m/z (EI) 338.1699 (M
+
, 
C13H19O3B requires 338.1684), 239 (50), 105 (25). 
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4-(6-Amino-pyridazin-3-yl)-phenol (157) 
 
To a microwave vial containing 3-amino-6-chloropyridazine (102 mg, 0.740 mmol), 
4-hydroxyphenylboronic acid (163 mg, 1.26 mmol), 
bis(triphenylphosphine)palladium(II) dichloride (27 mg, 0.040 mmol) and K2CO3 
(202 mg, 1.46 mmol) were added CH3CN (2.0 mL) and H2O (1.3 mL). The resulting 
solution was degassed for 5 min and subjected to microwave irradiation for 10 min at 
120 °C. The mixture was diluted with water (50 mL) and extracted with EtOAc (3 * 
100 mL), washed with brine (100 mL), dried (MgSO4) and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/CH3OH 19:1) to give 
the pyridazine 157 (87 mg, 0.459 mmol, 62%) as an orange solid. m.p. 250-252 °C; 
Rf = 0.10 (EtOAc);
 
IR +max (film)/cm
-1
 3414, 3121, 1646, 1617, 1447; 
1
H NMR 
(CD3OD/CDCl3 1:1, 600 MHz) % 6.88 (2 H, d, J 8.9, HOCCH), 6.97 (1 H, d, J 9.3, 
NH2CCH), 7.64 (1 H, d, J 9.3, NH2CCHCH), 7.68 (2 H, d, J 8.9, HOCCHCH); 
13
C 
NMR (CD3OD, 125 MHz) ' 114.4 (CH), 115.5 (CH), 124.7 (CH), 126.7 (CH), 128.0 
(C), 150.0 (C), 157.8 (C), 159.3 (C); m/z (EI) 187.0732 (M
+
, C9H9N3O requires 
187.0740). 
6-(4-Benzyloxyphenyl)-pyridazin-3-yl amine (156) 
 
157 (250 mg, 1.34 mmol) and sodium hydride (54 mg, 1.34 mmol) in DMF (2 mL) 
was cooled to 0 °C. Benzyl bromide (239 mg, 1.40 mmol) was added dropwise and 
the reaction mixture was stirred at 0 °C for 2 h. The reaction mixture was extracted 
with Et2O (100 mL) and washed with water (100 mL). The aqueous layer was further 
extracted with Et2O (4 * 50 mL). The organic extracts were combined and dried 
(MgSO4). The solvent was removed in vacuo and the residue subjected to column 
chromatography (EtOAc) to give the pyridazine 156 (151 mg, 0.544 mmol, 41%) as 
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a white solid. m.p. 190-192 °C; Rf = 0.30 (EtOAc/CH3OH 20:1); IR +max (film)/cm
-1
 
3431, 3282, 3113, 1647, 1609; 
1
H NMR (CD3OD, 500 MHz) ' 5.13 (2 H, s, OCH2), 
6.98 (1 H, d, J 9.3, NH2CCH), 7.08 (2 H, d, J 6.8, OCCH), 7.30 (1 H, t, J 7.2, 
OCH2CCHCHCH), 7.36 (2 H, dd, J 7.3 and 7.2, OCH2CCHCHCH), 7.44 (2 H, d, J 
7.3, OCH2CCHCHCH), 7.72 (1 H, d, J 9.3, NH2CCHCH), 7.81 (2 H, d, J 6.8, 
OCCHCH); 
13
C NMR (CD3OD, 125 MHz) ' 71.0 (CH2), 116.3 (CH), 117.7 (CH), 
127.9 (C), 128.2 (CH), 128.5 (CH), 128.6 (CH), 129.0 (CH), 129.6 (CH), 130.7 (C), 
136.2 (C), 138.5 (C), 161.0 (C); m/z (ES+) 278.1293 (M+H, C17H15N3O requires 
278.1281), 243 (45), 187 (50). 
1-(3-Allyloxycarbonylpropyl)-6-amino-3-(4-benzyloxyphenyl)-pyridazinium 
bromide (155) 
 
To a solution of 156 (50 mg, 0.180 mmol) in DMF (0.2 mL) was added allyl-4-
bromobutyrate (56 mg, 0.271 mmol). The solution was heated to 80 °C for 16 h. The 
hot solution was poured into EtOAc (5 mL) to yield a solid, which was then isolated 
by filtration. The product was dried under high vacuum to give the ester 155 (51 mg, 
0.105 mmol, 59%) as a grey solid. m.p. 174-177 °C; Rf = 0.60 (CHCl3/CH3OH 8:2); 
IR +max (film)/cm
-1
 2930, 1724, 1681, 1649, 1612, 1554, 1541, 1509; 
1
H NMR 
(CD3OD, 500 MHz) ' 2.14-2.19 (2 H, m, NCH2CH2); 2.60 (2 H, t, J 6.8, 
NCH2CH2CH2), 4.44-4.46 (4 H, m, NCH2 and CO2CH2CHCH2), 5.13 (1 H, dd, J 8.0 
and 1.5, CO2CH2CHCHH), 5.15 (2 H, s, OCH2), 5.22 (1 H, dd, J 15.7 and 1.5, 
CO2CH2CHCHH), 5.81 (1 H, m, CO2CH2CH), 7.13 (2 H, d, J 5.6, OCCH), 7.32 (1 
H, t, J 7.1, OCH2CCHCHCH), 7.37 (2 H, dd, J 7.4 and 7.1, OCH2CCHCHCH), 7.44 
(2 H, d, J 7.4, OCH2CCHCHCH), 7.59 (1 H, d, J 9.6, NHCCH), 7.93 (2 H, d, J 5.6, 
OCCHCH), 8.27 (1 H, d, J 9.6, NHCCHCH); 
13
C NMR (CD3OD, 125 MHz) ' 22.5 
(CH2), 31.3 (CH2), 56.9 (CH2), 66.5 (CH2), 71.1 (CH2), 116.7 (CH), 118.6 (CH2), 
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126.6 (CH), 126.7 (C), 128.6 (CH), 129.1 (CH), 129.3 (CH), 129.6 (CH), 132.6 
(CH), 133.4 (CH), 138.2 (C), 151.9 (C), 153.9 (C), 162.7 (C), 174.0 (C=O); m/z 
(ES+) 403.1864 (M+H, C24H25N3O3 requires 403.1896). 
1-(3-Carboxypropyl)-6-amino-3-(4-benzyloxyphenyl)-pyridazinium bromide 
(154) 
 
To a solution of NaHCO3 (20 mg, 0.240 mmol), and dimedone (18 mg, 0.128 mmol) 
in water (0.70 mL) was successively added THF (4.5 mL), triethyl phosphite (11 mg, 
0.066 mmol) and palladium(II) acetate (2.0 mg, 0.0089 mmol) under argon. After 
stirring for 3 min, 155 (51 mg, 0.105 mmol) was added and the mixture was stirred at 
35 °C for 17 h. The mixture was diluted with water (5 mL) and washed thoroughly 
with CH2Cl2 (3 * 15 mL). The aqueous phase was separated and evaporated in 
vacuo. The residue was purified by column chromatography (CHCl3/CH3OH 9:1) to 
give the acid 154 (26 mg, 0.059 mmol, 56%) as a white solid. m.p. 180-183 °C; Rf = 
0.30 (CHCl3/CH3OH 8:2); IR +max (film)/cm
-1
 2924, 2214, 1712, 1671, 1647, 1609, 
1566, 1535, 1512; 
1
H NMR (CDCl3/CD3OD 1:1, 600 MHz) ' 2.14-2.19 (2 H, m, 
NCH2CH2), 2.45-2.50 (2 H, m, NCH2CH2CH2), 4.41-4.44 (2 H, m, NCH2), 5.15 (2 
H, s, OCH2), 7.11 (2 H, d, J 8.8, OCCH), 7.33 (1 H, t, J 7.3, OCH2CCHCHCH), 7.39 
(2 H, dd, J 7.6 and 7.3, OCH2CCHCHCH), 7.44 (2 H, d, J 7.6, OCH2CCHCHCH), 
7.66 (1 H, d, J 12.7, NHCCH), 7.88 (2 H, d, J 8.8, OCCHCH), 8.14 (1 H, d, J 12.7, 
NHCCHCH); 
13
C NMR (CDCl3/CD3OD 1:1), 150 MHz) ' 22.2 (CH2), 30.9 (CH2), 
56.2 (CH2), 70.1 (CH2), 115.5 (CH), 125.0 (C), 125.4 (CH), 127.4 (CH), 128.0 (CH), 
128.1 (CH), 128.5 (CH), 131.1 (CH), 136.3 (C), 150.5 (C), 152.2 (C), 161.3 (C), 
177.3 (C=O); m/z (ES+) 364.1661 (M+H, C21H22N3O3 requires 364.1671), 278 (25), 
273 (20). 
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4-Azidotoluene
113
 (50) 
 
To a solution of 4-toluidine (3.75 g, 35.0 mmol) in HCl (50 mL, 2 M) at !5 °C was 
added sodium nitrite (2.90 g, 42.0 mmol) in water (10 mL). The temperature was 
maintained at !5 °C for 5 min. Urea (250 mg, 4.16 mmol) was then added to the 
reaction mixture. The resulting solution was added over 5 min to a solution of 
sodium azide (4.55 g, 70.0 mmol) and sodium acetate (8.4 g, 105 mmol) in water (50 
mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h, then extracted with 
Et2O (2 * 100 mL), washed with water (2 * 100 mL), dried (MgSO4) and 
concentrated in vacuo. The residue was dried under high vacuum to give the azide 50 
(4.00 g, 30.0 mmol, 86%) as a yellow oil. Rf = 0.25 (petrol); IR +max (film)/cm
-1
 
2933, 2111; 
1
H NMR (CDCl3, 500 MHz) ' 2.33 (3 H, s, CH3), 6.93 (2 H, d, J 9.0, N-
3CCHCH), 7.15 (2 H, d, J 9.0, N3CCH); 
13
C NMR (CDCl3, 125 MHz) ' 20.9 (CH3), 
118.9 (CH), 130.4 (CH), 134.7 (C), 137.2 (C); m/z (ES+) 133.0641 (M
+
, C7H7N3 
requires 133.0640), 105 (50). 
1-Azido-4-bromomethyl-benzene
113
 (166) 
 
To a solution of 50 (2.27 g, 17.0 mmol) in anhydrous benzene (20 mL) was added 
NBS (3.78 g, 21.3 mmol) and AIBN (1.40 g, 8.52 mmol). The reaction mixture was 
heated to 80 °C for 4 h. After cooling to rt, the solvent was concentrated in vacuo. 
The residue was purified by column chromatography (petrol) to give the azide 166 
(1.60 g, 7.58 mmol, 44%) as a colourless oil. Rf = 0.30 (petrol); IR +max (film)/cm
-1
 
2954, 2125; 
1
H NMR (CDCl3, 500 MHz) ' 4.48 (2 H, s, CH2Br), 7.01 (2 H, d, J 8.5, 
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N3CCHCH), 7.37 (2 H, d, J 8.5, N3CCH); 
13
C NMR (CDCl3, 125 MHz) ' 33.0 
(CH2), 119.4 (CH), 130.9 (CH), 134.6 (C), 140.3 (C); m/z (EI) 210.9745 (M
+
, 
C7H6N3
79
Br requires 210.9740), 212 (100), 132 (90). 
6-[4-(4-Azidobenzyloxy)-phenyl]-pyridazin-3-yl amine (167) 
 
157 (300 mg, 1.60 mmol) and potassium tert-butoxide (186 mg, 1.66 mmol) in DMF 
(2 mL) were cooled to 0 °C. 166 (348 mg, 1.65 mmol) was dissolved in DMF (1 mL) 
and added dropwise. The reaction mixture was stirred at 0 °C for 3 h. The reaction 
mixture was extracted with EtOAc (100 mL) and washed with water (100 mL). The 
aqueous layer was further extracted with EtOAc (4 * 50 mL). The organic extracts 
were combined and dried (MgSO4). The solvent was removed in vacuo and the 
residue subjected to column chromatography (CHCl3/CH3OH 19:1) to give the 
pyridazine 167 (193 mg, 0.606 mmol, 38%) as a white solid. m.p. 204-206 °C; Rf = 
0.20 (CHCl3/CH3OH 19:1); IR +max (film)/cm
-1
 3431, 3282, 3113, 2954, 2125, 1647; 
1
H NMR (DMSO, 500 MHz) ' 5.13 (2 H, s, OCH2), 6.37 (2 H, s, NH2), 6.82 (1 H, d, 
J 9.6, NH2CCH), 7.07 (2 H, d, J 8.6, OCCH), 7.15 (2 H, d, J 8.7, N3CCHCH), 7.49 (2 
H, d, J 8.7, N3CCH), 7.74 (1 H, d, J 9.6, NH2CCHCH), 7.88 (2 H, d, J 8.6, 
OCCHCH); 
13
C NMR (DMSO, 125 MHz) ' 66.7 (CH2), 114.4 (CH), 115.0 (CH), 
119.2 (CH), 125.0 (CH), 126.6 (CH), 129.5 (CH), 129.8 (C), 133.9 (C), 138.9 (C), 
149.6 (C), 158.5 (C), 159.4 (C); m/z (EI) 319.1312 (M+H, C17H14N6O requires 
319.1307), 242 (80). 
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1-(3-Allyloxycarbonyl-propyl)-6-amino-3-(4-hydroxy-phenyl)-pyridazinium 
bromide (168) 
 
To a solution of 167 (194 mg, 0.609 mmol) in DMF (1 mL) was added allyl-4-
bromobutyrate (194 mg, 0.937 mmol). The solution was heated to 80 °C for 18 h. 
The hot solution was then poured into EtOAc (20 mL) to yield a solid, which was 
then isolated by filtration. The residue was purified by column chromatography 
(CHCl3/CH3OH 9:1) to give the ester 168 (64 mg, 0.162 mmol, 27%) as a white 
solid. m.p. >250 °C; Rf = 0.10 (EtOAc/CH3OH 9:1); IR +max (film)/cm
-1
 3113, 1731, 
1614, 1553; 
1
H NMR (DMSO, 600 MHz) ' 2.10 (2 H, m, NCH2CH2), 2.55 (2 H, m, 
NCH2CH2CH2), 4.37 (2 H, m, NCH2), 4.48 (2 H, m, CO2CH2CHCH2), 5.17 (1 H, dd, 
J 11.0 and 1.2, CO2CH2CHCHH), 5.27 (1 H, dd, J 17.5 and 1.2, CO2CH2CHCHH), 
5.82 (1 H, m, CO2CH2CH), 6.92 (2 H, d, J 8.6, OCCH), 7.61 (1 H, d, J 9.3, 
NHCCHCH), 7.82 (2 H, d, J 8.6, OCCHCH), 8.35 (1 H, d, J 9.3, NHCCH); 
13
C 
NMR (DMSO, 150 MHz) ' 21.6 (CH2), 30.0 (CH2), 55.0 (CH2), 64.6 (CH2), 116.0 
(CH), 118.0 (CH2), 125.7 (C), 128.1 (CH), 131.0 (CH), 132.5 (CH), 149.5 (C), 151.9 
(C), 160.1 (C), 171.9 (C=O); m/z (ES+) 314.1507 (M+H, C17H20N3O3 requires 
314.1505), 188 (20). 
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1-(3-Allyloxycarbonyl-propyl)-6-amino-3-[4-(4-azido-benzyloxy)-phenyl]-
pyridazinium bromide (169) 
 
To a solution of 167 (194 mg, 0.609 mmol) in DMF (1 mL) was added allyl-4-
bromobutyrate (194 mg, 0.937 mmol). The solution was heated to 80 °C for 6 h. The 
hot solution was then poured into EtOAc (20 mL) to yield a solid, which was then 
isolated by filtration. The product was dried under high vacuum to give the ester 169 
(120 mg, 0.228 mmol, 37%) as a white solid. m.p. degraded >200 °C; Rf = 0.20 
(EtOAc/CH3OH 9:1); IR +max (film)/cm
-1
 3184, 2112, 1727, 1646, 1607, 1543; 
1
H 
NMR (CD3OD, 500 MHz) ' 2.27 (2 H, m, NCH2CH2), 2.61 (2 H, t, J 8.5, NCH2CH-
2CH2), 4.46-4.48 (4 H, m, NCH2 and CO2CH2CHCH2), 5.11 (2 H, s, OCH2), 5.17 (1 
H, dd, J 10.5 and 1.1, CO2CH2CHCHH), 5.25 (1 H, dd, J 17.3 and 1.1, 
CO2CH2CHCHH), 5.82 (1 H, m, CO2CH2CH), 7.03 (2 H, d, J 8.7, N3CCHCH), 7.07 
(2 H, d, J 8.6, OCCH), 7.45 (2 H, d, J 8.7, N3CCH), 7.74 (1 H, d, J 9.6, 
NHCCHCH), 7.88 (2 H, d, J 8.6, OCCHCH), 8.20 (1 H, d, J 9.6, NHCCH); 
13
C 
NMR (CD3OD, 125 MHz) ' 22.4 (CH2), 31.3 (CH2), 56.8 (CH2), 66.5 (CH2), 70.6 
(CH2), 117.0 (CH), 118.6 (CH2), 120.1 (CH), 125.0 (C), 126.5 (CH), 129.4 (CH), 
130.5 (C), 130.5 (CH), 131.4 (C), 132.5 (CH), 133.4 (CH), 152.2 (C), 153.8 (C), 
161.9 (C), 174.0 (C=O); m/z (FAB+) 445.1994 (M+H, C24H25N6O3 requires 
445.1988), 307 (40). 
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6-Amino-3-[4-(4-azido-benzyloxy)-phenyl]-1-(3-carboxy-propyl)-pyridazinium 
bromide (165) 
 
To a solution of 169 (120 mg, 0.228 mmol) in THF (4 mL) and CH3OH (1 mL) was 
added morpholine (198 mg, 2.28 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (26 mg, 0.023 mmol) under argon. The 
reaction mixture was stirred at rt for 30 min, then concentrated in vacuo. The residue 
was purified by column chromatography (CHCl3/CH3OH/AcOH 17:2.9:0.1) to give 
the acid 165 (104 mg, 0.214 mmol, 94%) as a white solid. m.p. degraded >200 °C; Rf 
= 0.20 (CHCl3/CH3OH 17:3); IR +max (film)/cm
-1
 2930, 2111, 1710, 1656, 1538, 
1509; 
1
H NMR (CDCl3/CD3OD 1:1, 600 MHz) ' 2.05-2.11 (2 H, m, NCH2CH2), 
2.33-2.37 (2 H, m, NCH2CH2CH2), 4.41-4.47 (2 H, m, NCH2), 5.14 (2 H, s, OCH2), 
7.06 (2 H, d, J 8.4, N3CCHCH), 7.10 (2 H, d, J 8.6, OCCH), 7.45 (2 H, d, J 8.4, 
N3CCH), 7.71 (1 H, d, J 9.5, NHCCHCH), 7.87 (2 H, d, J 8.6, OCCHCH), 8.12 (1 H, 
d, J 9.5, NHCCH); 
13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) ' 22.7 (CH2), 31.9 
(CH2), 56.7 (CH2), 69.4 (CH2), 115.5 (CH), 119.1 (CH), 125.3 (C), 125.4 (CH), 
128.0 (CH), 128.7 (CH), 129.1 (CH), 131.0 (CH), 133.1 (C), 139.9 (C), 150.3 (C), 
152.2 (C), 161.0 (C), 177.9 (C=O); m/z (ES-) 403.1529 (M
+
, C21H20N3O3 requires 
403.1519); UV (CHCl3/CH3OH 1:1) (283 = 11900 and (313 = 2165 cm
-1
 M
-1
 d
3
. 
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{4-[4-(6-Amino-pyridazin-3-yl)-phenoxymethyl]-phenyl}-phenyl-methanone 
(171) 
 
A solution of 157 (300 mg, 1.60 mmol) and potassium tert-butoxide (181 mg, 1.60 
mmol) in DMF (2 mL) were cooled to 0 °C. 4-Bromomethyl benzophenone (486 mg, 
1.77 mmol) was dissolved in DMF (1 mL) and added dropwise. The reaction mixture 
was stirred at 0 °C for 3 h. The reaction mixture was extracted with EtOAc (100 mL) 
and washed with water (100 mL). The aqueous layer was further extracted with 
EtOAc (4 * 50 mL). The organic extracts were combined and dried (MgSO4). The 
solvent was removed in vacuo and the residue subjected to column chromatography 
(CHCl3/CH3OH 19:1) to give the pyridazine 171 (190 mg, 0.498 mmol, 31%) as a 
white solid. m.p. 167-169 °C; Rf = 0.30 (CHCl3/CH3OH 9:1); IR +max (film)/cm
-1
 
2923, 2491, 1727, 1644, 1596; 
1
H NMR (DMSO, 500 MHz) ' 5.29 (2 H, s, OCH2), 
6.38 (2 H, s, NH2), 6.82 (1 H, d, J 9.6, NH2CCH), 7.12 (2 H, d, J 8.6, OCCH), 7.56 (2 
H, dd, J 7.6 and 7.4, O=CCCHCHCH), 7.68 (3 H, m, OCH2CCH and 
O=CCCHCHCH), 7.76 (5 H, m, NH2CCHCH, OCH2CCHCH and O=CCCHCHCH), 
7.90 (2 H, d, J 8.6, OCCHCH); 
13
C NMR (DMSO, 125 MHz) ' 69.0 (CH2), 114.8 
(CH), 115.5 (CH), 125.4 (CH), 127.1 (CH), 127.8 (CH), 129.1 (CH), 130.0 (CH), 
130.3 (CH), 130.6 (C), 133.2 (CH), 136.8 (C), 137.5 (C), 142.5 (C), 144.9 (C), 158.8 
(C), 159.9 (C), 195.9 (C=O); m/z (EI) 381.1485 (M
+
, C24H19N3O2 requires 
381.1472), 195 (10). 
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1-(3-Allyloxycarbonyl-propyl)-6-amino-3-[4-(4-benzoyl-benzyloxy)-phenyl]-
pyridazinium bromide (172) 
 
To a solution of 171 (147 mg, 0.385 mmol) in DMF (1 mL) was added allyl-4-
bromobutyrate (120 mg, 0.578 mmol). The solution was heated to 80 °C for 18 h. 
The hot solution was then poured into EtOAc (20 mL) to yield a solid, which was 
then isolated by filtration. The product was dried under high vacuum to give the ester 
172 (135 mg, 0.229 mmol, 60%) as a white solid. m.p. 160-162 °C; Rf = 0.20 
(EtOAc/CH3OH 9:1); IR +max (film)/cm
-1
 3042, 1732, 1644, 1606, 1541; 
1
H NMR 
(CD3OD, 600 MHz) ' 2.28 (2 H, quint, NCH2CH2), 2.64 (2 H, t, J 6.8, NCH2CH-
2CH2), 4.46-4.48 (4 H, m, NCH2 and CO2CH2CHCH2), 5.17 (1 H, dd, J 10.4 and 1.1, 
CO2CH2CHCHH), 5.25 (1 H, dd, J 17.4 and 1.1, CO2CH2CHCHH), 5.32 (2 H, s, 
OCH2), 5.84 (1 H, m, CO2CH2CH), 7.20 (2 H, d, J 8.8, OCCH), 7.55 (2 H, dd, J 7.6 
and 7.4, O=CCCHCHCH), 7.63 (1 H, d, J 9.6, NHCCHCH), 7.66-7.68 (3 H, m, 
OCH2CCH and O=CCCHCHCH), 7.78 (4 H, m, OCH2CCHCH and 
O=CCCHCHCH), 7.99 (2 H, d, J 8.8, OCCHCH), 8.31 (1 H, d, J 9.6, NHCCH); 
13
C 
NMR (CD3OD, 150 MHz) ' 21.1 (CH2), 29.9 (CH2), 55.5 (CH2), 65.1 (CH2), 69.0 
(CH2), 115.3 (CH), 117.3 (CH2), 125.3 (CH), 125.5 (C), 126.9 (CH), 128.0 (CH), 
128.2 (CH), 129.6 (CH), 130.0 (CH), 131.2 (CH), 132.0 (CH), 132.5 (CH), 136.9 
(C), 137.4 (C), 141.9 (C), 150.4 (C), 152.5 (C), 161.0 (C), 172.6 (C=O), 196.7 
(C=O); m/z (FAB+) 508.2243 (M+H, C31H30N3O4 requires 508.2236), 313 (5). 
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6-Amino-3-[4-(4-benzoyl-benzyloxy)-phenyl]-1-(3-carboxy-propyl)-
pyridazinium bromide (170) 
 
To a solution of 172 (150 mg, 0.254 mmol) in THF (4 mL) and CH3OH (1 mL) was 
added 1,4-dimethyl barbituric acid (398 mg, 2.54 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (29 mg, 0.025 mmol) under argon. The 
reaction mixture was stirred at rt for 3 h, then concentrated in vacuo. The residue was 
purified by column chromatography (CHCl3/CH3OH 17:3), then triturated with water 
to give the acid 170 (90 mg, 0.164 mmol, 65%) as a white solid. m.p. 152-154 °C; Rf 
= 0.25 (CHCl3/CH3OH 8:2); IR +max (film)/cm
-1
 3418, 1734, 1720, 1645, 1578; 
1
H 
NMR (CDCl3/CD3OD 1:1, 600 MHz) ' 2.10-2.17 (2 H, m, NCH2CH2), 2.39-2.42 (2 
H, m, NCH2CH2CH2), 4.41-4.45 (2 H, m, NCH2), 5.28 (2 H, s, OCH2), 7.14 (2 H, d, 
J 8.2, OCCH), 7.49 (2 H, dd, J 7.6 and 7.4, O=CCCHCHCH), 7.59-7.62 (4 H, m, 
NHCCHCH, OCH2CCH and O=CCCHCHCH), 7.79-7.83 (4 H, m, OCH2CCHCH 
and O=CCCHCHCH), 7.90 (2 H, d, J 8.2, OCCHCH), 8.13 (1 H, d, J 9.6, NHCCH); 
13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) ' 23.8 (CH2), 32.8 (CH2), 57.9 (CH2), 70.7 
(CH2), 116.9 (CH), 126.7 (CH) 126.8 (C), 128.4 (CH), 129.5 (CH), 129.7 (CH), 
131.3 (CH), 131.7 (CH), 132.5 (CH), 134.2 (CH), 138.4 (C), 138.6 (C), 143.0 (C), 
151.7 (C), 153.6 (C), 162.3 (C), 179.5 (C=O), 198.6 (C=O); m/z (FAB+) 468.1910 
(M+H, C28H26N3O4 requires 468.1923), 391 (60); UV (CHCl3/CH3OH 1:1) (303 = 
10300 cm
-1
 M
-1
 d
3
. 
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2,2,2-Trifluoro-1-(4-methylphenyl)-1-ethanone
150
 (175) 
 
4-Bromotoluene (10.0 g, 58.5 mmol) was dissolved in Et2O (280 mL) and cooled to  
!40 °C. n-BuLi (40.5 mL, 60.7 mmol, 1.1 M in hexanes) was added dropwise, and 
the solution was warmed to 0 °C over 2 h. The solution was then cooled to !78 °C 
and a solution of ethyl trifluoroacetate (9.55 g, 67.2 mmol) in Et2O (60 mL) was 
added. The reaction mixture was stirred at !78 °C for 3 h, before being warmed to rt. 
The solution was hydrolysed with saturated ammonium chloride solution (50 mL), 
then washed with water (3 * 50 mL) and dried (MgSO4). The solvent was removed 
in vacuo and the residue purified by column chromatography (petrol) to give the 
ketone 175 (4.24 g, 22.5 mmol, 38%) as a colourless oil. Rf = 0.50 (petrol); IR +max 
(film)/cm
-1
 3433, 1719; 
1
H NMR (CDCl3, 600 MHz) ' 2.15 (3 H, s, CH3), 7.30 (2 H, 
d, J 8.2, CH3CCH), 7.97 (2 H, d, J 8.2, CH3CCHCH); 
13
C NMR (CDCl3, 150 MHz) 
' 22.8 (CH3), 118.1 (q, 
1
JCF 288.5, CF3), 127.3 (C), 130.0 (CH), 130.7 (CH), 147.4 
(C), 174.9 (q, 
2
JCF 37.6, C=O); m/z (EI) 188.1512 (M
+
, C9H7F3O requires 188.1465). 
2,2,2-Trifluoro-1-(4-methylphenyl)-1-ethanone oxime
123
 (176) 
 
To a solution of 175 (13.5 g, 71.7 mmol) dissolved in pyridine (155 mL), was added 
hydroxylamine hydrochloride (14.9 g, 215 mmol). The reaction mixture was then 
heated at 70 °C for 3 h. After cooling to rt, the solvent was removed in vacuo. The 
remaining residue was dissolved in Et2O (300 mL) and washed with aqueous HCl 
(300 mL, 0.01 M), water (3 * 50 mL) and dried (MgSO4). The solvent was removed 
in vacuo to give the oxime 176 (14.5 g, 71.4 mmol, 99%) as a pale yellow solid used 
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without further purification as a 1:1 mixture of isomers. Rf = 0.60 (petrol/EtOAc 
3:1); IR +max (film)/cm
-1
 3290, 1888, 1631; 
1
H NMR (CDCl3, 600 MHz) ' 2.43 (6 H, 
s, 2 * CH3), 7.25-7.35 (8 H, m, 2 * CH3CCH and 2 * CH3CCHCH), 8.30 (1 H, s, 
OH), 8.42 (1 H, s, OH); 
13
C NMR (CDCl3, 150 MHz) ' 21.8 (CH3), 118.2 (q, 
1
JCF 
277.5, CF3), 123.3 (C), 129.0 (CH), 130.0 (CH), 141.7 (C), 148.8 (q, 
2
JCF 37.6, 
CNO); m/z (EI) 203.0551 (M
+
, C9H8F3NO requires 203.0558). 
2,2,2-Trifluoro-1-(4-methylphenyl)-1-ethanone O-(p-toluenesulfonyl) oxime
123
 
(177) 
 
To a solution of 176 (14.5 g, 71.4 mmol) dissolved in pyridine (250 mL) was added 
p-toluenesulfonyl chloride (20.5 g, 107 mmol). The reaction mixture was refluxed at 
110 °C for 18 h. After cooling to rt, the solvent was removed in vacuo, and the 
residue was purified by column chromatography (CH2Cl2) to give the tosylate 177 
(19.2 g, 53.5 mmol, 75%) as a white solid used without further purification as a 1:1 
mixture of isomers. Rf = 0.80 (CHCl3); IR +max (film)/cm
-1
 2994, 1917, 1637, 1588, 
1489; 
1
H NMR (CDCl3, 600 MHz) ' 2.40 (3 H, s, CH3), 2.49 (3 H, s, CH3) 7.29-7.34 
(4 H, m, Ar-H), 7.38 (2 H, d, J 7.1, SO2CCHCH), 7.88 (2 H, d, J 7.1, SO2CCH); 
13
C 
NMR (CDCl3, 150 MHz) ' 21.8 (CH3), 22.0 (CH3), 119.3 (q, 
1
JCF 264, CF3), 123.6 
(C), 126.8 (C), 129.4 (CH), 130.2 (CH), 130.3 (CH), 131.0 (C), 132.2 (CH), 147.5 
(C), 155.0 (q, 
2
JCF 36.5, CNO); m/z (EI) 357.3481 (M
+
, C16H14F3NO3S requires 
357.3475). 
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3-p-Tolyl-3-trifluoromethyl-diaziridine
123
 (178) 
 
177 (19.2g, 53.6 mmol) was added to a sealed vessel containing Et2O (130 mL) at 
!78 °C. Ammonia (25 mL) was condensed in dropwise and the solution was stirred 
at !78 °C for 8 h. The vessel was then unsealed and allowed to warm to rt. The 
solution was then extracted with Et2O (300 mL) and washed with water (300 mL). 
The organic layer was dried (MgSO4), and the solvent removed in vacuo. The 
product was purified by flash column chromatography (CHCl3) to give the 
diaziridine 178 (9.46 g, 47.3 mmol, 88%) as a white solid. m.p. 59-61 °C; Rf = 0.40 
(CHCl3); IR +max (film)/cm
-1
 3005, 1650, 1598, 1489; 
1
H NMR (CDCl3, 600 MHz) ' 
2.18 (1 H, s, NH), 2.40 (3 H, s, CH3), 2.80 (1 H, s, NH), 7.36 (2 H, d, J 8.3, 
CH3CCH), 7.81 (2 H, d, J 8.3, CH3CCHCH); 
13
C NMR (CDCl3, 150 MHz) ' 21.8 
(CH3), 57.7 (q, 
2
JCF 30.2, C(NH)2), 123.0 (q, 
1
JCF 276.6, CF3), 129.9 (CH), 131.4 (C), 
138.4 (CH), 140.0 (C); m/z (EI) 202.1753 (M
+
, C9H9F3N2 requires 202.1764). 
3-p-Tolyl-3-trifluoromethyl-3H-diazirine
123
 (179) 
 
To a solution of 178 (1.00 g, 4.95 mmol) dissolved in CH2Cl2 (20 mL) was added 
triethylamine (2.06 mL, 14.8 mmol) at 0 °C. Iodine (1.38 g, 5.45 mmol) was added 
gradually, until the solution became brown in colour. The reaction mixture was 
washed with aqueous NaOH (20 mL, 1 M), water (20 mL), brine (20 mL) and dried 
(MgSO4). The solvent was carefully removed in vacuo at 20 °C owing to the 
volatility of the product. The residue was purified by column chromatography 
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(petrol/CH2Cl2 20:1) to give the diazirine 179 (601 mg, 3.00 mmol, 61%) as a 
colourless oil. Rf = 0.90 (CHCl3); IR +max (film)/cm
-1
 3196, 1650; 
1
H NMR (CDCl3, 
400 MHz) ' 2.39 (3 H, s, CH3), 7.10 (2 H, d, J 8.0, CH3CCH), 7.21 (2 H, d, J 8.0, 
CH3CCHCH); 
13
C NMR (CDCl3, 150 MHz) ' 21.3 (CH3), 28.4 (q, 
2
JCF 40.5, C(N)2), 
122.7 (q, 
1
JCF 273.0, CF3), 126.2 (C), 126.5 (CH), 129.6 (CH), 140.0 (C); m/z (EI) 
200.1110 (M
+
, C9H7F3N2 requires 200.1065). 
3-(4-Bromomethylphenyl)-3-trifluoromethyl-3H-diazirine
123
 (114) 
 
To a solution of 179 (1.80 g, 8.97 mmol) in CCl4 (40 mL) was added NBS (2.39 g, 
13.5 mmol) and AIBN (20 mg, 0.128 mmol). The reaction mixture was refluxed at 
70 °C for 4 h. After cooling to rt, the precipitate was filtered and the solvent was 
removed in vacuo at 20 °C owing to the volatility of the product. The residue was 
purified by column chromatography (petrol/CH2Cl2 20:1) to give the bromide 114 
(1.63 g, 5.83 mmol, 65%) as a colourless oil. Rf = 0.45 (petrol/CH2Cl2 19:1); IR +max 
(film)/cm
-1
 3277, 1644; 
1
H NMR (CDCl3, 400 MHz) ' 4.49 (2 H, s, CH2Br), 7.19 (2 
H, d, J 8.0, Ar-H), 7.46 (2 H, d, J 8.0, Ar-H); 
13
C NMR (CDCl3, 150 MHz) ' 28.4 (q, 
2
JCF 40.5, C(N)2), 32.1 (CH2), 122.1 (q, 
1
JCF 273.0, CF3), 127.0 (CH), 129.3 (C), 
129.6 (CH), 139.5 (C); m/z (EI) 277.9732 (M
+
, C9H6
79
BrF3N2 requires 277.9666), 
279 (100). 
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6-{4-[4-(3-Trifluoromethyl-3H-diazirin-3-yl)-benzyloxy]-phenyl}-pyridazin-3-
ylamine (180) 
 
A solution of 157 (160 mg, 0.854 mmol), 18-crown-6 (226 mg, 0.854 mmol) and 
potassium tert-butoxide (96 mg, 0.854 mmol) in DMF (3 mL) were cooled to 0 °C. 
114 (140 mg, 0.501 mmol) was dissolved in DMF (1 mL) and added dropwise, then 
stirred at 0 °C for 3 h. The reaction mixture was extracted with EtOAc (100 mL) and 
washed with water (100 mL). The aqueous layer was further extracted with EtOAc (4 
* 50 mL). The organic extracts were combined and dried (MgSO4). The solvent was 
removed in vacuo and the residue subjected to column chromatography 
(CHCl3/CH3OH 19:1) to give the pyridazine 180 (120 mg, 0.311 mmol, 62%) as a 
white solid. m.p. degraded >150 °C; Rf = 0.25 (CHCl3/CH3OH 9:1); IR +max 
(film)/cm
-1
 2930, 1654, 1562; 
1
H NMR (CD3OD, 500 MHz) ' 5.18 (2 H, s, OCH2), 
6.99 (1 H, d, J 9.3, NH2CCH), 7.07 (2 H, d, J 7.7, OCCH), 7.25 (2 H, d, J 8.5, 
OCH2CCHCH), 7.55 (2 H, d, J 8.5, OCH2CCH), 7.70 (1 H, d, J 9.3, NH2CCHCH), 
7.79 (2 H, d, J 7.7, OCCHCH); 
13
C NMR (CD3OD, 150 MHz) ' 29.6 (q, 
2
JCF 39.2 
C(N)2), 70.2 (CH2), 116.3 (CH), 117.8 (CH), 123.7 (q, 
1
JCF 274.7, CF3), 127.6 (CH), 
127.8 (CH), 128.7 (CH), 129.0 (CH), 129.7 (C), 131.0 (C), 133.1 (C), 140.6 (C), 
152.8 (C), 160.6 (C); m/z (FAB+) 386.1222 (M+H, C19H14N5OF3 requires 386.1229), 
279 (90). 
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1-(3-Allyloxycarbonyl-propyl)-6-amino-3-{4-[4-(3-trifluoromethyl-3H-diazirin-
3-yl)-benzyloxy]-phenyl}-pyridazinium bromide (181) 
 
To a solution of 180 (120 mg, 0.311 mmol) in DMF (1 mL) was added allyl-4-
bromobutyrate (96 mg, 0.467 mmol). The solution was heated to 80 °C for 5 h. The 
hot solution was then poured into EtOAc (20 mL) to yield a solid, which was then 
isolated by filtration. The product was dried under high vacuum to give the ester 181 
(80 mg, 0.135 mmol, 44%) as a white solid. m.p. degraded >200 °C; Rf = 0.20 
(EtOAc/CH3OH 8:2); IR +max (film)/cm
-1
 3033, 1732, 1647, 1541; 
1
H NMR 
(CD3OD, 600 MHz) ' 2.27 (2 H, quint, NCH2CH2), 2.62 (2 H, t, J 6.7, NCH2CH-
2CH2), 4.43-4.47 (4 H, m, NCH2 and CO2CH2CH), 5.15 (1 H, dd, J 9.9 and 1.6, 
CO2CH2CHCHH), 5.22-5.23 (3 H, m, CO2CH2CHCHH and OCH2), 5.82 (1 H, m, 
CO2CH2CH), 7.15 (2 H, d, J 8.9, OCCH), 7.28 (2 H, d, J 8.4, OCH2CCHCH), 7.58 
(2 H, d, J 8.4, OCH2CCH), 7.61 (1 H, d, J 9.5, NHCCHCH), 7.94 (2 H, d, J 8.9, 
OCCHCH), 8.29 (1 H, d, J 9.5, NHCCH); 
13
C NMR (CD3OD, 150 MHz) ' 22.5 
(CH2), 29.4 (q, 
2
JCF 40.1, C(N)2), 31.3 (CH2), 56.9 (CH2), 66.5 (CH2), 70.2 (CH2), 
116.7 (CH), 118.6 (CH2), 123.6 (q, 
1
JCF 273.9, CF3), 126.7 (CH), 126.9 (C), 127.9 
(CH), 128.6 (CH), 129.1 (CH), 129.5 (C), 132.6 (CH), 133.4 (CH), 140.6 (C), 151.8 
(C), 153.9 (C), 162.4 (C), 174.0 (C=O); m/z (FAB+) 512.1900 (M+H, C26H25N5O3F3 
requires 512.1900), 484 (100), 458 (10). 
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1-(3-Methoxycarbonyl-propyl)-6-amino-3-{4-[4-(3-trifluoromethyl-3H-diazirin-
3-yl)-benzyloxy]-phenyl}-pyridazinium chloride (182) 
N N
NH.HClO
O
O
F3C
N
N
 
To a solution of 181 (2.0 mg, 0.0034 mmol) in THF (0.4 mL) and CH3OH (0.1 mL) 
was added morpholine (2.9 mg, 0.034 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (1.0 mg, 0.00087 mmol) under argon. The 
reaction mixture was stirred at rt for 30 min, then concentrated in vacuo. Methanolic 
HCl (0.5 mL) was added to the residue and the mixture was stirred at rt for 2 h, then 
concentrated in vacuo. The residue was purified by column chromatography 
(CHCl3/CH3OH 17:3) to give the ester 182 (0.8 mg, 0.0015 mmol, 45%) as a white 
solid. m.p. degraded >200 °C; Rf = 0.25 (EtOAc/CH3OH 8:2); IR +max (film)/cm
-1
 
3010, 1727, 1651, 1559; 
1
H NMR (CD3OD, 600 MHz) ' 2.25 (2 H, quint, 
NCH2CH2), 2.59 (2 H, t, J 6.7, NCH2CH2CH2), 3.57 (3 H, s, CO2CH3), 4.42 (2 H, t, 
J 6.7, NCH2), 5.22 (2 H, s, OCH2), 7.15 (2 H, d, J 8.8, OCCH), 7.28 (2 H, d, J 8.4, 
OCH2CCHCH), 7.58-7.61 (4 H, m, OCH2CCH and NHCCHCH), 7.95 (2 H, d, J 8.8, 
OCCHCH), 8.28 (1 H, d, J 9.5, NHCCH); 
13
C NMR (CD3OD, 150 MHz) ' 22.5 
(CH2), 29.5 (q, 
2
JCF 40.1, C(N)2), 31.1 (CH2), 52.3 (CH3), 56.8 (CH2), 70.2 (CH2), 
116.7 (CH), 123.5 (q, 
1
JCF 273.9, CF3), 126.7 (CH), 126.9 (C), 127.8 (CH), 128.6 
(CH), 129.1 (CH), 129.4 (CH), 129.5 (C), 132.6 (CH), 140.6 (C), 151.8 (C), 153.9 
(C), 162.4 (C), 174.9 (C=O); m/z (FAB+) 486.1753 (M+H, C24H23N5O3F3 requires 
486.1759), 458 (10). 
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2-(3-Carboxypropyl)-6-amino-3-(4-hydroxy-phenyl)-pyridazinium bromide
72
 
(183) 
N N
NH.HBrHO
OH
O  
To a solution of 181 (2.0 mg, 0.0034 mmol) in AcOH (0.4 mL) was added aqueous 
HBr (0.5 mL, 5 M) at rt. The reaction mixture was stirred at 80 °C for 18 h, then 
concentrated in vacuo to give the acid 183 (0.9 mg, 0.0025 mmol, 74%) as a white 
solid. m.p. degraded >200 °C; Rf = 0.25 (CHCl3/CH3OH 8:2); IR +max (film)/cm
-1
 
3032, 1728, 1641, 1529; 
1
H NMR (DMSO, 600 MHz) ' 2.11-2.14 (2 H, m, 
NCH2CH2), 2.52-2.54 (2 H, m, NCH2CH2CH2), 4.34-4.36 (2 H, m, NCH2), 6.93 (2 
H, d, J 8.8, OCCH), 7.60 (1 H, d, J 9.3, NHCCHCH), 7.83 (2 H, d, J 8.8, 
OCCHCH), 8.29 (1 H, d, J 9.3, NHCCH); 
13
C NMR (DMSO, 150 MHz) ' 21.6 
(CH2), 30.0 (CH2), 55.0 (CH2), 116.7 (CH), 126.7 (C), 128.0 (CH), 131.0 (CH), 
132.5 (CH), 151.5 (C), 153.9 (C), 162.1 (C), 179.5 (C=O); m/z (ES+) 274.1197 
(M+H, C14H16N3O3 requires 274.1192), 188 (30). 
6-Amino-1-(3-carboxy-propyl)-3-{4-[4-(3-trifluoromethyl-3H-diazirin-3-yl)-
benzyloxy]-phenyl}-pyridazinium bromide (173) 
 
To a solution of 181 (10.0 mg, 0.0168 mmol) in THF (0.2 mL) and CH3OH (0.05 
mL) was added 1,4-dimethyl barbituric acid (26 mg, 0.168 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (2.0 mg, 0.0017 mmol) under argon. The 
reaction mixture was stirred at rt for 3 h, then concentrated in vacuo. The residue was 
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purified by column chromatography (CHCl3/CH3OH 17:3), then triturated with water 
to give the acid 173 (5.5 mg, 0.010 mmol, 59%) as a white solid. m.p. degraded 
>200 °C; Rf = 0.25 (CHCl3/CH3OH 8:2); IR +max (film)/cm
-1
 3420, 1719, 1650, 1577; 
1
H NMR (CDCl3/CD3OD 1:1, 400 MHz) ' 2.10-2.17 (2 H, m, NCH2CH2), 2.39-2.45 
(2 H, m, NCH2CH2CH2), 4.41-4.43 (2 H, m, NCH2), 5.20 (2 H, s, OCH2), 7.11 (2 H, 
d, J 8.8, OCCH), 7.24 (2 H, d, J 8.0, OCH2CCHCH), 7.53 (2 H, d, J 8.0, OCH2CH), 
7.58 (1 H, d, J 9.6, NHCCHCH), 7.89 (2 H, d, J 8.8, OCCHCH), 8.16 (1 H, d, J 9.6, 
NHCCH); 
13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) ' 23.7 (CH2), 29.4 (q, 
2
JCF 40.4, 
C(N)2), 32.7 (CH2), 57.8 (CH2), 70.4 (CH2), 116.8 (CH), 123.5 (q, 
1
JCF 272.6, CF3), 
126.7 (CH) 126.8 (C), 128.0 (CH), 129.1 (CH), 129.4 (CH), 130.0 (C), 132.5 (CH), 
140.0 (C), 151.8 (C), 153.7 (C), 162.3 (C), 179.5 (C=O); m/z (ES+) 472.1574 (M+H, 
C23H21N5O3F3 requires 472.1596), 444 (75); UV (CHCl3/CH3OH 1:1) (280 = 6100 
and (335 = 2100 cm
-1
 M
-1
 d
3
. 
[4-(6-Amino-pyridazin-3-yl)-phenyl]-phenyl-methanone (189) 
 
To a microwave vial containing 3-amino-6-chloropyridazine (101 mg, 0.779 mmol), 
4-benzoylphenylboronic acid (262 mg, 1.16 mmol), 
bis(triphenylphosphine)palladium(II) dichloride (27 mg, 0.040 mmol) and K2CO3 
(201 mg, 1.45 mmol) were added CH3CN (2.0 mL) and H2O (1.3 mL). The resulting 
solution was degassed for 5 min and subjected to microwave irradiation for 10 min at 
120 °C. The mixture was diluted with water (50 mL), extracted with EtOAc (3 * 100 
mL), washed with brine (100 mL) and dried (MgSO4). The solvent was concentrated 
in vacuo. The residue was purified by column chromatography (EtOAc/CH3OH 
19:1) to give the pyridazine 189 (130 mg, 0.472 mmol, 61%) as a white solid. m.p. 
147-149 °C; Rf = 0.15 (EtOAc);
 
IR +max (film)/cm
-1
 3052, 2923, 1727, 1644, 1596; 
1
H NMR (CD3OD, 500 MHz) % 7.02 (1 H, d, J 9.3, NH2CCH), 7.49 (2 H, dd, J 7.9 
and 7.5, O=CCCHCHCH), 7.61 (1 H, t, J 7.5, O=CCCHCHCH), 7.77 (3 H, m, 
NH2CCHCH and NH2CCHCHCCCH), 7.85 (2 H, d, J 7.9, O=CCCHCHCH), 8.00 (2 
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H, s, J 7.5, NH2CCHCHCCCHCH); 
13
C NMR (CD3OD, 125 MHz) ' 117.4 (CH), 
126.8 (CH), 128.3 (CH), 129.3 (CH), 130.9 (CH), 131.6 (CH), 133.7 (CH), 138.3 
(C), 138.4 (C), 141.5 (C), 151.4 (C), 160.4 (C), 198.1 (C=O); m/z (FAB+) 276.1141 
(M+H, C17H14N3O requires 276.1137), 238 (20), 169 (35). 
1-(3-Allyloxycarbonyl-propyl)-6-amino-3-(4-benzoyl-phenyl)-pyridazinium 
bromide (190) 
 
To a solution of 189 (100 mg, 0.363 mmol) in DMF (1 mL) was added allyl-4-
bromobutyrate (103 mg, 0.497 mmol). The solution was heated to 80 °C for 18 h. 
The hot solution was then poured into EtOAc (20 mL) to yield a solid, which was 
then isolated by filtration. The product was dried under high vacuum to give the ester 
190 (133 mg, 0.276 mmol, 76%) as a white solid. m.p. 142-144 °C; Rf = 0.20 
(EtOAc/CH3OH 8:2);
 
IR +max (film)/cm
-1
 3165, 2999, 1725, 1648, 1533; 
1
H NMR 
(CDCl3/CD3OD 1:1, 600 MHz) % 2.32 (2 H, quint, NCH2CH2), 2.67 (2 H, t, J 6.7, 
NCH2CH2CH2), 4.51-4.54 (4 H, m, NCH2 and CO2CH2CHCH2), 5.17 (1 H, dd, J 
10.4 and 1.2, CO2CH2CHCHH), 5.27 (1 H, dd, J 17.2 and 1.2, CO2CH2CHCHH), 
5.86 (1 H, m, CO2CH2CH), 7.57 (2 H, dd, J 7.8 and 7.6, O=CCCHCHCH), 7.71 (1 
H, t, J 7.6, O=CCCHCHCH), 7.74 (1 H, d, J 9.5, NHCCHCH), 7.82 (2 H, d, J 8.2, 
NHCCHCHCCCH), 7.95 (2 H, d, J 7.8, O=CCCHCHCH), 8.18 (2 H, d, J 8.2, 
NHCCHCHCCCHCH), 8.45 (1 H, d, J 9.5, NHCCH); 
13
C NMR (CD3OD, 150 MHz) 
' 21.1 (CH2), 29.9 (CH2), 55.7 (CH2), 65.1 (CH2), 117.2 (CH2), 125.7 (CH), 126.4 
(CH), 128.3 (CH), 129.7 (CH), 130.3 (CH), 131.5 (CH), 132.0 (CH), 132.9 (CH), 
136.4 (C), 136.9 (C), 139.3 (C), 149.7 (C), 153.1 (C), 172.7 (C=O), 196.1 (C=O); 
m/z (FAB+) 402.1822 (M+H, C24H24N3O3 requires 402.1818), 238 (35). 
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6-Amino-3-(4-benzoyl-phenyl)-1-(3-carboxy-propyl)-pyridazinium bromide 
(187) 
 
To a solution of 190 (64 mg, 0.133 mmol) in THF (4 mL) and CH3OH (1 mL) was 
added morpholine (116 mg, 1.33 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.0133 mmol) under argon. The 
reaction mixture was stirred at rt for 30 min, then concentrated in vacuo. The residue 
was purified by column chromatography (CHCl3/CH3OH/AcOH 17:2.9:0.1) to give 
the acid 187 (54 mg, 0.122 mmol, 92%) as a white solid. m.p. 140-142 °C; Rf = 0.25 
(CHCl3/CH3OH 8:2); IR +max (film)/cm
-1
 2933, 1740, 1651, 1570, 1533, 1511; 
1
H 
NMR (CDCl3/CD3OD 1:1, 600 MHz) ' 2.10-2.15 (2 H, m, NCH2CH2), 2.37-2.43 (2 
H, m, NCH2CH2CH2), 4.47-4.51 (2 H, m, NCH2), 7.54 (2 H, dd, J 7.7 and 7.5, 
O=CCCHCHCH), 7.67 (1 H, t, J 7.5, O=CCCHCHCH), 7.78 (1 H, d, J 9.5, 
NHCCHCH), 7.80 (2 H, d, J 8.2, NHCCHCHCCCH), 7.93 (2 H, d, J 7.7, 
O=CCCHCHCH), 8.09 (2 H, d, J 8.2, NHCCHCHCCCHCH), 8.25 (1 H, d, J 9.5, 
NHCCH); 
13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) ' 22.7 (CH2), 31.9 (CH2), 56.9 
(CH2), 126.1 (CH), 126.4 (CH), 128.5 (CH), 130.0 (CH), 130.7 (CH), 131.1 (CH), 
133.1 (CH), 136.3 (C), 136.8 (C), 139.3 (C), 149.3 (C), 152.9 (C), 179.3 (C=O), 
196.6 (C=O); m/z (FAB+) 362.1510 (M+H, C21H20N3O3 requires 362.1505), 329 
(80); UV (CHCl3/CH3OH 1:1) (306 = 10600 cm
-1
 M
-1
 d
3
. 
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1-(4-Iodophenyl)-2,2,2-trifluoroacetophenone
160
 (193) 
 
1,4-Diiodobenzene (15.0 g, 45.5 mmol) was dissolved in THF (60 mL) and cooled to 
!78 °C. n-BuLi (30 mL, 48.0 mmol, 1.6 M in hexanes) was added dropwise. Ethyl 
trifluoroacetate (9.05 g, 63.7 mmol) was then added in one portion. The reaction 
mixture was stirred at !78 °C for 18 h, before being warmed to rt. The solution was 
hydrolysed with saturated ammonium chloride solution (40 mL) then washed further 
with aqueous HCl (50 mL, 6 M), water (2 * 100 mL) and dried (MgSO4). The 
solvent was removed in vacuo and the residue purified by vacuum distillation to give 
the ketone 193 (5.65 g, 18.8 mmol, 41%) as a brown oil. Rf = 0.10 (petrol); IR +max 
(film)/cm
-1
 3530, 1722, 1594, 1493, 1410; 
1
H NMR (500 MHz, CDCl3) % 7.70 (2 H, 
d, J 10.8, ICCH), 7.93 (2 H, d, J 10.8, ICCHCH); 
13
H NMR (500 MHz, CDCl3) % 
104.7 (C), 117.1 (q, 
1
JCF 290.5, CF3), 129.2 (C), 131.1 (CH), 138.7 (CH), 180.1 (q, 
2
JCF 35.5, C=O); m/z (EI) 299.9241 (M
+
, C8H4IF3O requires 299.9254). 
1-(4-Iodophenyl)-2,2,2-trifluoroethanone oxime
160
 (194)  
 
To a solution of 193 (5.11 g, 17.0 mmol) in pyridine (5 mL), was added a solution of 
hydroxylamine hydrochloride (14.9 g, 215 mmol) in pyridine (5 mL) and ethanol (16 
mL). The reaction mixture was then heated at 60 °C for 4 h. After cooling to rt, the 
solvent was removed in vacuo. The residue was dissolved in Et2O (100 mL) and 
washed with aqueous HCl (2 * 100 mL, 0.1 M), water (100 mL) and dried (Na2SO4). 
The solvent was removed in vacuo. The residue was subjected to column 
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chromatography (petrol/EtOAc 3:1) to give the oxime 194 (4.40 g, 14.0 mmol, 82%) 
used without further purification as a 1:1 mixture of isomers. Rf = 0.60 
(petrol/EtOAC 3:1); IR +max (film)/cm
-1
 3284, 1896, 1641, 1586, 1493, 1459; 
1
H 
NMR (CDCl3, 500 MHz) ' 7.25-7.35 (4 H, m, 2 * ICCHCH), 7.74-7.82 (4 H, m, 2 * 
ICCH), 8.60 (1 H, s, OH), 8.63 (1 H, s, OH); 
13
C NMR (CDCl3, 125 MHz) ' 96.4 
(C), 119.7 (q, 
1
JCF 161.3, CF3), 130.4 (CH), 137.6 (CH), 138.7 (C), 146.3 (C), 148.8 
(q, 
2
JCF 37.5, CNO); m/z (EI) 314.9370 (M
+
, C8H5F3INO requires 314.9363). 
1-(4-Iodophenyl)-2,2,2-trifluoroethanone O-(p-tolylsulfonyl) oxime
160
 (195) 
 
To a solution of 194 (4.39 g, 13.94 mmol) in pyridine (55 mL) was added p-
toluenesulfonyl chloride (3.32 g, 17.43 mmol). The reaction mixture was refluxed at 
110 °C for 18 h. After cooling to rt, the solvent was removed in vacuo, and the 
residue was purified by column chromatography (CHCl3) to give the tosylate 195 
(3.89 g, 8.29 mmol, 59%) as a white solid. Rf = 0.50 (petrol/EtOAc 2:1); IR +max 
(film)/cm
-1
 2920, 1917, 1647, 1589, 1486; 
1
H NMR (CDCl3, 500 MHz) ' 2.48 (3 H, 
s, CH3), 7.12 (2 H, d, J 8.5, Ar-H), 7.38 (2 H, d, J 8.4, SO2CCHCH), 7.84 (2 H, d, J 
8.5, Ar-H), 7.89 (2 H, d, J 8.4, SO2CCH); 
13
C NMR (CDCl3, 125 MHz) ' 21.9 
(CH3), 123.9 (q, 
1
JCF 276.3, CF3), 127.1 (C), 129.4 (CH), 129.9 (CH), 130.0 (CH), 
130.3 (C), 138.3 (C), 138.3 (CH), 146.3 (C), 153.0 (q, 
2
JCF 33.7, CNO); m/z (EI) 
468.9477 (M
+
, C15H11IF3NO3S requires 468.9451). 
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3-p-Iodophenyl-3-trifluoromethyl-diaziridine
160
 (196) 
 
195 (1.94g, 4.15 mmol) was added to a sealed vessel containing CH2Cl2 (9 mL) at 
!78 °C. Ammonia (2.5 mL) was condensed in dropwise and the solution was stirred 
at !78 °C for 8 h. The vessel was then unsealed and allowed to warm to rt. The 
solution extracted with CH2Cl2 (25 mL) and washed with water (25 mL). The 
organic layer was dried (Na2SO4) and then concentrated in vacuo. The product was 
purified by flash column chromatography (petrol/EtOAc 4:1) to give the diaziridine 
196 (632 mg, 1.98 mmol, 48%) as a white solid. m.p. 57-59 °C Rf = 0.30 
(petrol/EtOAc 2:1); IR +max (film)/cm
-1
 3196, 1666, 1591, 1489, 1393; 
1
H NMR 
(CDCl3, 500 MHz) ' 2.19 (1 H, s, NH), 2.77 (1 H, s, NH), 7.36 (2 H, d, J 7.5, 
ICCH), 7.76 (2 H, d, J 7.5, ICCHCH); 
13
C NMR (CDCl3, 150 MHz) ' 57.7 (q, 
2
JCF 
36.2, C(NH)2), 96.7 (C), 123.0 (q, 
1
JCF 276.6, CF3), 129.8 (CH), 131.8 (C), 138.1 
(CH); m/z (EI) 312.9452 (M-H, C8H6IF3N2 requires 312.9450). 
3-p-Iodophenyl-3-trifluoromethyl-3H-diazirine
123, 160
 (121) 
 
To a solution of 196 (150 mg, 0.479 mmol) dissolved in CH2Cl2 (3 mL) was added 
triethylamine (0.301 mL, 2.21 mmol) at 0 °C. Iodine (203 mg, 0.799 mmol) was 
added gradually, until the solution became brown in colour. The reaction mixture 
was then washed with aqueous NaOH (3 mL, 1 M), water (10 mL), brine (10 mL) 
and dried (MgSO4). The solvent was carefully removed in vacuo at 20 °C owing to 
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the volatility of the product. The residue was purified by column chromatography 
(petrol/CH2Cl2 20:1) to give the diazirine 121 (95 mg, 0.304 mmol, 64%) as a 
colourless oil. Rf = 0.90 (CHCl3); IR +max (film)/cm
-1
 3132, 1659; 
1
H NMR (CDCl3, 
600 MHz) ' 6.92 (2 H, d, J 8.3, ICCH), 7.21 (2 H, d, J 8.3, ICCHCH); 13C NMR 
(CDCl3, 150 MHz) ' 28.4 (q, 
2
JCF 40.7, C(N)2), 96.1 (C), 122.0 (q, 
1
JCF 274.6, CF3), 
128.2 (CH), 128.9 (C), 138.0 (CH); m/z (EI) 311.9371 (M
+
, C8H4F3IN2 requires 
311.9372). 
4,4’-Bis-(3-trifluoromethyl-3H-diazirine)-biphenyl (198) 
 
To a solution of 121 (166 mg, 0.532 mmol) in DMSO (5 mL) was added 
successively [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (11 mg, 
0.015 mmol), bis(pinacolato)diboron (202 mg, 1.06 mmol) and potassium acetate 
(157 mg, 1.06 mmol). The reaction mixture was heated to 80 °C for 8 h. After 
cooling to rt, the mixture was diluted with EtOAc (200 mL) and washed with 
aqueous HCl (100 mL, 0.1 M), water (2 * 100 mL), brine (100 mL) and dried 
(MgSO4). The solvent was removed in vacuo. The residue was purified by column 
chromatography (CH2Cl2) to give the diazirine 198 (24 mg, 0.063 mmol, 12%) as a 
white solid. Rf = 0.70 (CHCl3); IR +max (film)/cm
-1
 3122, 1642; 
1
H NMR (CDCl3, 
600 MHz) ' 7.30 (4 H, d, J 7.5, Ar-H), 7.59 (4 H, d, J 7.5, Ar-H); 13C NMR (CDCl3, 
150 MHz) ' 28.5 (q, 2JCF 40.7, C(N)2), 122.2 (q, 
1
JCF 274.6, CF3), 127.2 (CH), 127.6 
(CH), 128.9 (C), 141.2 (C); m/z (EI) 370.0649 (M
+
, C8H4F3IN2 requires 370.0653). 
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3-Bromo-4-methyl-benzoyl chloride
217
 (206) 
O
Cl
Br
 
To 3-bromo-4-methylbenzoic acid (1.00 g, 3.95 mmol) was added to SOCl2 (12 mL) 
and the reaction mixture was stirred at rt for 2 min, then under reflux at 80 °C for 2 
h. The solvent was removed in vacuo and further evaporated using CH2Cl2 (2 * 25 
mL) to give the acid chloride 206 (1.08 g, 3.95 mmol, quant.) as a brown solid which 
was used in the next step without further purification.
 1
H NMR (CDCl3, 600 MHz) % 
2.49 (3 H, s, CH3), 7.38 (1 H, d, J 7.8, BrCCCH), 7.94 (1 H, dd, J 7.8 and 1.8, 
BrCCCHCH), 8.27 (1 H, d, J 1.8, BrCCH);
 13
C NMR (CDCl3, 150 MHz) % 23.6 
(CH3), 125.4 (C), 130.2 (CH), 131.3 (CH), 132.5 (C), 135.1 (CH), 146.4 (C), 167.1 
(C=O).  
(3-Bromo-4-methyl-phenyl)-phenyl-methanone
217
 (205) 
O
Br
 
To a solution of 206 (1.08 g, 3.95 mmol) in benzene (12 mL) was added AlCl3 (930 
mg, 6.97 mmol) at rt. The reaction mixture was then heated to 50 °C for 2 h. The 
solvent was removed in vacuo. The residue was purified by column chromatography 
(petrol) to give the ketone 205 (1.06 g, 3.85 mmol, 98%) as a white solid. m.p. 80-82 
°C; Rf = 0.30 (petrol); IR +max (film)/cm
-1
 2933, 1740, 1651; 
1
H NMR (CDCl3, 600 
MHz) ' 2.48 (3 H, s, CH3), 7.34 (1 H, d, J 7.8, BrCCCH), 7.48 (2 H, dd, J 7.6 and 
7.5, O=CCCHCHCH), 7.60 (1 H, t, J 7.5, O=CCCHCHCH), 7.63 (1 H, dd, J 7.8 and 
1.7, BrCCCHCH), 7.77 (2 H, d, J 7.6, O=CCCHCHCH), 7.99 (1 H, d, J 1.7, 
BrCCH); 
13
C NMR (CDCl3, 150 MHz) ' 23.4 (CH3), 125.0 (C), 128.5 (CH), 129.1 
(CH), 130.1 (CH), 130.7 (CH), 132.7 (CH), 134.0 (CH), 137.0 (C), 137.4 (C), 143.0 
(C), 195.2 (C=O); m/z (EI) 273.9996 (M+H, C14H11O
79
Br requires 273.9988), 276 
(100). 
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(3-Bromo-4-bromomethyl-phenyl)-phenyl-methanone
217
 (204) 
O
Br
Br
 
To a solution of 205 (1.04 g, 3.78 mmol) in CCl4 (20 mL) was added AIBN (82 mg, 
0.50 mmol) and NBS (672 mg, 3.78 mmol) at rt. The reaction mixture was then 
heated under reflux at 70 °C for 17 h. The solvent was removed in vacuo. The 
residue was purified by column chromatography (petrol) to give the ketone 204 (368 
mg, 1.04 mmol, 27%) as a white solid. m.p. 53-55 °C; Rf = 0.35 (petrol); IR +max 
(film)/cm
-1
 2994, 1737; 
1
H NMR (CDCl3, 600 MHz) ' 4.64 (2 H, s, BrCH2), 7.51 (2 
H, dd, J 7.6 and 7.5, O=CCCHCHCH), 7.57 (1 H, d, J 7.8, BrCCCH), 7.63 (1 H, t, J 
7.5, O=CCCHCHCH), 7.71 (1 H, dd, J 7.8 and 1.9, BrCCCHCH), 7.79 (2 H, d, J 
7.6, O=CCCHCHCH), 8.02 (1 H, d, J 1.9, BrCCH); 
13
C NMR (CDCl3, 150 MHz) ' 
32.5 (CH2), 124.6 (C), 128.5 (CH), 129.5 (CH), 130.1 (CH), 131.2 (CH), 133.1 
(CH), 134.7 (CH), 136.8 (C), 139.2 (C), 141.2 (C), 194.6 (C=O); m/z (EI) 351.9099 
(M+H, C14H10O
79
Br2 requires 351.9093), 356 (50), 354 (100). 
(3-Bromo-4-diethylaminomethyl-phenyl)-phenyl-methanone (208) 
O
Br
N
 
To a solution of 204 (80 mg, 0.225 mmol) in diethylamine (4 mL) was added 
bis(triphenylphosphine)palladium(II) dichloride (24 mg, 0.034 mmol) and copper(I) 
iodide (3.0 mg, 0.015 mmol) at rt. The reaction mixture was stirred for 30 min. 5-
Hexynoic acid (65 mg, 0.282 mmol) in diethylamine (2 mL) was added dropwise 
over a period of 3 h. The reaction mixture was then stirred at rt for 12 h. The solvent 
was removed in vacuo. The residue was dissolved in Et2O (100 mL) and washed 
with aqueous HCl (2 * 100 mL, 0.1 M), water (100 mL) and dried (MgSO4). The 
solvent was removed in vacuo. The residue was subjected to column chromatography 
(petrol/EtOAc 19:1) to give the amine 208 (40 mg, 0.116 mmol, 51%) as a colourless 
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oil. Rf = 0.30 (petrol/EtOAc 19:1); IR +max (film)/cm
-1
 2968, 1747, 1658, 1597, 1548; 
1
H NMR (CDCl3, 400 MHz) ' 1.09 (6 H, t, J 7.1, CH3CH2N), 2.59 (4 H, q, J 7.1, 
CH3CH2N), 3.72 (2 H, s, CH3CH2NCH2), 7.51 (2 H, dd, J 7.8 and 7.7, 
O=CCCHCHCH), 7.62 (1 H, t, J 7.7, O=CCCHCHCH), 7.74 (2 H, m, 
CH3CH2NCH2CCH and CH3CH2NCH2CCHCH), 7.81 (2 H, d, J 7.8, 
O=CCCHCHCH), 7.99 (1 H, s, BrCCH); 
13
C NMR (CDCl3, 150 MHz) ' 12.1 (CH3), 
47.5 (CH2), 57.4 (CH2), 123.9 (C), 128.5 (CH), 129.1 (CH), 130.1 (CH), 130.2 (CH), 
132.8 (CH), 134.0 (CH), 137.3 (C), 137.4 (C), 144.8 (C), 195.3 (C=O); m/z (CI) 
345.0728 (M
+
, C18H20ON
79
Br requires 345.0734), 347 (100), 247 (95), 245 (95). 
Hex-5-ynoic acid 4-benzoyl-2-bromo-benzyl ester (209) 
O
Br
O
O  
To a solution of 204 (257 mg, 0.727 mmol) in triethylamine (6 mL) was added 
bis(triphenylphosphine)palladium(II) dichloride (68 mg, 0.097 mmol) and copper(I) 
iodide (14 mg, 0.073 mmol). The reaction mixture was stirred at rt for 30 min. 5-
Hexynoic acid (112 mg, 1.00 mmol) in triethylamine (2 mL) was added dropwise 
over a period of 3 h. The reaction mixture was then stirred at rt for 48 h. The solvent 
was removed in vacuo. The remaining residue was dissolved in Et2O (100 mL) and 
washed with aqueous HCl (2 * 100 mL, 0.1 M), water (100 mL) and dried (MgSO4). 
The solvent was removed in vacuo. The residue was subjected to column 
chromatography (petrol/EtOAc 19:1) to give the alkyne 209 (20 mg, 0.069 mmol, 
9.5%) as a colourless oil. Rf = 0.45 (petrol/EtOAc 4:1); IR +max (film)/cm
-1
 3301, 
2939, 2127, 1736, 1659; 
1
H NMR (CDCl3, 400 MHz) ' 1.93 (2 H, quint, J 7.1, 
O=CCH2CH2), 2.01 (1 H, t, J 2.6, HCCCH2), 2.34 (2 H, td, J 7.1 and 2.6, 
O=CCH2CH2CH2), 2.62 (2 H, t, J 7.1, O=CCH2), 5.29 (2 H, s, OCH2), 7.52 (3 H, m, 
O=CCCHCHCH and BrCCCH), 7.63 (1 H, t, J 7.4, O=CCCHCHCH), 7.74 (2 H, dd, 
J 7.7 and 1.7, BrCCCHCH), 7.77 (2 H, d, J 7.7, O=CCHCHCH), 8.02 (1 H, d, J 1.7, 
BrCCH); 
13
C NMR (CDCl3, 150 MHz) ' 18.0 (CH2), 23.6 (CH2), 32.9 (CH2), 65.6 
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(CH2), 69.5 (C), 83.2 (CH), 123.1 (C), 128.6 (CH), 129.1 (CH), 129.1 (CH), 130.1 
(CH), 133.1 (CH), 134.2 (CH), 136.9 (C), 138.9 (C), 139.7 (C), 172.7 (C=O), 194.9 
(C=O); m/z (EI) 384.0366 (M
+
, C20H17O3
79
Br requires 384.0361). 
4-Benzoyl-2-bromo-benzaldehyde (210) 
O
Br
H
O  
To a solution of 204 (257 mg, 0.727 mmol) in triethylamine (6 mL) was added 
bis(triphenylphosphine)palladium(II) dichloride (68 mg, 0.097 mmol) and copper(I) 
iodide (14 mg, 0.073 mmol) at rt. The reaction mixture was stirred for 30 min. 5-
Hexynoic acid (112 mg, 1.00 mmol) in triethylamine (2 mL) was added dropwise 
over a period of 3 h. The reaction mixture was then stirred at rt for 48 h. The solvent 
was removed in vacuo. The remaining residue was dissolved in Et2O (100 mL) and 
washed with aqueous HCl (2 ) 100 mL, 0.1 M), water (100 mL) and dried (MgSO4). 
The solvent was removed in vacuo. The residue was subjected to column 
chromatography (petrol/EtOAc 19:1) to give the aldehyde 210 (86 mg, 0.223 mmol, 
31%) as a colourless oil. Rf = 0.80 (petrol/EtOAc 4:1); IR +max (film)/cm
-1
 2970, 
1724, 1698, 1662; 
1
H NMR (CDCl3, 400 MHz) ' 7.55 (2 H, dd, J 7.7 and 7.4, 
O=CCCHCHCH), 7.67 (1 H, t, J 7.4, O=CCCHCHCH), 7.81 (3 H, m, 
O=CCHCHCH and BrCCCH), 8.01 (2 H, d, J 7.4, BrCCCHCH), 8.04 (1 H, s, 
BrCCH), 10.48 (1 H, s, CHO); 
13
C NMR (CDCl3, 150 MHz) ' 126.9 (C), 128.8 
(CH), 129.0 (CH), 129.8 (CH), 130.2 (CH), 133.6 (CH), 135.0 (CH), 135.6 (C), 
136.3 (C), 143.6 (C), 191.4 (CHO), 194.4 (C=O); m/z (EI) 287.9786 (M
+
, 
C14H9O2
79
Br requires 287.9785), 290 (100), 213 (40), 211 (40). 
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Hex-5-ynoic acid tert-butyl ester (213) 
 
To a solution of 5-hexynoic acid (1.00 g, 8.91 mmol) in THF (15 mL) at !40 °C, was 
added trifluoroacetic anhydride (1.68 g, 8.00 mmol) dropwise across 30 min. tert-
Butyl alcohol (10 mL) was added in one portion. The reaction mixture was stirred at 
!40 °C for 3 h. The solvent was removed in vacuo and the residue was purified by 
column chromatography (petrol/EtOAc 9:1) to give the ester 213 (80 mg, 0.475 
mmol, 6%). Rf = 0.80 (petrol/EtOAc 4:1); IR +max (film)/cm
-1
 3304, 2970, 2152, 
1727, 1661; 
1
H NMR (CDCl3, 600 MHz) ' 1.44 (9 H, s, OC(CH3)3), 1.80 (2 H, 
quint, J 7.1, O=CCH2CH2), 1.95 (1 H, t, J 2.6, HCCCH2), 2.24 (2 H, td, J 7.1 and 
2.6, O=CCH2CH2CH2), 2.32 (2 H, t, J 7.1, O=CCH2); 
13
C NMR (CDCl3, 150 MHz) 
' 18.0 (CH2), 23.9 (CH2), 28.2 (CH3), 34.8 (CH2), 69.1 (C), 80.4 (C), 83.6 (CH), 
172.4 (C=O); m/z (EI) 168.1148 (M
+
, C10H16O2 requires 168.1150), 105 (65). 
Hex-5-ynoic acid 2-oxo-2-phenyl-ethyl ester (214) 
 
To a solution of phenacyl chloride (1.52 g, 9.83 mmol), triethylamine (1.13 g, 11.1 
mmol) and tetrabutylammonium iodide (3.62 g, 9.83 mmol) in EtOAc (20 mL) was 
added 5-hexynoic acid (1.00 g, 8.91 mmol) in one portion. The reaction mixture was 
stirred at rt for 3 h. The solvent was removed in vacuo and the residue was purified 
by column chromatography (petrol/EtOAc 4:1) to give the ester 214 (974 mg, 4.23 
mmol, 47%). Rf = 0.55 (petrol/EtOAc 4:1); IR +max (film)/cm
-1
 3288, 2938, 2157, 
1740; 
1
H NMR (CDCl3, 600 MHz) ' 1.92 (2 H, quint, J 7.4, O=CCH2CH2CH2), 1.99 
(1 H, t, J 2.6, HCCCH2), 2.33 (2 H, td, J 7.4 and 2.6, O=CCH2CH2CH2), 2.65 (2 H, t, 
J 7.3, O=CCH2CH2CH2), 5.35 (2 H, s, CO2CH2), 7.49 (2 H, dd, J 7.8 and 7.7, 
O=CCCHCH), 7.61 (1 H, t, J 7.8, O=CCCHCHCH), 7.91 (2 H, d, J 7.8, O=CCCH); 
13
C NMR (CDCl3, 150 MHz) ' 17.9 (CH2), 23.8 (CH2), 32.7 (CH2), 66.1 (CH2), 69.3 
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(C), 83.6 (CH), 127.9 (CH), 129.0 (CH), 134.1 (CH), 134.3 (C), 172.7 (C=O), 192.2 
(C=O); m/z (CI) 231.1024 (M+H, C14H15O3 requires 231.1021). 
6-(5-Benzoyl-2-methyl-phenyl)-hex-5-ynoic acid (217) 
O O
OH
 
To a solution of 205 (200 mg, 0.727 mmol) in diethylamine (6 mL) was added 
bis(triphenylphosphine)palladium(II) dichloride (68 mg, 0.097 mmol) and copper(I) 
iodide (14 mg, 0.073 mmol) at rt. The reaction mixture was stirred for 30 min. 5-
Hexynoic acid (112 mg, 1.00 mmol) in diethylamine (2 mL) was added dropwise 
over a period of 3 h. The reaction mixture was then stirred at rt for 48 h. The solvent 
was removed in vacuo. The remaining residue was dissolved in Et2O (100 mL) and 
washed with aqueous HCl (100 mL, 0.1 M), water (2 * 100 mL) and dried (MgSO4). 
The solvent was removed in vacuo. The residue was subjected to column 
chromatography (EtOAc) to give the acid 217 (100 mg, 0.327 mmol, 45%) as a 
white solid. m.p. 100-102 °C; Rf = 0.20 (EtOAc); IR +max (film)/cm
-1
 3332, 2213, 
1741, 1659; 
1
H NMR (CD3OD, 400 MHz) ' 1.98 (2 H, quint, J 7.2, O=CCH2CH2), 
2.51 (3 H, s, CH3) 2.56-2.61 (4 H, m, O=CCH2CH2CH2 and O=CCH2), 7.31 (1 H, d, 
J 7.9, CH3CCH), 7.52 (2 H, dd, J 7.6 and 7.4, O=CCCHCHCH), 7.59 (1 H, t, J 7.4, 
O=CCCHCHCH), 7.65 (1 H, dd, J 7.9 and 2.0, CH3CCHCH), 7.79 (1 H, d, J 2.0, 
CH3CCCH), 7.81 (2 H, d, J 7.6, O=CCCHCHCH); 
13
C NMR (DMSO, 150 MHz) ' 
18.3 (CH3), 20.6 (CH2), 48.6 (CH2), 65.6 (CH2), 69.5 (C), 83.2 (C), 123.1 (C), 128.6 
(CH), 129.1 (CH), 130.1 (CH), 131.6 (CH), 133.1 (CH), 134.2 (CH), 136.9 (C), 
138.9 (C), 139.7 (C), 172.7 (C=O), 194.9 (C=O); m/z (EI) 306.1254 (M
+
, C20H18O3 
requires 306.1250), 247 (30). 
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6-(5-Benzoyl-2-methyl-phenyl)-hex-5-ynoic acid tert-butyl ester (216)  
O O
O
 
To a solution of 217 (290 mg, 0.946 mmol) in THF (4 mL) at !40 °C, was added 
trifluoroacetic anhydride (189 mg, 0.900 mmol) dropwise across 30 min. tert-Butyl 
alcohol (1 mL) was added in one portion. The reaction mixture was stirred at !40 °C 
for 3 h. The solvent was removed in vacuo and the residue was purified by column 
chromatography (petrol/EtOAc 9:1) to give the ester 216 (153 mg, 0.422 mmol, 
47%) as a colourless oil. Rf = 0.80 (petrol/EtOAc 4:1); IR +max (film)/cm
-1
 3221, 
2209, 1741, 1726; 
1
H NMR (CDCl3, 600 MHz) ' 1.44 (9 H, s, OC(CH3)3), 1.89 (2 H, 
quint, J 7.4, O=CCH2CH2), 2.41 (2 H, t, J 7.4, O=CCH2), 2.49 (3 H, s, Ar-CH3), 2.51 
(2 H, t, J 7.4, O=CCH2CH2CH2), 7.30 (1 H, d, J 7.9, CH3CCH), 7.48 (2 H, dd, J 7.6 
and 7.4, O=CCCHCHCH), 7.59 (1 H, t, J 7.4, O=CCCHCHCH), 7.63 (1 H, dd, J 7.9 
and 1.8, CH3CCHCH), 7.77 (2 H, d, J 7.6, O=CCCHCHCH), 7.79 (1 H, d, J 1.8, 
CH3CCCH); 
13
C NMR (CDCl3, 150 MHz) ' 19.1 (CH2), 21.2 (CH3), 24.3 (CH2), 
28.2 (CH3), 34.5 (CH2), 79.4 (C), 80.5 (C), 94.4 (C), 124.0 (C), 128.4 (CH), 129.3 
(CH), 129.5 (CH), 130.1 (CH), 132.5 (CH), 133.7 (CH), 135.2 (C), 137.7 (C), 145.1 
(C), 172.6 (C=O), 196.1 (C=O); m/z (EI) 362.1881 (M
+
, C24H26O3 requires 
362.1882), 306 (50). 
6-(5-Benzoyl-2-methyl-phenyl)-5,6-dibromo-hex-5-enoic acid tert-butyl ester 
(218)  
O Br
Br
O
O
 
To a solution of 216 (150 mg, 0.413 mmol) in benzene (1 mL) was added NBS (91 
mg, 0.516 mmol) and AIBN (33 mg, 0.206 mmol). The reaction mixture was heated 
to 60 °C for 6 h. After cooling to rt, the precipitate was filtered and the solvent was 
removed in vacuo. The residue was purified by column chromatography 
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(petrol/EtOAc 9:1) to give the ester 218 (84 mg, 0.160 mmol, 39%) as a colourless 
oil. Rf = 0.30 (petrol/EtOAc 9:1); IR +max (film)/cm
-1
 3317, 1742, 1731; 
1
H NMR 
(CDCl3, 600 MHz) ' 1.47 (9 H, s, OC(CH3)3), 2.00 (2 H, m, O=CCH2CH2), 2.35 (2 
H, t, J 7.4, O=CCH2), 2.37 (3 H, s, Ar-CH3), 2.81 (1 H, dt, J 13.4 and 6.4, 
O=CCH2CH2CHH), 2.94 (1 H, dt, J 13.4 and 6.4, O=CCH2CH2CHH), 7.34 (1 H, d, J 
7.9, CH3CCH), 7.48 (2 H, dd, J 7.6 and 7.4, O=CCCHCHCH), 7.59 (1 H, t, J 7.4, 
O=CCCHCHCH), 7.60 (1 H, d, J 1.7, CH3CCCH), 7.72 (1 H, dd, J 7.9 and 1.7, 
CH3CCHCH), 7.79 (2 H, d, J 7.6, O=CCCHCHCH); 
13
C NMR (CDCl3, 150 MHz) ' 
19.6 (CH3), 23.0 (CH2), 28.2 (CH3), 34.2 (CH2), 39.5 (CH2), 80.6 (C), 115.6 (C), 
124.8 (C), 128.5 (C), 130.1 (CH), 130.6 (CH), 130.7 (CH), 130.9 (CH), 132.5 (CH), 
135.7 (C), 137.7 (C), 140.4 (C), 140.9 (C), 172.4 (C=O), 195.9 (C=O); m/z (EI) 
520.0245 (M
+
, C24H26
79
Br2O3 requires 520.0249), 522 (100), 524 (50). 
{4-[4-(6-Amino-pyridazin-3-yl)-phenoxymethyl]-3-bromo-phenyl}-phenyl-
methanone (219) 
 
A solution of 157 (260 mg, 1.39 mmol), 18-crown-6 (157 mg, 1.39 mmol) and 
potassium tert-butoxide (157 mg, 1.39 mmol) in DMF (6 mL) were cooled to 0 °C. 
A solution of 205 (368 mg, 1.04 mmol) in DMF (2 mL) was added dropwise and the 
reaction mixture stirred at 0 °C for 3 h. The reaction mixture was extracted with 
EtOAc (100 mL) and washed with water (100 mL). The aqueous layer was further 
extracted with EtOAc (4 * 50 mL). The organic extracts were combined and dried 
(MgSO4). The solvent was removed in vacuo and the residue subjected to column 
chromatography (CHCl3/CH3OH 19:1) to give the pyridazine 219 (389 mg, 0.845 
mmol, 81%) as a white solid. m.p. 164-166 °C; Rf = 0.30 (CHCl3/CH3OH 19:1); IR 
+max (film)/cm
-1
 3013, 1735, 1646; 
1
H NMR (CDCl3/CD3OD 1:1, 600 MHz) ' 5.25 
(2 H, s, OCH2), 7.04 (1 H, d, J 9.0, NH2CCH), 7.10 (2 H, d, J 8.3, OCCH) 7.51 (2 H, 
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dd, J 7.6 and 7.5, O=CCCHCHCH), 7.63 (1 H, t, J 7.5, O=CCCHCHCH), 7.69-7.75 
(3 H, m, BrCCCH, BrCCCHCH and NH2CCHCH), 7.76 (2 H, d, J 7.6, 
O=CCCHCHCH), 7.76 (2 H, d, J 8.3, OCCHCH), 8.00 (1 H, d, J 1.8, BrCCH);
 13
C 
NMR (CDCl3, 150 MHz) ' 70.4 (CH2), 116.5 (CH), 118.7 (CH), 123.4 (C), 129.0 
(CH), 129.0 (CH), 129.8 (CH), 129.9 (CH), 130.6 (CH), 130.9 (C), 131.2 (C), 131.3 
(CH), 134.5 (CH), 135.2 (CH), 138.1 (C), 139.7 (C), 142.2 (C), 160.5 (C), 197.0 
(C=O) * 1 (C) absent; m/z (ES+) 460.0641 (M+H, C24H19N3O2
79
Br requires 
460.0661), 462 (100). 
6-{2-[4-(6-Amino-pyridazin-3-yl)-phenoxymethyl]-5-benzoyl-phenyl}-hex-5-
ynoic acid (201) 
 
To a solution of 219 (200 mg, 0.434 mmol) in diethylamine (15 mL) and THF (15 
mL) was added bis(triphenylphosphine)palladium(II) dichloride (40 mg, 0.057 
mmol) and copper(I) iodide (8.0 mg, 0.043 mmol) at rt. The reaction mixture was 
stirred for 30 min. 5-Hexynoic acid (67 mg, 2.17 mmol) in diethylamine (10 mL) 
was added dropwise over a period of 4 h. The reaction mixture was then stirred at rt 
for 48 h. The solvent was removed in vacuo. The residue was dissolved in THF (100 
mL), washed with aqueous HCl (2 * 100 mL, 0.1 M), water (100 mL) and dried 
(MgSO4). The solvent was removed in vacuo. The residue was subjected to column 
chromatography (CHCl3/CH3OH 9:1) to give the acid 201 (164 mg, 0.333 mmol, 
77%) as a white solid. m.p. 186-188 °C; Rf = 0.30 (CHCl3/CH3OH 9:1); IR +max 
(film)/cm
-1
 3328, 2178, 1740, 1638; m/z (ES+) 492.1901 (M+H, C30H26N3O requires 
492.1923). 
3. Experimental Section 
151 
 
6-{2-[4-(6-Amino-pyridazin-3-yl)-phenoxymethyl]-5-benzoyl-phenyl}-hex-5-
ynoic acid (2-methoxy-ethyl)-amide (220) 
 
To a solution of 201 (5.0 mg, 0.0102 mmol) in DMF (0.3 mL) at rt, was added N-
hydroxysuccinimide (1.3 mg, 0.011 mmol) and stirred at rt for 30 min. The solution 
was added dropwise to a solution of diisopropylcarbodiimide hydrochloride (2.0 mg, 
0.012 mmol) and 2-methoxyethamine (2.0 mg, 0.027 mmol) in DMF (0.3 mL) and 
the reaction mixture was stirred at rt for 3 h. The solvent was removed in vacuo and 
the residue was purified by column chromatography (EtOAc) to give the pyridazine 
220 (3.3 mg, 0.0060 mmol, 60%) as a white solid. Rf = 0.45 (CHCl3/CH3OH 9:1); IR 
+max (film)/cm
-1
 3277, 2137, 1734, 1644; 
1
H NMR (CDCl3, 600 MHz) ' 1.87 (2 H, 
quint, J 7.3, O=CCH2CH2), 2.34 (2 H, t, J 7.4, O=CCH2), 2.51 (2 H, t, J 7.4, 
O=CCH2CH2CH2), 3.38 (2 H, t, J 7.0, NHCH2), 5.37 (2 H, s, COCH2C), 7.00 (1 H, 
d, J 9.3, NH2CCH), 7.13 (2 H, d, J 8.8, OCCH) 7.55 (2 H, dd, J 7.6 and 7.4, 
O=CCCHCHCH), 7.59 (1 H, t, J 7.4, O=CCCHCHCH), 7.70-7.75 (2 H, m, 
OCH2CCH and NH2CCHCH), 7.76-7.79 (3 H, m, OCH2CCHCH and OCCHCH), 
7.81 (1 H, d, J 1.8, OCH2CCCH), 7.87 (2 H, d, J 7.6, O=CCCHCHCH); 
13
C NMR 
(CDCl3, 150 MHz) ' 19.7 (CH2), 25.9 (CH2), 35.9 (CH2), 40.2 (CH2), 58.9 (CH3), 
69.2 (CH2), 71.9 (CH2), 79.6 (C), 97.3 (C), 116.2 (CH), 117.5 (CH), 124.5 (C), 128.0 
(CH), 128.6 (CH), 128.6 (CH), 129.6 (CH), 130.4 (CH), 131.0 (CH), 131.2 (C), 
134.0 (CH), 134.4 (CH), 138.3 (C), 138.5 (C), 144.4 (C), 152.1 (C), 160.9 (C), 175.4 
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(C=O), 197.4 (C=O), *1 (C) absent; m/z (ES+) 571.2321 ([MNa]
+
, C33H32N4O4Na 
requires 571.2321), 549 (100). 
tert-Butyl N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (222) 
 
To a solution of di-tert-butyl-dicarbonate (1.10 g, 5.00 mmol) in CH2Cl2 (5 mL) was 
added a solution of 2-[2-(2-aminoethoxy)ethoxy]ethanamine (7.32 g, 50.0 mmol) in 
CH2Cl2 (15 mL). The resulting reaction mixture was stirred at rt for 24 h. The 
solvent was removed in vacuo. EtOAc (125 mL) was added to the residue and the 
resulting white precipitate was washed with Na2CO3 (3 * 50 mL) and dried 
(MgSO4). The solvent was removed in vacuo and the residue was purified by column 
chromatography (CH2Cl2/CH3OH 8:2) to give the amine 222 (690 mg, 2.80 mmol, 
56%) as a colourless oil. Rf = 0.30 (CH2Cl2/CH3OH 8:2); IR +max (film)/cm
-1
 3344, 
2869, 1692; 
1
H NMR (CDCl3, 500 MHz) % 1.35 (9 H, s, CH3), 2.05 (2 H, s, NH2), 
2.80 (2 H, t, J 5.0, NCH2), 3.22-3.23 (2 H, m, NCH2), 3.42-3.47 (4 H, m, OCH2), 
3.52-3.54 (4 H, m, OCH2), 5.27 (1 H, s, NH); 
13
C NMR (CDCl3, 125 MHz) % 28.4 
(CH3), 40.3 (CH2), 41.6 (CH2), 70.2 (CH2), 70.2 (CH2), 73.2 (CH2), 79.1 (C), 156.1 
(C=O), * 1 CH2 absent; m/z (CI) 249.1825 (M+H, C11H25N2O4 requires 249.1814). 
tert-Butyl-N-(2-(2-(2-(5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno(3,4-d)imidazol-6-
yl)pentanoylamino)ethoxy)ethoxy)ethyl)carbamate (223) 
 
A solution of biotin (590 mg, 2.42 mmol), HBTU (790 mg, 2.10 mmol) and DIPEA 
(606 mg, 2.60 mmol) in DMF (15 mL) was stirred for 20 min at rt before being 
added dropwise to a solution of 222 (400 mg, 1.61 mmol) in DMF (10 mL). The 
reaction mixture was stirred for 2 h at rt. The solvent was removed in vacuo and the 
residue was purified by column chromatography (CH2Cl2/CH3OH 19:1) to give the 
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amine 223 (640 mg, 1.34 mmol, 83%) as a white solid. m.p. 106-108 °C; Rf = 0.30 
(CH2Cl2/CH3OH 19:1); [#]D
20.0
 +23.0 (c 0.6, CH2Cl2); IR +max (film)/cm
-1
 3317, 
2945, 1697; 
1
H NMR (CDCl3, 500 MHz) % 1.47 (11 H, m, C(CH3)3 and 
NHC=OCH2CH2CH2CH2), 1.71 (4 H, m, NHC=OCH2CH2CH2CH2), 2.27 (2 H, t, J 
7.0, NHC=OCH2CH2CH2), 2.79 (1 H, d, J 13.0, SCHH), 2.92 (1 H, dd, J 13.0 and 
5.0, SCHH), 3.17 (1 H, dt, J 5.0 and 3.0, SCH), 3.31 (2 H, m, NCH2), 3.46 (2 H, m, 
NCH2), 3.55-3.59 (2 H, m, OCH2), 3.62 (6 H, m, OCH2), 4.36 (1 H, dd, J 7.5 and 
5.0, CHNHC=ONHCH), 4.55 (1 H, dd, J 7.5 and 5.0, CHNHC=ONHCH); 
13
C NMR 
(CDCl3, 125 MHz) % 25.2 (CH2), 27.7 (CH2), 27.8 (CH2), 28.1 (CH3), 35.4 (CH2), 
38.9 (CH2), 40.0 (CH2), 40.2 (CH2), 55.2 (CH), 60.1 (CH), 61.6 (CH), 69.7 (CH2), 
70.0 (CH2), 79.1 (C), 156.0 (C=O), 163.9 (C=O), 173.7 (C=O), * 2 CH2 absent; m/z 
(ES) 497.2423 ([MNa]
+
, C21H38N4O6SNa requires 497.2410). 
2-(2-(2-(5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno(3,4-d)imidazol-6-
yl)pentanoylamino)ethoxy)ethoxy)ethylammonium 2,2,2-trifluoroacetate salt 
(224) 
 
A solution of 223 (610 mg, 1.29 mmol) in CH2Cl2 (5 mL) and TFA (5 mL) was 
stirred at rt for 3 h. The solvent was removed in vacuo to give the amine 224 (630 
mg, 1.29 mmol, quant.) as a colourless oil. Rf = 0.05 (CH2Cl2/CH3OH 19:1); [#]D
20.0
 
+40.0 (c 0.5, CH3OH); IR +max (film)/cm
-1
 3312, 2936, 1689; 
1
H NMR (CD3OD, 400 
MHz) % 1.43-1.76 (6 H, m, NHC=OCH2CH2CH2CH2), 2.24 (2 H, t, J 7.5, 
NHC=OCH2CH2CH2), 2.74 (1 H, d, J 13.0, SCHH), 2.94 (1 H, dd, J 13.0 and 5.0, 
SCHH), 3.21 (1 H, dt, J 8.5 and 5.0, SCH), 3.38 (2 H, t, J 5.0, OCH2), 3.57 (2 H, t, J 
5.0, OCH2), 3.65 (4 H, m, OCH2), 3.71 (2 H, t, J 5.0, OCH2CH2NH3), 4.33 (1 H, dd, 
J 7.5 and 5.0, CHNHC=ONHCH), 4.53 (1 H, dd, J 7.5 and 5.0, CHNHC=ONHCH); 
13
C NMR (CD3OD, 125 MHz) % 25.4 (CH2), 28.1 (CH2), 28.3 (CH2), 35.3 (CH2), 
38.8 (CH2), 39.3 (CH2), 39.7 (CH2), 55.6 (CH), 60.4 (CH), 62.1 (CH), 66.5 (CH2), 
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69.2 (CH2), 69.8 (CH2), 69.9 (CH2), 164.8 (C=O), 175.0 (C=O); m/z (ES) 375.2060 
(M+H, C16H31N4O4S requires 375.2066). 
6-{2-[4-(6-Amino-pyridazin-3-yl)-phenoxymethyl]-5-benzoyl-phenyl}-hex-5-
ynoic acid [2-(2-{2-[5-(2-oxo-1,3,3a,4,6,6a-hexahydro-thieno[3,4-d]imidazol-6-
yl)-pentanoylamino]-ethoxy}-ethoxy)-ethyl]-amide (200) 
 
To a solution of 224 (87 mg, 0.177 mmol) in DMF (5 mL) at rt, was added HBTU 
(67 mg, 0.177 mmol) and DIPEA (68 mg, 0.531 mmol). The reaction mixture was 
stirred at rt for 20 min. The resulting solution was then added dropwise to a solution 
of 201 (83 mg, 0.177 mmol) in DMF (5 mL). The reaction mixture was stirred at rt 
for 3 h. The solvent was removed in vacuo. The residue was purified by column 
chromatography (CHCl3/CH3OH 9:1) to give the pyridazine 200 (18 mg, 0.021 
mmol, 12%). m.p. degraded >150 °C; Rf = 0.20 (CHCl3/CH3OH 9:1); [#]D
20.0
 +27.0 
(c 0.2, CH3OH); IR +max (film)/cm
-1
 3295, 2930, 2102, 1737, 1660, 1597, 1446; 
1
H 
NMR (CDCl3/CD3OD 1:1, 600 MHz) % 1.43-1.76 (6 H, m, 
NHC=OCH2CH2CH2CH2), 1.90 (2 H, quint, J 7.1, NHC=OCH2CH2CH2CC),  2.16 
(2 H, t, J 7.0, NHC=OCH2CH2CH2CH2), 2.34 (2 H, t, J 7.1, 
NHC=OCH2CH2CH2CC), 2.51 (2 H, t, J 7.1, NHC=OCH2CH2CH2CC), 2.69 (1 H, d, 
J 12.8, SCHH), 2.94 (1 H, dd, J 12.8 and 4.7, SCHH), 3.21 (1 H, m, SCH), 3.35 (4 
H, m, 2 * NHCH2CH2O), 3.57-3.63 (8 H, m, 4 * OCH2), 4.26 (1 H, m, 
CHNHC=ONHCH), 4.53 (1 H, m, CHNHC=ONHCH), 5.35 (2 H, s, OCH2C), 7.08 
(2 H, d, J 8.3, OCCH), 7.50 (2 H, dd, J 7.6 and 7.5, O=CCCHCHCH), 7.60-7.70 (4 
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H, m, O=CCCHCHCH, OCH2CCH, OCH2CCHCH and NH2CCHCH), 7.73-7.76 (3 
H, m, OCCHCH and OCH2CCCH), 7.83 (2 H, m, O=CCCHCHCH) * 1 H absent – 
NH2CCH not observed due to deuteration in CDCl3/CD3OD but signal is observed at 
6.82 ppm in DMSO; 
13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) % 20.3 (CH2), 26.0 
(CH2), 26.9 (CH2), 29.5 (CH2), 29.8 (CH2), 36.2 (CH2), 37.0 (CH2), 40.3 (CH2), 40.4 
(CH2), 41.5 (CH2), 57.0 (CH), 61.6 (CH), 63.4 (CH), 69.4 (CH2), 70.9 (CH2), 70.9 
(CH2), 71.4 (CH2), 79.1 (C), 97.6 (C), 116.5 (CH), 123.9 (C), 128.4 (CH), 129.0 
(CH), 129.0 (CH), 129.8 (CH), 130.6 (C), 130.7 (CH), 131.3 (CH), 134.3 (CH), 
134.9 (CH), 138.2 (C), 138.4 (C), 144.3 (C), 160.9 (C), 165.9 (C=O), 175.2 (C=O), 
176.0 (C=O), 197.9 (C=O) * 1 CH2, 1 CH and 2 (C) absent; m/z (ES+) 870.3621 
([MNa]
+
, C46H53N7O7SNa requires 870.3625), 848 (25). 
1-(3-Allyloxycarbonyl-propyl)-6-amino-3-[4-(4-benzoyl-2-{5-[2-(2-{2-[5-(2-oxo-
1,3,3a,4,6,6a-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-ethoxy}-
ethoxy)-ethylcarbamoyl]-pent-1-ynyl}-benzyloxy)-phenyl]-pyridazinium 
bromide (225) 
 
To a solution of 200 (17 mg, 0.020 mmol) in DMF (0.5 mL) was added allyl-4-
bromobutyrate (6.0 mg, 0.029 mmol). The solution was heated to 80 °C for 5 h. The 
hot solution was then poured into EtOAc (2 mL) to yield a solid, which was then 
isolated by filtration. The product was dried under high vacuum to give the ester 225 
(9.2 mg, 0.0085 mmol, 43%) as a white solid. m.p. degraded >150 °C; Rf = 0.10 
(EtOAc/CH3OH 9:1); [#]D
20.0
 +29.0 (c 0.1, CH3OH); IR +max (film)/cm
-1
 3318, 2943, 
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2831, 2120, 1725, 1666, 1449;
 1
H NMR (CDCl3/CD3OD 1:1, 600 MHz) % 1.45-1.71 
(6 H, m, NHC=OCH2CH2CH2CH2), 1.92 (2 H, quint, J 7.4, 
NHC=OCH2CH2CH2CC),  2.17 (2 H, t, J 7.0, NHC=OCH2CH2CH2CH2), 2.29-2.36 
(4 H, m, NHC=OCH2CH2CH2CC and NNCH2CH2CH2), 2.50-2.55 (4 H, m, 
NHC=OCH2CH2CH2CC and NNCH2CH2CH2), 2.69 (1 H, d, J 12.6, SCHH), 2.89 (1 
H, dd, J 12.6 and 4.7, SCHH), 3.13 (1 H, m, SCH), 3.35 (4 H, m, 2 * NHCH2CH2O), 
3.53-3.58 (8 H, m, 4 * OCH2), 4.28 (1 H, m, CHNHC=ONHCH), 4.49-4.57 (5 H, m, 
CHNHC=ONHCH, CO2CH2CH and NNCH2CH2CH2), 5.18 (1 H, dd, J 10.2 and 1.6, 
CO2CH2CHCHH), 5.23 (1 H, dd, J 17.4 and 1.6, CO2CH2CHCHH), 5.35 (2 H, s, 
OCH2C), 5.82 (1 H, m, CO2CH2CH), 7.14 (2 H, d, J 8.3, OCCH), 7.50 (2 H, dd, J 
7.6 and 7.5, O=CCCHCHCH), 7.60-7.66 (3 H, m, O=CCCHCHCH, OCH2CCH, 
OCH2CCHCH), 7.69 (1 H, d, J 9.3, NHCCHCH), 7.76 (2 H, d, J 7.6, 
O=CCCHCHCH), 7.84 (1 H, d, J 1.4, OCH2CCCH), 7.96 (2 H, d, J 8.3, OCCHCH), 
8.37 (1 H, d, J 9.3, NHCCH);
 13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) % 20.4 
(CH2), 26.1 (CH2), 26.9 (CH2), 29.5 (CH2), 29.8 (CH2), 32.1 (CH2), 36.4 (CH2), 37.0 
(CH2), 40.4 (CH2), 40.4 (CH2), 41.6 (CH2), 43.8 (CH2), 57.0 (CH), 58.0 (CH2), 61.6 
(CH), 63.3 (CH), 66.8 (CH2), 69.4 (CH2), 70.9 (CH2), 71.4 (CH2), 71.4 (CH2), 79.1 
(C), 97.8 (C), 117.0 (CH), 119.7 (CH2), 123.8 (C), 126.7 (C), 127.1 (CH), 127.2 
(CH), 128.3 (CH), 129.9 (CH), 130.8 (CH), 131.3 (CH), 133.1 (CH), 133.3 (CH), 
134.4 (CH), 135.0 (CH), 138.2 (C), 143.8 (C), 153.8 (C), 153.9 (C), 158.9 (C), 162.3 
(C), 165.8 (C=O), 173.8 (C=O), 175.1 (C=O), 175.9 (C=O), 197.9 (C=O) * 1 CH2 
absent; m/z (ES+) 974.4557 (M+H, C53H64N7O9S requires 974.4486), 788 (50). 
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6-[4-(4-Benzoyl-2-{5-[2-(2-{2-[5-(2-oxo-1,3,3a,4,6,6a-hexahydro-thieno[3,4-
d]imidazol-6-yl)-pentanoylamino]-ethoxy}-ethoxy)-ethylcarbamoyl]-pent-1-
ynyl}-benzyloxy)-phenyl]-2-(3-carboxy-propyl)-pyridazinium chloride (226) 
N N
NH.HClO
O
O
NH O O NH
O
S
HN
NHH
H
O
O
OH
 
To a solution of 225 (7.0 mg, 0.0065 mmol) in THF (0.5 mL) and water (0.5 mL) 
was added NaOH (1.0 mg, 0.025 mmol) at rt. The resulting mixture was stirred at 50 
°C for 3 h. After cooling to 10 °C, the reaction mixture was washed with ethyl 
acetate (2 mL). The aqueous layer was separated and treated with aqueous HCl 
(0.1M) to adjust the pH to 1.0 at rt. The resulting mixture was then stirred at 0°C for 
1 h, and the solvent was removed in vacuo. The reaction vessel was then triturated 
with water (3 * 2 mL), and the residue was dried under high vacuum to give the ester 
226 (3.3 mg, 0.0034 mmol, 53%) as a white solid. m.p. degraded >150 °C; Rf = 0.10 
(CH3Cl/CH3OH 8:2); [#]D
20.0
 +20.0 (c 0.05, CH3OH); IR +max (film)/cm
-1
 3359, 
2143, 1730, 1644, 1457;
 1
H NMR (CDCl3/CD3OD 1:1, 600 MHz) % 1.45-1.66 (6 H, 
m, NHC=OCH2CH2CH2CH2), 1.91 (2 H, quint, J 7.4, NHC=OCH2CH2CH2CC),  
2.16 (4 H, m, NHC=OCH2CH2CH2CH2 and NHC=OCH2CH2CH2CC), 2.36 (2 H, t, J 
6.8, NNCH2CH2CH2), 2.50-2.57 (4 H, m, NHC=OCH2CH2CH2CC and 
NNCH2CH2CH2), 2.69 (1 H, d, J 12.6, SCHH), 2.89 (1 H, dd, J 12.6 and 4.7, 
SCHH), 3.13 (1 H, m, SCH), 3.35 (4 H, m, 2 * NHCH2CH2O), 3.51-3.59 (8 H, m, 4 
* OCH2), 4.28 (1 H, m, CHNHC=ONHCH), 4.42-4.48 (3 H, m, CHNHC=ONHCH 
and NNCH2CH2CH2), 5.35 (2 H, s, OCH2C), 7.14 (2 H, d, J 8.3, OCCH), 7.52 (2 H, 
dd, J 7.6 and 7.5, O=CCCHCHCH), 7.65-7.69 (3 H, m, O=CCCHCHCH, 
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OCH2CCH, OCH2CCHCH), 7.71 (1 H, d, J 9.3, NHCCHCH), 7.76 (2 H, d, J 7.6, 
O=CCCHCHCH), 7.81 (1 H, s, OCH2CCCH), 7.92 (2 H, d, J 8.3, OCCHCH), 8.22 
(1 H, d, J 9.3, NHCCH);
 13
C NMR (CDCl3/CD3OD 1:1, 150 MHz) % 20.2 (CH2), 
26.0 (CH2), 26.9 (CH2), 29.5 (CH2), 30.9 (CH2), 31.7 (CH2), 36.3 (CH2), 37.0 (CH2), 
40.1 (CH2), 40.3 (CH2), 40.4 (CH2), 57.0 (CH2), 59.2 (CH), 61.6 (CH), 63.3 (CH), 
69.4 (CH2), 69.5 (CH2), 70.8 (CH2), 71.4 (CH2), 71.4 (CH2), 79.2 (C), 97.6 (C), 
116.9 (CH), 123.7 (C), 126.6 (C), 126.8 (CH), 128.4 (CH), 129.6 (CH), 129.8 (CH), 
130.7 (CH), 131.3 (CH), 132.8 (CH), 134.4 (CH), 134.8 (CH), 138.2 (C), 144.0 (C), 
152.1 (C), 153.8 (C), 158.9 (C), 162.7 (C), 169.8 (C=O), 175.9 (C=O), 176.5 (C=O), 
177.1 (C=O), 198.0 (C=O) * 1 CH2 absent; m/z (ES+) 956.3971 ([MNa]
+
, 
C50H59N7O9SNa requires 956.3993), 933 (15). 
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